TABLE 14.2__1000.4.1.1.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	48	80.90	26.011	0.0	66.67	91.67	100.00	100.0			
	ADA	57	83.48	24.321	0.0	75.00	100.00	100.00	100.0			
	TOT	105	82.30	25.019	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	48	74.39	32.366	0.0	62.50	91.67	100.00	100.0			
	ADA	57	80.56	27.292	0.0	66.67	100.00	100.00	100.0			
	TOT	105	77.74	29.733	0.0	66.67	91.67	100.00	100.0			
CHG FROM BEST*	PLO	48	-6.51	17.444	-75.0	-16.67	0.00	0.00	29.2			
	ADA	57	-2.92	18.799	-75.0	0.00	0.00	0.00	50.0			
	TOT	105	-4.56	18.194	-75.0	-8.33	0.00	0.00	50.0			
										3.59	(-3.48, 10.65)	0.317A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	41	67.48	31.114	0.0	50.00	83.33	91.67	100.0			
	ADA	56	65.77	29.917	0.0	45.83	75.00	87.50	100.0			
	TOT	97	66.49	30.280	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	41	59.35	30.058	0.0	41.67	66.67	83.33	100.0			
	ADA	56	63.24	30.392	0.0	45.83	70.83	83.33	100.0			
	TOT	97	61.60	30.156	0.0	41.67	66.67	83.33	100.0			
CHG FROM BEST*	PLO	41	-8.13	16.821	-50.0	-16.67	0.00	0.00	50.0			
	ADA	56	-2.53	14.708	-41.7	-8.33	0.00	0.00	50.0			
	TOT	97	-4.90	15.798	-50.0	-8.33	0.00	0.00	50.0			
										5.60	(-0.78, 11.98)	0.085A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	48	95.83	10.735	50.0	100.00	100.00	100.00	100.0			
	ADA	57	92.54	14.146	25.0	75.00	100.00	100.00	100.0			
	TOT	105	94.05	12.749	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	48	93.75	13.148	50.0	100.00	100.00	100.00	100.0			
	ADA	57	89.91	17.589	25.0	75.00	100.00	100.00	100.0			
	TOT	105	91.67	15.761	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	48	-2.08	10.097	-50.0	0.00	0.00	0.00	25.0			
	ADA	57	-2.63	15.443	-75.0	0.00	0.00	0.00	25.0			
	TOT	105	-2.38	13.212	-75.0	0.00	0.00	0.00	25.0			
										-0.55	(-5.71, 4.61)	0.833A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	48	78.13	21.027	25.0	75.00	75.00	100.00	100.0			
	ADA	57	79.82	24.748	25.0	75.00	100.00	100.00	100.0			
	TOT	105	79.05	23.029	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	48	73.44	24.950	0.0	62.50	75.00	100.00	100.0			
	ADA	57	75.44	26.513	25.0	50.00	75.00	100.00	100.0			
	TOT	105	74.52	25.707	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	48	-4.69	11.128	-25.0	0.00	0.00	0.00	25.0			
	ADA	57	-4.39	16.450	-50.0	0.00	0.00	0.00	25.0			
	TOT	105	-4.52	14.202	-50.0	0.00	0.00	0.00	25.0			
										0.30	(-5.24, 5.85)	0.914A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 30 TO < 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	48	76.76	16.116	39.2	66.38	79.09	90.51	98.2			
	ADA	57	75.04	19.469	14.7	61.52	83.86	92.42	100.0			
	TOT	105	75.83	17.950	14.7	62.77	79.89	91.36	100.0			
FINAL/ET VALUE	PLO	48	71.95	19.543	30.5	63.30	76.25	87.72	98.0			
	ADA	57	74.81	20.492	18.5	62.08	82.54	92.12	99.4			
	TOT	105	73.50	20.019	18.5	62.65	76.97	90.30	99.4			
CHG FROM BEST*	PLO	48	-4.81	9.531	-37.7	-8.83	-2.08	1.79	10.7			
	ADA	57	-0.23	10.581	-38.3	-4.09	0.49	3.96	25.8			
	TOT	105	-2.33	10.324	-38.3	-5.42	-1.14	3.22	25.8			
										4.58	(0.65, 8.51)	0.023A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	40	62.50	22.646	25.0	50.00	50.00	75.00	100.0			
	ADA	32	62.50	23.760	25.0	50.00	50.00	75.00	100.0			
	TOT	72	62.50	22.982	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	40	45.00	28.420	0.0	25.00	50.00	62.50	100.0			
	ADA	32	46.09	23.852	0.0	25.00	50.00	62.50	100.0			
	TOT	72	45.49	26.313	0.0	25.00	50.00	62.50	100.0			
CHG FROM BEST*	PLO	40	-17.50	26.067	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	32	-16.41	28.119	-100.0	-25.00	-12.50	0.00	50.0			
	TOT	72	-17.01	26.810	-100.0	-25.00	-25.00	0.00	50.0			
										1.09	(-11.68, 13.86)	0.865A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	40	68.50	15.616	40.0	60.00	70.00	80.00	100.0			
	ADA	32	63.44	12.078	40.0	60.00	60.00	80.00	80.0			
	TOT	72	66.25	14.285	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	40	58.50	20.946	20.0	40.00	60.00	80.00	100.0			
	ADA	32	58.44	17.618	20.0	50.00	60.00	60.00	100.0			
	TOT	72	58.47	19.404	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	40	-10.00	18.674	-60.0	-20.00	0.00	0.00	20.0			
	ADA	32	-5.00	16.264	-40.0	-20.00	0.00	0.00	30.0			
	TOT	72	-7.78	17.700	-60.0	-20.00	0.00	0.00	30.0			
										5.00	(-3.35, 13.35)	0.236A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	40	85.94	16.791	50.0	75.00	87.50	100.00	100.0			
	ADA	32	88.28	14.871	50.0	75.00	100.00	100.00	100.0			
	TOT	72	86.98	15.900	50.0	75.00	93.75	100.00	100.0			
FINAL/ET VALUE	PLO	40	71.25	27.764	12.5	50.00	75.00	100.00	100.0			
	ADA	32	82.42	20.045	50.0	62.50	93.75	100.00	100.0			
	TOT	72	76.22	25.102	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	40	-14.69	25.459	-87.5	-12.50	0.00	0.00	12.5			
	ADA	32	-5.86	15.549	-37.5	-12.50	0.00	0.00	25.0			
	TOT	72	-10.76	21.934	-87.5	-12.50	0.00	0.00	25.0			
										8.83	(-1.41, 19.06)	0.090A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	40	67.50	20.912	25.0	54.17	66.67	83.33	100.0			
	ADA	32	66.28	20.695	25.0	50.00	75.00	83.33	100.0			
	TOT	72	66.96	20.678	25.0	50.00	70.83	83.33	100.0			
FINAL/ET VALUE	PLO	40	58.33	25.529	8.3	33.33	58.33	79.17	100.0			
	ADA	32	60.68	23.497	25.0	45.83	66.67	75.00	100.0			
	TOT	72	59.38	24.504	8.3	37.50	58.33	75.00	100.0			
CHG FROM BEST*	PLO	40	-9.17	20.569	-58.3	-25.00	-4.17	0.00	41.7			
	ADA	32	-5.60	18.802	-66.7	-8.33	0.00	4.17	25.0			
	TOT	72	-7.58	19.747	-66.7	-16.67	0.00	0.00	41.7			
										3.57	(-5.80, 12.94)	0.450A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	40	69.27	22.422	16.7	54.17	75.00	83.33	100.0			
	ADA	32	70.18	20.661	33.3	50.00	75.00	87.50	100.0			
	TOT	72	69.68	21.512	16.7	50.00	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	40	61.77	28.866	8.3	35.42	68.75	85.42	100.0			
	ADA	32	61.52	24.792	25.0	37.50	62.50	83.33	100.0			
	TOT	72	61.66	26.946	8.3	35.42	66.67	83.33	100.0			
CHG FROM BEST*	PLO	40	-7.50	18.081	-50.0	-22.92	-8.33	2.08	41.7			
	ADA	32	-8.66	17.294	-66.7	-16.67	-8.33	0.00	16.7			
	TOT	72	-8.02	17.621	-66.7	-16.67	-8.33	0.00	41.7			
										-1.16	(-9.55, 7.23)	0.784A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	40	85.94	17.262	50.0	75.00	87.50	100.00	100.0			
	ADA	32	83.59	20.926	37.5	75.00	87.50	100.00	100.0			
	TOT	72	84.90	18.874	37.5	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	40	77.19	24.821	12.5	68.75	87.50	100.00	100.0			
	ADA	32	78.32	23.438	25.0	56.25	87.50	100.00	100.0			
	TOT	72	77.69	24.054	12.5	62.50	87.50	100.00	100.0			
CHG FROM BEST*	PLO	40	-8.75	19.652	-50.0	-25.00	0.00	0.00	37.5			
	ADA	32	-5.27	15.153	-37.5	-12.50	0.00	0.00	37.5			
	TOT	72	-7.20	17.760	-50.0	-18.75	0.00	0.00	37.5			
										3.48	(-4.94, 11.90)	0.413A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	40	66.56	24.659	18.8	50.00	75.00	87.50	100.0			
	ADA	32	68.62	23.611	18.8	53.13	71.88	87.50	100.0			
	TOT	72	67.48	24.052	18.8	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	40	59.48	27.671	12.5	34.38	59.38	81.25	100.0			
	ADA	32	61.65	26.298	6.3	43.75	64.58	84.38	100.0			
	TOT	72	60.45	26.902	6.3	37.50	62.50	81.25	100.0			
CHG FROM BEST*	PLO	40	-7.08	21.318	-75.0	-12.50	0.00	6.25	31.3			
	ADA	32	-6.97	18.174	-62.5	-12.50	-6.25	3.13	25.0			
	TOT	72	-7.03	19.846	-75.0	-12.50	-4.17	6.25	31.3			
										0.12	(-9.34, 9.57)	0.980A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	40	67.19	26.355	25.0	50.00	62.50	93.75	100.0			
	ADA	32	70.70	24.718	12.5	50.00	75.00	93.75	100.0			
	TOT	72	68.75	25.523	12.5	50.00	75.00	93.75	100.0			
FINAL/ET VALUE	PLO	40	56.25	30.619	0.0	25.00	50.00	75.00	100.0			
	ADA	32	58.20	30.223	0.0	37.50	56.25	81.25	100.0			
	TOT	72	57.12	30.244	0.0	37.50	50.00	75.00	100.0			
CHG FROM BEST*	PLO	40	-10.94	22.679	-75.0	-25.00	0.00	0.00	25.0			
	ADA	32	-12.50	26.941	-75.0	-31.25	0.00	0.00	37.5			
	TOT	72	-11.63	24.495	-75.0	-25.00	0.00	0.00	37.5			
										-1.56	(-13.23, 10.10)	0.790A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	40	81.46	22.605	25.0	70.83	91.67	100.00	100.0			
	ADA	32	82.29	22.969	16.7	66.67	91.67	100.00	100.0			
	TOT	72	81.83	22.610	16.7	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	40	71.25	29.354	8.3	50.00	83.33	100.00	100.0			
	ADA	32	77.34	27.291	16.7	58.33	91.67	100.00	100.0			
	TOT	72	73.96	28.421	8.3	50.00	83.33	100.00	100.0			
CHG FROM BEST*	PLO	40	-10.21	22.208	-75.0	-20.83	-4.17	0.00	50.0			
	ADA	32	-4.95	16.239	-41.7	-16.67	0.00	0.00	33.3			
	TOT	72	-7.87	19.824	-75.0	-16.67	0.00	0.00	50.0			
										5.26	(-4.10, 14.62)	0.266A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	38	58.00	31.066	0.0	33.33	66.67	83.33	100.0			
	ADA	28	62.20	30.470	0.0	37.50	66.67	91.67	100.0			
	TOT	66	59.79	30.649	0.0	33.33	66.67	83.33	100.0			
FINAL/ET VALUE	PLO	38	46.82	35.241	0.0	8.33	50.00	83.33	100.0			
	ADA	28	53.87	35.896	0.0	16.67	62.50	83.33	100.0			
	TOT	66	49.81	35.419	0.0	16.67	54.17	83.33	100.0			
CHG FROM BEST*	PLO	38	-11.18	23.493	-75.0	-25.00	-8.33	0.00	33.3			
	ADA	28	-8.33	17.568	-66.7	-16.67	0.00	0.00	16.7			
	TOT	66	-9.97	21.080	-75.0	-16.67	-8.33	0.00	33.3			
										2.85	(-7.70, 13.40)	0.591A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	40	90.63	15.697	50.0	75.00	100.00	100.00	100.0			
	ADA	32	92.97	11.420	75.0	75.00	100.00	100.00	100.0			
	TOT	72	91.67	13.916	50.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	40	86.56	20.292	25.0	75.00	100.00	100.00	100.0			
	ADA	32	86.72	19.033	50.0	75.00	100.00	100.00	100.0			
	TOT	72	86.63	19.605	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	40	-4.06	15.604	-50.0	-6.25	0.00	0.00	25.0			
	ADA	32	-6.25	17.961	-50.0	-25.00	0.00	0.00	25.0			
	TOT	72	-5.03	16.607	-50.0	-18.75	0.00	0.00	25.0			
										-2.19	(-10.08, 5.71)	0.582A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	40	77.81	24.918	25.0	50.00	75.00	100.00	100.0			
	ADA	31	79.84	23.646	25.0	75.00	75.00	100.00	100.0			
	TOT	71	78.70	24.219	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	40	70.63	24.604	25.0	50.00	75.00	100.00	100.0			
	ADA	31	66.13	24.621	25.0	50.00	75.00	75.00	100.0			
	TOT	71	68.66	24.538	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	40	-7.19	20.780	-50.0	-25.00	0.00	0.00	50.0			
	ADA	31	-13.71	20.247	-50.0	-25.00	0.00	0.00	25.0			
	TOT	71	-10.04	20.661	-50.0	-25.00	0.00	0.00	50.0			
										-6.52	(-16.33, 3.29)	0.189A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: AGE >= 50 YEARS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	40	71.40	17.391	39.1	56.25	72.56	87.42	98.3			
	ADA	32	72.83	15.286	48.8	59.00	73.95	87.94	92.2			
	TOT	72	72.03	16.391	39.1	57.42	72.71	87.90	98.3			
FINAL/ET VALUE	PLO	40	65.28	21.002	27.0	51.02	66.48	82.18	97.2			
	ADA	32	67.52	18.988	29.7	52.08	65.08	84.34	98.5			
	TOT	72	66.28	20.024	27.0	51.27	65.42	84.11	98.5			
CHG FROM BEST*	PLO	40	-6.12	14.671	-48.0	-15.52	-1.80	2.42	20.6			
	ADA	32	-5.30	10.851	-38.7	-10.71	-3.88	0.95	11.0			
	TOT	72	-5.75	13.031	-48.0	-12.71	-2.80	1.89	20.6			
										0.81	(-5.39, 7.02)	0.794A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	82	63.41	21.586	0.0	50.00	62.50	75.00	100.0			
	ADA	79	63.29	20.738	25.0	50.00	50.00	75.00	100.0			
	TOT	161	63.35	21.108	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	82	49.70	24.688	0.0	25.00	50.00	75.00	100.0			
	ADA	79	56.01	22.722	0.0	50.00	50.00	75.00	100.0			
	TOT	161	52.80	23.880	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	82	-13.72	20.089	-75.0	-25.00	0.00	0.00	25.0			
	ADA	79	-7.28	25.049	-100.0	-25.00	0.00	0.00	50.0			
	TOT	161	-10.56	22.817	-100.0	-25.00	0.00	0.00	50.0			
										6.44	(-0.61, 13.50)	0.073A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	82	72.20	14.318	40.0	60.00	80.00	80.00	100.0			
	ADA	79	70.76	13.279	40.0	60.00	80.00	80.00	100.0			
	TOT	161	71.49	13.794	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	82	60.49	19.870	20.0	40.00	60.00	80.00	100.0			
	ADA	79	69.24	16.700	20.0	60.00	80.00	80.00	100.0			
	TOT	161	64.78	18.844	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	82	-11.71	18.040	-60.0	-20.00	0.00	0.00	20.0			
	ADA	79	-1.52	14.330	-40.0	-20.00	0.00	0.00	40.0			
	TOT	161	-6.71	17.058	-60.0	-20.00	0.00	0.00	40.0			
										10.19	(5.11, 15.27)	<0.001A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	82	83.23	16.104	37.5	75.00	87.50	100.00	100.0			
	ADA	79	83.39	17.646	25.0	62.50	87.50	100.00	100.0			
	TOT	161	83.31	16.825	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	82	70.58	23.925	12.5	50.00	75.00	87.50	100.0			
	ADA	79	81.80	19.591	25.0	62.50	87.50	100.00	100.0			
	TOT	161	76.09	22.552	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-12.65	20.365	-75.0	-25.00	0.00	0.00	25.0			
	ADA	79	-1.58	12.717	-37.5	-12.50	0.00	0.00	37.5			
	TOT	161	-7.22	17.878	-75.0	-12.50	0.00	0.00	37.5			
										11.07	(5.76, 16.38)	<0.001A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	82	75.56	18.608	16.7	66.67	75.00	91.67	100.0			
	ADA	79	74.00	23.364	16.7	50.00	75.00	100.00	100.0			
	TOT	161	74.79	21.024	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	82	67.12	24.428	8.3	50.00	75.00	87.50	100.0			
	ADA	79	73.63	23.206	16.7	50.00	75.00	100.00	100.0			
	TOT	161	70.32	23.984	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	82	-8.43	18.344	-66.7	-16.67	-8.33	0.00	33.3			
	ADA	79	-0.37	13.009	-33.3	-8.33	0.00	0.00	50.0			
	TOT	161	-4.48	16.408	-66.7	-8.33	0.00	0.00	50.0			
										8.07	(3.10, 13.03)	0.002A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	82	76.68	19.288	16.7	66.67	83.33	91.67	100.0			
	ADA	79	76.05	22.093	12.5	58.33	83.33	100.00	100.0			
	TOT	161	76.37	20.649	12.5	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	82	71.09	24.404	8.3	58.33	75.00	91.67	100.0			
	ADA	79	74.58	23.566	16.7	58.33	75.00	100.00	100.0			
	TOT	161	72.80	23.986	8.3	58.33	75.00	91.67	100.0			
CHG FROM BEST*	PLO	82	-5.59	14.702	-50.0	-16.67	0.00	0.00	41.7			
	ADA	79	-1.48	10.550	-33.3	-8.33	0.00	0.00	25.0			
	TOT	161	-3.57	12.959	-50.0	-8.33	0.00	0.00	41.7			
										4.11	(0.12, 8.11)	0.044A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	82	88.72	17.415	25.0	87.50	100.00	100.00	100.0			
	ADA	79	89.40	18.135	37.5	87.50	100.00	100.00	100.0			
	TOT	161	89.05	17.719	25.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	82.01	22.745	12.5	75.00	87.50	100.00	100.0			
	ADA	79	85.05	21.521	25.0	75.00	100.00	100.00	100.0			
	TOT	161	83.50	22.136	12.5	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-6.71	14.593	-50.0	-12.50	0.00	0.00	25.0			
	ADA	79	-4.35	11.644	-50.0	-12.50	0.00	0.00	25.0			
	TOT	161	-5.55	13.240	-50.0	-12.50	0.00	0.00	25.0			
										2.36	(-1.76, 6.47)	0.260A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	82	68.29	23.749	0.0	50.00	75.00	87.50	100.0			
	ADA	79	69.01	22.627	12.5	50.00	75.00	87.50	100.0			
	TOT	161	68.65	23.136	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	82	62.65	27.383	0.0	50.00	68.75	87.50	100.0			
	ADA	79	70.57	24.620	12.5	56.25	75.00	93.75	100.0			
	TOT	161	66.54	26.284	0.0	50.00	75.00	87.50	100.0			
CHG FROM BEST*	PLO	82	-5.64	18.021	-75.0	-12.50	0.00	6.25	18.8			
	ADA	79	1.56	14.501	-43.8	-6.25	0.00	12.50	43.8			
	TOT	161	-2.11	16.732	-75.0	-6.25	0.00	6.25	43.8			
										7.20	(2.09, 12.30)	0.006A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	82	71.65	26.061	12.5	50.00	75.00	100.00	100.0			
	ADA	79	72.31	25.763	0.0	50.00	75.00	100.00	100.0			
	TOT	161	71.97	25.837	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	61.74	30.260	0.0	37.50	75.00	87.50	100.0			
	ADA	79	70.89	29.056	0.0	50.00	75.00	100.00	100.0			
	TOT	161	66.23	29.936	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-9.91	19.714	-75.0	-25.00	0.00	0.00	37.5			
	ADA	79	-1.42	19.301	-75.0	0.00	0.00	12.50	37.5			
	TOT	161	-5.75	19.912	-75.0	-12.50	0.00	0.00	37.5			
										8.48	(2.41, 14.56)	0.006A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	82	81.81	24.987	0.0	75.00	91.67	100.00	100.0			
	ADA	79	83.86	23.771	0.0	66.67	100.00	100.00	100.0			
	TOT	161	82.82	24.344	0.0	66.67	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	73.68	30.188	0.0	58.33	83.33	100.00	100.0			
	ADA	79	82.38	25.035	16.7	66.67	100.00	100.00	100.0			
	TOT	161	77.95	28.035	0.0	66.67	91.67	100.00	100.0			
CHG FROM BEST*	PLO	82	-8.13	19.065	-75.0	-16.67	0.00	0.00	50.0			
	ADA	79	-1.48	16.919	-66.7	-8.33	0.00	0.00	58.3			
	TOT	161	-4.87	18.294	-75.0	-8.33	0.00	0.00	58.3			
										6.65	(1.04, 12.27)	0.021A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	75	67.39	29.585	0.0	50.00	75.00	91.67	100.0			
	ADA	74	69.54	27.647	0.0	50.00	83.33	91.67	100.0			
	TOT	149	68.46	28.562	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	75	57.50	32.369	0.0	33.33	66.67	83.33	100.0			
	ADA	74	66.50	29.986	0.0	50.00	75.00	83.33	100.0			
	TOT	149	61.97	31.429	0.0	41.67	75.00	83.33	100.0			
CHG FROM BEST*	PLO	75	-9.89	21.288	-75.0	-16.67	-8.33	0.00	50.0			
	ADA	74	-3.04	13.000	-41.7	-8.33	0.00	0.00	33.3			
	TOT	149	-6.49	17.937	-75.0	-16.67	0.00	0.00	50.0			
										6.85	(1.13, 12.57)	0.019A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	82	93.90	12.766	50.0	100.00	100.00	100.00	100.0			
	ADA	79	94.62	11.087	50.0	100.00	100.00	100.00	100.0			
	TOT	161	94.25	11.940	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	90.55	16.499	50.0	75.00	100.00	100.00	100.0			
	ADA	79	90.51	16.652	25.0	75.00	100.00	100.00	100.0			
	TOT	161	90.53	16.523	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-3.35	12.887	-50.0	0.00	0.00	0.00	25.0			
	ADA	79	-4.11	15.207	-75.0	0.00	0.00	0.00	25.0			
	TOT	161	-3.73	14.034	-75.0	0.00	0.00	0.00	25.0			
										-0.76	(-5.14, 3.62)	0.732A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	82	79.57	22.949	25.0	75.00	75.00	100.00	100.0			
	ADA	78	80.77	24.483	25.0	75.00	100.00	100.00	100.0			
	TOT	160	80.16	23.642	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	74.39	24.208	0.0	50.00	75.00	100.00	100.0			
	ADA	78	77.24	26.169	25.0	75.00	75.00	100.00	100.0			
	TOT	160	75.78	25.145	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-5.18	16.545	-50.0	-25.00	0.00	0.00	50.0			
	ADA	78	-3.53	16.963	-50.0	0.00	0.00	0.00	25.0			
	TOT	160	-4.38	16.718	-50.0	-12.50	0.00	0.00	50.0			
										1.66	(-3.58, 6.89)	0.532A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	82	76.23	16.645	25.7	64.62	79.09	90.11	98.7			
	ADA	79	76.46	17.343	31.5	62.77	82.73	91.82	100.0			
	TOT	161	76.34	16.938	25.7	63.71	80.19	90.80	100.0			
FINAL/ET VALUE	PLO	82	70.38	19.693	21.1	58.94	74.05	87.65	100.0			
	ADA	79	76.55	18.887	29.6	63.22	83.22	93.07	99.4			
	TOT	161	73.41	19.488	21.1	62.08	75.64	90.49	100.0			
CHG FROM BEST*	PLO	82	-5.85	11.758	-48.0	-9.85	-2.84	2.20	19.7			
	ADA	79	0.09	8.273	-38.0	-3.71	0.19	3.79	17.9			
	TOT	161	-2.94	10.594	-48.0	-7.39	-1.06	2.65	19.7			
										5.94	(2.77, 9.12)	<0.001A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	28	66.96	27.262	25.0	50.00	75.00	100.00	100.0			
	ADA	30	63.33	19.402	25.0	50.00	62.50	75.00	100.0			
	TOT	58	65.09	23.386	25.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	28	48.21	33.972	0.0	25.00	50.00	75.00	100.0			
	ADA	30	50.00	24.565	0.0	25.00	50.00	75.00	100.0			
	TOT	58	49.14	29.232	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	28	-18.75	25.115	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	30	-13.33	19.402	-50.0	-25.00	-12.50	0.00	25.0			
	TOT	58	-15.95	22.311	-100.0	-25.00	-25.00	0.00	25.0			
										5.42	(-6.34, 17.18)	0.360A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	28	70.00	18.459	40.0	60.00	80.00	80.00	100.0			
	ADA	29	65.52	17.645	20.0	60.00	60.00	80.00	100.0			
	TOT	57	67.72	18.029	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	28	65.71	23.637	20.0	50.00	60.00	80.00	100.0			
	ADA	29	53.10	20.891	20.0	40.00	60.00	60.00	80.0			
	TOT	57	59.30	22.980	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	28	-4.29	18.344	-60.0	-20.00	0.00	0.00	20.0			
	ADA	29	-12.41	20.293	-60.0	-20.00	0.00	0.00	20.0			
	TOT	57	-8.42	19.620	-60.0	-20.00	0.00	0.00	20.0			
										-8.13	(-18.41, 2.15)	0.119A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	28	89.73	15.977	37.5	81.25	100.00	100.00	100.0			
	ADA	30	85.83	18.492	25.0	75.00	93.75	100.00	100.0			
	TOT	58	87.72	17.284	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	78.13	24.913	12.5	62.50	87.50	100.00	100.0			
	ADA	30	77.08	21.295	25.0	62.50	75.00	100.00	100.0			
	TOT	58	77.59	22.913	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	28	-11.61	22.548	-87.5	-12.50	-6.25	0.00	12.5			
	ADA	30	-8.75	22.057	-75.0	-25.00	0.00	0.00	25.0			
	TOT	58	-10.13	22.146	-87.5	-25.00	0.00	0.00	25.0			
										2.86	(-8.88, 14.59)	0.628A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	28	76.49	26.455	25.0	62.50	83.33	100.00	100.0			
	ADA	30	74.17	24.207	16.7	50.00	79.17	91.67	100.0			
	TOT	58	75.29	25.120	16.7	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	28	71.13	30.045	8.3	50.00	75.00	100.00	100.0			
	ADA	30	62.36	24.964	25.0	41.67	58.33	83.33	100.0			
	TOT	58	66.59	27.644	8.3	41.67	66.67	91.67	100.0			
CHG FROM BEST*	PLO	28	-5.36	16.231	-41.7	-16.67	-4.17	0.00	41.7			
	ADA	30	-11.81	21.445	-66.7	-16.67	-8.33	0.00	16.7			
	TOT	58	-8.69	19.218	-66.7	-16.67	-8.33	0.00	41.7			
										-6.45	(-16.51, 3.61)	0.204A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	28	75.60	25.853	25.0	50.00	83.33	100.00	100.0			
	ADA	30	72.50	22.199	16.7	50.00	75.00	91.67	100.0			
	TOT	58	73.99	23.870	16.7	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	69.49	32.156	16.7	41.67	75.00	100.00	100.0			
	ADA	30	60.35	27.868	16.7	33.33	66.67	83.33	100.0			
	TOT	58	64.76	30.103	16.7	33.33	66.67	100.00	100.0			
CHG FROM BEST*	PLO	28	-6.10	14.276	-50.0	-8.33	0.00	0.00	16.7			
	ADA	30	-12.15	18.212	-66.7	-16.67	-8.33	0.00	8.3			
	TOT	58	-9.23	16.571	-66.7	-16.67	-4.17	0.00	16.7			
										-6.05	(-14.70, 2.60)	0.167A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	28	87.95	19.977	37.5	75.00	100.00	100.00	100.0			
	ADA	30	84.17	20.483	25.0	75.00	93.75	100.00	100.0			
	TOT	58	85.99	20.153	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	81.70	27.530	12.5	75.00	100.00	100.00	100.0			
	ADA	30	77.08	23.231	12.5	62.50	81.25	100.00	100.0			
	TOT	58	79.31	25.278	12.5	62.50	87.50	100.00	100.0			
CHG FROM BEST*	PLO	28	-6.25	18.789	-62.5	-12.50	0.00	0.00	37.5			
	ADA	30	-7.08	15.975	-50.0	-12.50	0.00	0.00	37.5			
	TOT	58	-6.68	17.240	-62.5	-12.50	0.00	0.00	37.5			
										-0.83	(-9.99, 8.32)	0.856A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	28	70.76	26.300	6.3	50.00	75.00	90.63	100.0			
	ADA	30	62.29	25.873	0.0	43.75	65.63	87.50	100.0			
	TOT	58	66.38	26.200	0.0	43.75	71.88	87.50	100.0			
FINAL/ET VALUE	PLO	28	66.52	33.774	0.0	31.25	78.13	93.75	100.0			
	ADA	30	57.01	28.199	0.0	31.25	59.38	81.25	100.0			
	TOT	58	61.60	31.110	0.0	31.25	68.75	93.75	100.0			
CHG FROM BEST*	PLO	28	-4.24	18.946	-56.3	-6.25	0.00	0.00	31.3			
	ADA	30	-5.28	20.622	-62.5	-12.50	-4.17	6.25	31.3			
	TOT	58	-4.78	19.664	-62.5	-12.50	-1.04	0.00	31.3			
										-1.04	(-11.48, 9.40)	0.843A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	28	74.55	27.319	12.5	50.00	75.00	100.00	100.0			
	ADA	30	66.67	25.708	0.0	50.00	62.50	87.50	100.0			
	TOT	58	70.47	26.563	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	70.98	30.057	0.0	50.00	75.00	100.00	100.0			
	ADA	30	58.33	33.850	0.0	37.50	62.50	87.50	100.0			
	TOT	58	64.44	32.428	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	28	-3.57	18.589	-50.0	-12.50	0.00	0.00	50.0			
	ADA	30	-8.33	32.552	-87.5	-37.50	0.00	12.50	50.0			
	TOT	58	-6.03	26.619	-87.5	-25.00	0.00	0.00	50.0			
										-4.76	(-18.84, 9.32)	0.501A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	28	83.63	25.608	16.7	75.00	100.00	100.00	100.0			
	ADA	30	78.06	27.376	0.0	66.67	91.67	100.00	100.0			
	TOT	58	80.75	26.454	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	28	76.64	33.069	0.0	45.83	100.00	100.00	100.0			
	ADA	30	70.83	33.459	0.0	58.33	75.00	100.00	100.0			
	TOT	58	73.64	33.108	0.0	50.00	91.67	100.00	100.0			
CHG FROM BEST*	PLO	28	-6.99	20.256	-66.7	-12.50	0.00	0.00	29.2			
	ADA	30	-7.22	20.846	-75.0	-16.67	0.00	0.00	33.3			
	TOT	58	-7.11	20.383	-75.0	-16.67	0.00	0.00	33.3			
										-0.23	(-11.05, 10.60)	0.966A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	24	67.36	36.192	0.0	45.83	83.33	100.00	100.0			
	ADA	25	58.50	34.537	0.0	41.67	66.67	83.33	100.0			
	TOT	49	62.84	35.272	0.0	41.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	24	60.42	37.450	0.0	33.33	70.83	100.00	100.0			
	ADA	25	49.00	35.135	0.0	16.67	50.00	75.00	100.0			
	TOT	49	54.59	36.366	0.0	25.00	58.33	83.33	100.0			
CHG FROM BEST*	PLO	24	-6.94	17.834	-58.3	-16.67	0.00	0.00	33.3			
	ADA	25	-9.50	21.568	-66.7	-16.67	-8.33	0.00	50.0			
	TOT	49	-8.25	19.663	-66.7	-16.67	0.00	0.00	50.0			
										-2.56	(-13.95, 8.84)	0.654A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	28	95.54	11.890	50.0	100.00	100.00	100.00	100.0			
	ADA	30	90.00	16.867	25.0	75.00	100.00	100.00	100.0			
	TOT	58	92.67	14.815	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	94.20	15.768	25.0	100.00	100.00	100.00	100.0			
	ADA	30	86.67	19.402	50.0	75.00	100.00	100.00	100.0			
	TOT	58	90.30	17.992	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	28	-1.34	8.566	-25.0	0.00	0.00	0.00	25.0			
	ADA	30	-3.33	17.036	-50.0	0.00	0.00	0.00	25.0			
	TOT	58	-2.37	13.543	-50.0	0.00	0.00	0.00	25.0			
										-1.99	(-9.17, 5.18)	0.580A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	28	82.59	21.874	50.0	56.25	100.00	100.00	100.0			
	ADA	30	78.33	21.509	25.0	75.00	75.00	100.00	100.0			
	TOT	58	80.39	21.601	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	28	75.89	27.624	25.0	50.00	75.00	100.00	100.0			
	ADA	30	66.67	23.973	25.0	50.00	75.00	75.00	100.0			
	TOT	58	71.12	25.990	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	28	-6.70	16.833	-75.0	0.00	0.00	0.00	12.5			
	ADA	30	-11.67	19.402	-50.0	-25.00	0.00	0.00	25.0			
	TOT	58	-9.27	18.221	-75.0	-25.00	0.00	0.00	25.0			
										-4.97	(-14.56, 4.61)	0.303A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.1.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NON-WHITE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	28	77.43	20.223	39.2	64.80	84.64	95.15	98.2			
	ADA	30	71.53	20.075	14.7	56.14	73.01	91.17	98.2			
	TOT	58	74.38	20.189	14.7	57.50	78.67	91.74	98.2			
FINAL/ET VALUE	PLO	28	73.57	24.839	27.6	47.06	79.75	95.28	100.0			
	ADA	30	65.19	21.600	18.5	50.91	65.11	84.81	97.6			
	TOT	58	69.24	23.398	18.5	50.42	74.29	92.25	100.0			
CHG FROM BEST*	PLO	28	-3.86	12.398	-44.4	-7.61	-1.52	2.94	20.6			
	ADA	30	-6.34	15.144	-39.0	-12.42	-4.22	0.63	25.8			
	TOT	58	-5.14	13.822	-44.4	-8.52	-3.13	2.92	25.8			
										-2.48	(-9.79, 4.83)	0.500A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	12	72.92	24.905	25.0	50.00	75.00	100.00	100.0
	ADA	11	68.18	16.167	50.0	50.00	75.00	75.00	100.0
	TOT	23	70.65	20.851	25.0	50.00	75.00	75.00	100.0
FINAL/ET VALUE	PLO	12	56.25	38.620	0.0	25.00	50.00	100.00	100.0
	ADA	11	54.55	24.541	0.0	50.00	50.00	75.00	75.0
	TOT	23	55.43	31.941	0.0	25.00	50.00	75.00	100.0
CHG FROM BEST*	PLO	12	-16.67	26.827	-50.0	-37.50	-25.00	0.00	25.0
	ADA	11	-13.64	20.505	-50.0	-25.00	-25.00	0.00	25.0
	TOT	23	-15.22	23.524	-50.0	-25.00	-25.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	12	73.33	17.753	40.0	60.00	80.00	80.00	100.0
	ADA	11	61.82	16.624	20.0	60.00	60.00	80.00	80.0
	TOT	23	67.83	17.827	20.0	60.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	12	68.33	28.868	20.0	40.00	70.00	100.00	100.0
	ADA	11	52.73	20.538	20.0	40.00	60.00	60.00	80.0
	TOT	23	60.87	25.922	20.0	40.00	60.00	80.00	100.0
CHG FROM BEST*	PLO	12	-5.00	17.321	-40.0	-20.00	0.00	0.00	20.0
	ADA	11	-9.09	24.271	-60.0	-20.00	0.00	0.00	20.0
	TOT	23	-6.96	20.546	-60.0	-20.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	12	88.54	20.267	37.5	81.25	100.00	100.00	100.0
	ADA	11	84.09	25.673	25.0	75.00	100.00	100.00	100.0
	TOT	23	86.41	22.586	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	12	69.79	30.831	12.5	50.00	75.00	100.00	100.0
	ADA	11	76.14	27.644	25.0	50.00	75.00	100.00	100.0
	TOT	23	72.83	28.864	12.5	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	12	-18.75	30.850	-87.5	-18.75	-12.50	0.00	12.5
	ADA	11	-7.95	28.653	-75.0	-25.00	0.00	12.50	25.0
	TOT	23	-13.59	29.655	-87.5	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	12	77.08	25.899	33.3	58.33	83.33	100.00	100.0
	ADA	11	64.39	25.574	16.7	41.67	66.67	91.67	100.0
	TOT	23	71.01	25.975	16.7	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	12	66.67	31.583	25.0	33.33	66.67	100.00	100.0
	ADA	11	51.89	24.107	25.0	25.00	54.17	75.00	91.7
	TOT	23	59.60	28.632	25.0	33.33	54.17	91.67	100.0
CHG FROM BEST*	PLO	12	-10.42	16.714	-41.7	-20.83	-4.17	0.00	16.7
	ADA	11	-12.50	29.988	-66.7	-50.00	-4.17	16.67	16.7
	TOT	23	-11.41	23.443	-66.7	-25.00	-4.17	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	12	75.00	29.085	25.0	45.83	91.67	100.00	100.0
	ADA	11	62.50	24.224	16.7	50.00	62.50	83.33	100.0
	TOT	23	69.02	27.027	16.7	50.00	75.00	91.67	100.0
FINAL/ET VALUE	PLO	12	65.28	37.240	16.7	25.00	79.17	100.00	100.0
	ADA	11	46.97	27.201	16.7	25.00	33.33	75.00	100.0
	TOT	23	56.52	33.424	16.7	25.00	41.67	100.00	100.0
CHG FROM BEST*	PLO	12	-9.72	16.603	-50.0	-16.67	-8.33	0.00	8.3
	ADA	11	-15.53	21.416	-66.7	-25.00	-16.67	0.00	8.3
	TOT	23	-12.50	18.844	-66.7	-25.00	-8.33	0.00	8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	12	87.50	21.976	37.5	81.25	100.00	100.00	100.0
	ADA	11	79.55	25.170	25.0	62.50	87.50	100.00	100.0
	TOT	23	83.70	23.366	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	12	77.08	31.003	12.5	56.25	93.75	100.00	100.0
	ADA	11	65.91	25.057	12.5	50.00	75.00	75.00	100.0
	TOT	23	71.74	28.258	12.5	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	12	-10.42	22.508	-62.5	-18.75	0.00	0.00	25.0
	ADA	11	-13.64	16.254	-50.0	-25.00	-12.50	0.00	0.0
	TOT	23	-11.96	19.394	-62.5	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	12	68.75	33.710	6.3	40.63	81.25	96.88	100.0
	ADA	11	53.41	30.792	0.0	31.25	43.75	81.25	100.0
	TOT	23	61.41	32.566	0.0	31.25	75.00	87.50	100.0
FINAL/ET VALUE	PLO	12	60.94	43.229	0.0	18.75	90.63	96.88	100.0
	ADA	11	51.14	28.616	0.0	25.00	56.25	68.75	100.0
	TOT	23	56.25	36.492	0.0	18.75	62.50	93.75	100.0
CHG FROM BEST*	PLO	12	-7.81	20.492	-56.3	-15.63	0.00	0.00	18.8
	ADA	11	-2.27	20.591	-43.8	-12.50	0.00	12.50	31.3
	TOT	23	-5.16	20.266	-56.3	-12.50	0.00	6.25	31.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	12	78.13	32.036	12.5	62.50	100.00	100.00	100.0
	ADA	11	61.36	30.850	0.0	50.00	62.50	87.50	100.0
	TOT	23	70.11	31.922	0.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	12	69.79	35.539	0.0	43.75	87.50	100.00	100.0
	ADA	11	50.00	33.072	0.0	25.00	50.00	75.00	100.0
	TOT	23	60.33	35.084	0.0	37.50	50.00	100.00	100.0
CHG FROM BEST*	PLO	12	-8.33	17.944	-50.0	-18.75	0.00	0.00	12.5
	ADA	11	-11.36	35.113	-87.5	-37.50	0.00	0.00	37.5
	TOT	23	-9.78	26.904	-87.5	-25.00	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	12	82.64	29.400	16.7	66.67	100.00	100.00	100.0
	ADA	11	64.39	32.933	0.0	33.33	75.00	91.67	100.0
	TOT	23	73.91	31.812	0.0	50.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	12	68.06	39.701	0.0	29.17	95.83	100.00	100.0
	ADA	11	56.06	34.579	0.0	25.00	58.33	75.00	100.0
	TOT	23	62.32	37.002	0.0	25.00	66.67	100.00	100.0
CHG FROM BEST*	PLO	12	-14.58	23.335	-66.7	-25.00	0.00	0.00	8.3
	ADA	11	-8.33	19.720	-33.3	-25.00	-8.33	0.00	33.3
	TOT	23	-11.59	21.429	-66.7	-25.00	0.00	0.00	33.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	11	71.97	32.548	0.0	41.67	83.33	100.00	100.0
	ADA	10	47.50	31.926	0.0	25.00	54.17	66.67	100.0
	TOT	21	60.32	33.840	0.0	41.67	58.33	91.67	100.0
FINAL/ET VALUE	PLO	11	62.12	40.374	0.0	33.33	75.00	100.00	100.0
	ADA	10	34.17	30.289	0.0	16.67	29.17	50.00	100.0
	TOT	21	48.81	37.849	0.0	16.67	41.67	91.67	100.0
CHG FROM BEST*	PLO	11	-9.85	21.350	-58.3	-8.33	0.00	0.00	16.7
	ADA	10	-13.33	33.148	-66.7	-41.67	-8.33	0.00	50.0
	TOT	21	-11.51	26.936	-66.7	-16.67	-8.33	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	12	97.92	7.217	75.0	100.00	100.00	100.00	100.0
	ADA	11	81.82	22.613	25.0	75.00	75.00	100.00	100.0
	TOT	23	90.22	18.058	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	12	98.96	3.608	87.5	100.00	100.00	100.00	100.0
	ADA	11	81.82	19.656	50.0	75.00	75.00	100.00	100.0
	TOT	23	90.76	16.086	50.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	12	1.04	8.357	-12.5	0.00	0.00	0.00	25.0
	ADA	11	0.00	19.365	-25.0	-25.00	0.00	25.00	25.0
	TOT	23	0.54	14.341	-25.0	0.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	12	80.21	22.271	50.0	56.25	87.50	100.00	100.0
	ADA	11	68.18	25.226	25.0	50.00	75.00	75.00	100.0
	TOT	23	74.46	23.979	25.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	12	70.83	31.683	25.0	37.50	75.00	100.00	100.0
	ADA	11	61.36	23.355	25.0	50.00	75.00	75.00	100.0
	TOT	23	66.30	27.807	25.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	12	-9.38	23.309	-75.0	-12.50	0.00	0.00	12.5
	ADA	11	-6.82	16.167	-50.0	0.00	0.00	0.00	0.0
	TOT	23	-8.15	19.803	-75.0	0.00	0.00	0.00	12.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.2.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=BLACK)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	12	78.33	23.359	39.2	59.30	89.74	96.48	98.2
	ADA	11	62.60	23.117	14.7	50.42	63.03	72.31	98.2
	TOT	23	70.81	24.090	14.7	50.42	72.31	95.08	98.2
FINAL/ET VALUE	PLO	12	70.24	29.707	30.5	39.05	83.69	96.25	100.0
	ADA	11	56.83	21.034	18.5	50.91	53.07	76.21	93.3
	TOT	23	63.83	26.255	18.5	40.57	56.48	93.33	100.0
CHG FROM BEST*	PLO	12	-8.09	15.052	-44.4	-8.45	-3.09	0.72	4.9
	ADA	11	-5.77	20.368	-39.0	-20.08	-4.85	10.80	25.8
	TOT	23	-6.98	17.414	-44.4	-8.64	-4.47	3.79	25.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	10	55.00	30.732	25.0	25.00	50.00	75.00	100.0
	ADA	12	54.17	20.871	25.0	50.00	50.00	62.50	100.0
	TOT	22	54.55	25.162	25.0	25.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	10	32.50	28.988	0.0	25.00	25.00	50.00	100.0
	ADA	12	41.67	26.827	0.0	25.00	37.50	50.00	100.0
	TOT	22	37.50	27.549	0.0	25.00	25.00	50.00	100.0
CHG FROM BEST*	PLO	10	-22.50	29.930	-100.0	-25.00	-25.00	0.00	0.0
	ADA	12	-12.50	19.943	-50.0	-25.00	-12.50	0.00	25.0
	TOT	22	-17.05	24.864	-100.0	-25.00	-25.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	10	62.00	22.010	40.0	40.00	60.00	80.00	100.0
	ADA	12	61.67	18.007	40.0	40.00	60.00	80.00	80.0
	TOT	22	61.82	19.429	40.0	40.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	10	56.00	18.379	20.0	40.00	60.00	60.00	80.0
	ADA	12	50.00	20.000	20.0	40.00	50.00	60.00	80.0
	TOT	22	52.73	19.069	20.0	40.00	60.00	60.00	80.0
CHG FROM BEST*	PLO	10	-6.00	23.190	-60.0	-20.00	0.00	0.00	20.0
	ADA	12	-11.67	15.859	-40.0	-20.00	0.00	0.00	0.0
	TOT	22	-9.09	19.250	-60.0	-20.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	10	95.00	8.740	75.0	87.50	100.00	100.00	100.0
	ADA	12	90.63	10.825	75.0	81.25	93.75	100.00	100.0
	TOT	22	92.61	9.955	75.0	87.50	100.00	100.00	100.0
FINAL/ET VALUE	PLO	10	83.75	17.727	50.0	75.00	87.50	100.00	100.0
	ADA	12	77.08	17.543	50.0	68.75	75.00	93.75	100.0
	TOT	22	80.11	17.534	50.0	75.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	10	-11.25	10.945	-25.0	-25.00	-12.50	0.00	0.0
	ADA	12	-13.54	19.553	-37.5	-31.25	-12.50	0.00	25.0
	TOT	22	-12.50	15.905	-37.5	-25.00	-12.50	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	10	69.17	32.167	25.0	33.33	75.00	100.00	100.0
	ADA	12	73.61	22.426	33.3	58.33	79.17	91.67	100.0
	TOT	22	71.59	26.684	25.0	50.00	79.17	100.00	100.0
FINAL/ET VALUE	PLO	10	67.50	33.206	8.3	50.00	66.67	100.00	100.0
	ADA	12	63.19	23.693	33.3	41.67	62.50	83.33	100.0
	TOT	22	65.15	27.774	8.3	50.00	66.67	91.67	100.0
CHG FROM BEST*	PLO	10	-1.67	16.574	-16.7	-8.33	-4.17	0.00	41.7
	ADA	12	-10.42	12.373	-33.3	-20.83	-8.33	0.00	8.3
	TOT	22	-6.44	14.758	-33.3	-16.67	-8.33	0.00	41.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	10	71.67	27.555	25.0	50.00	70.83	100.00	100.0
	ADA	12	75.69	21.748	41.7	58.33	79.17	95.83	100.0
	TOT	22	73.86	24.028	25.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	10	66.25	32.302	16.7	41.67	62.50	100.00	100.0
	ADA	12	64.58	25.654	25.0	41.67	66.67	87.50	91.7
	TOT	22	65.34	28.154	16.7	41.67	66.67	91.67	100.0
CHG FROM BEST*	PLO	10	-5.42	12.430	-37.5	-8.33	0.00	0.00	8.3
	ADA	12	-11.11	14.794	-50.0	-16.67	-8.33	0.00	8.3
	TOT	22	-8.52	13.758	-50.0	-16.67	-8.33	0.00	8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	10	83.75	22.087	50.0	62.50	100.00	100.00	100.0
	ADA	12	86.46	17.237	50.0	75.00	93.75	100.00	100.0
	TOT	22	85.23	19.147	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	10	78.75	29.492	12.5	62.50	93.75	100.00	100.0
	ADA	12	80.21	23.512	37.5	56.25	87.50	100.00	100.0
	TOT	22	79.55	25.746	12.5	62.50	87.50	100.00	100.0
CHG FROM BEST*	PLO	10	-5.00	19.720	-37.5	-12.50	0.00	0.00	37.5
	ADA	12	-6.25	13.589	-37.5	-12.50	0.00	0.00	12.5
	TOT	22	-5.68	16.242	-37.5	-12.50	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	10	70.63	21.661	37.5	50.00	75.00	87.50	100.0
	ADA	12	70.31	23.556	18.8	59.38	75.00	87.50	93.8
	TOT	22	70.45	22.175	18.8	56.25	75.00	87.50	100.0
FINAL/ET VALUE	PLO	10	64.38	28.421	25.0	31.25	65.63	93.75	100.0
	ADA	12	62.33	30.236	6.3	31.25	73.96	87.50	93.8
	TOT	22	63.26	28.742	6.3	31.25	70.83	87.50	100.0
CHG FROM BEST*	PLO	10	-6.25	18.634	-37.5	-18.75	-6.25	0.00	31.3
	ADA	12	-7.99	21.611	-62.5	-12.50	-4.17	0.00	31.3
	TOT	22	-7.20	19.855	-62.5	-12.50	-6.25	0.00	31.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	10	70.00	25.820	25.0	50.00	75.00	87.50	100.0
	ADA	12	72.92	21.209	50.0	50.00	68.75	93.75	100.0
	TOT	22	71.59	22.881	25.0	50.00	75.00	87.50	100.0
FINAL/ET VALUE	PLO	10	65.00	28.137	12.5	50.00	68.75	87.50	100.0
	ADA	12	63.54	33.903	0.0	43.75	62.50	93.75	100.0
	TOT	22	64.20	30.690	0.0	50.00	62.50	87.50	100.0
CHG FROM BEST*	PLO	10	-5.00	16.874	-37.5	-12.50	0.00	0.00	25.0
	ADA	12	-9.38	32.910	-62.5	-37.50	-6.25	6.25	50.0
	TOT	22	-7.39	26.350	-62.5	-25.00	0.00	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	10	80.00	26.411	33.3	66.67	91.67	100.00	100.0
	ADA	12	84.03	23.154	25.0	75.00	95.83	100.00	100.0
	TOT	22	82.20	24.165	25.0	75.00	91.67	100.00	100.0
FINAL/ET VALUE	PLO	10	74.17	30.543	25.0	41.67	91.67	100.00	100.0
	ADA	12	77.08	30.799	16.7	58.33	95.83	100.00	100.0
	TOT	22	75.76	29.981	16.7	50.00	91.67	100.00	100.0
CHG FROM BEST*	PLO	10	-5.83	17.146	-50.0	-8.33	0.00	0.00	8.3
	ADA	12	-6.94	15.421	-41.7	-16.67	0.00	0.00	16.7
	TOT	22	-6.44	15.839	-50.0	-16.67	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	9	56.48	45.219	0.0	0.00	75.00	100.00	100.0
	ADA	9	60.19	37.680	0.0	41.67	75.00	83.33	100.0
	TOT	18	58.33	40.423	0.0	0.00	75.00	91.67	100.0
FINAL/ET VALUE	PLO	9	53.70	39.772	0.0	33.33	50.00	83.33	100.0
	ADA	9	54.63	35.870	0.0	25.00	75.00	83.33	83.3
	TOT	18	54.17	36.743	0.0	25.00	70.83	83.33	100.0
CHG FROM BEST*	PLO	9	-2.78	16.667	-25.0	-16.67	0.00	0.00	33.3
	ADA	9	-5.56	9.317	-16.7	-16.67	0.00	0.00	8.3
	TOT	18	-4.17	13.176	-25.0	-16.67	0.00	0.00	33.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	10	92.50	16.874	50.0	100.00	100.00	100.00	100.0
	ADA	12	93.75	11.307	75.0	87.50	100.00	100.00	100.0
	TOT	22	93.18	13.762	50.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	10	87.50	24.296	25.0	75.00	100.00	100.00	100.0
	ADA	12	85.42	22.508	50.0	62.50	100.00	100.00	100.0
	TOT	22	86.36	22.792	25.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	10	-5.00	10.541	-25.0	0.00	0.00	0.00	0.0
	ADA	12	-8.33	19.462	-50.0	-25.00	0.00	0.00	25.0
	TOT	22	-6.82	15.777	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	10	80.00	25.820	50.0	50.00	100.00	100.00	100.0
	ADA	12	83.33	19.462	50.0	75.00	87.50	100.00	100.0
	TOT	22	81.82	22.068	50.0	50.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	10	72.50	27.513	25.0	50.00	75.00	100.00	100.0
	ADA	12	68.75	26.382	25.0	50.00	62.50	100.00	100.0
	TOT	22	70.45	26.318	25.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	10	-7.50	12.076	-25.0	-25.00	0.00	0.00	0.0
	ADA	12	-14.58	22.508	-50.0	-25.00	-12.50	0.00	25.0
	TOT	22	-11.36	18.464	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.3.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=ASIAN)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	10	73.09	21.317	43.6	54.39	77.39	94.20	95.5
	ADA	12	75.05	17.811	49.2	54.41	78.92	91.27	95.5
	TOT	22	74.16	19.024	43.6	54.39	78.92	91.36	95.5
FINAL/ET VALUE	PLO	10	69.72	23.369	27.6	50.42	78.24	88.48	94.7
	ADA	12	68.12	22.215	29.7	45.63	71.66	87.84	92.9
	TOT	22	68.85	22.208	27.6	48.03	73.71	88.48	94.7
CHG FROM BEST*	PLO	10	-3.37	10.293	-16.0	-8.52	-3.48	-0.19	20.6
	ADA	12	-6.92	10.036	-26.4	-11.38	-5.68	-2.75	13.4
	TOT	22	-5.31	10.072	-26.4	-9.47	-5.30	-0.57	20.6

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	0							
	TOT	1	50.00		50.0	50.00	50.00	50.00	50.0
FINAL/ET VALUE	PLO	1	25.00		25.0	25.00	25.00	25.00	25.0
	ADA	0							
	TOT	1	25.00		25.0	25.00	25.00	25.00	25.0
CHG FROM BEST*	PLO	1	-25.00		-25.0	-25.00	-25.00	-25.00	-25.0
	ADA	0							
	TOT	1	-25.00		-25.0	-25.00	-25.00	-25.00	-25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	1	60.00		60.0	60.00	60.00	60.00	60.0
	ADA	0							
	TOT	1	60.00		60.0	60.00	60.00	60.00	60.0
FINAL/ET VALUE	PLO	1	60.00		60.0	60.00	60.00	60.00	60.0
	ADA	0							
	TOT	1	60.00		60.0	60.00	60.00	60.00	60.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	87.50		87.5	87.50	87.50	87.50	87.5
	ADA	0							
	TOT	1	87.50		87.5	87.50	87.50	87.50	87.5
CHG FROM BEST*	PLO	1	12.50		12.5	12.50	12.50	12.50	12.5
	ADA	0							
	TOT	1	12.50		12.5	12.50	12.50	12.50	12.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	66.67		66.7	66.67	66.67	66.67	66.7
	ADA	0							
	TOT	1	66.67		66.7	66.67	66.67	66.67	66.7
CHG FROM BEST*	PLO	1	-8.33		-8.3	-8.33	-8.33	-8.33	-8.3
	ADA	0							
	TOT	1	-8.33		-8.3	-8.33	-8.33	-8.33	-8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	1	58.33		58.3	58.33	58.33	58.33	58.3
	ADA	0							
	TOT	1	58.33		58.3	58.33	58.33	58.33	58.3
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BEST*	PLO	1	16.67		16.7	16.67	16.67	16.67	16.7
	ADA	0							
	TOT	1	16.67		16.7	16.67	16.67	16.67	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	1	68.75		68.8	68.75	68.75	68.75	68.8
	ADA	0							
	TOT	1	68.75		68.8	68.75	68.75	68.75	68.8
FINAL/ET VALUE	PLO	1	62.50		62.5	62.50	62.50	62.50	62.5
	ADA	0							
	TOT	1	62.50		62.5	62.50	62.50	62.50	62.5
CHG FROM BEST*	PLO	1	-6.25		-6.3	-6.25	-6.25	-6.25	-6.3
	ADA	0							
	TOT	1	-6.25		-6.3	-6.25	-6.25	-6.25	-6.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	1	50.00		50.0	50.00	50.00	50.00	50.0
	ADA	0							
	TOT	1	50.00		50.0	50.00	50.00	50.00	50.0
FINAL/ET VALUE	PLO	1	33.33		33.3	33.33	33.33	33.33	33.3
	ADA	0							
	TOT	1	33.33		33.3	33.33	33.33	33.33	33.3
CHG FROM BEST*	PLO	1	-16.67		-16.7	-16.67	-16.67	-16.67	-16.7
	ADA	0							
	TOT	1	-16.67		-16.7	-16.67	-16.67	-16.67	-16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	0							
	TOT	1	100.00		100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
FINAL/ET VALUE	PLO	1	75.00		75.0	75.00	75.00	75.00	75.0
	ADA	0							
	TOT	1	75.00		75.0	75.00	75.00	75.00	75.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	0							
	TOT	1	0.00		0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.4.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=AMERICAN INDIAN/ALASKA NATIVE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	1	70.67		70.7	70.67	70.67	70.67	70.7
	ADA	0							
	TOT	1	70.67		70.7	70.67	70.67	70.67	70.7
FINAL/ET VALUE	PLO	1	75.91		75.9	75.91	75.91	75.91	75.9
	ADA	0							
	TOT	1	75.91		75.9	75.91	75.91	75.91	75.9
CHG FROM BEST*	PLO	1	5.24		5.2	5.24	5.24	5.24	5.2
	ADA	0							
	TOT	1	5.24		5.2	5.24	5.24	5.24	5.2

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.5.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=NATIVE HAWAIIAN OR OTHER PACIFIC ISLANDER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX

** NO DATA IN THIS SEGMENT OR PART OF THIS TABLE. **

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	4	75.00	20.412	50.0	62.50	75.00	87.50	100.0
	ADA	6	70.83	18.819	50.0	50.00	75.00	75.00	100.0
	TOT	10	72.50	18.447	50.0	50.00	75.00	75.00	100.0
FINAL/ET VALUE	PLO	4	56.25	12.500	50.0	50.00	50.00	62.50	75.0
	ADA	6	54.17	18.819	25.0	50.00	50.00	75.00	75.0
	TOT	10	55.00	15.811	25.0	50.00	50.00	75.00	75.0
CHG FROM BEST*	PLO	4	-18.75	12.500	-25.0	-25.00	-25.00	-12.50	0.0
	ADA	6	-16.67	20.412	-50.0	-25.00	-12.50	0.00	0.0
	TOT	10	-17.50	16.874	-50.0	-25.00	-25.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	4	80.00	0.000	80.0	80.00	80.00	80.00	80.0
	ADA	5	80.00	14.142	60.0	80.00	80.00	80.00	100.0
	TOT	9	80.00	10.000	60.0	80.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	4	75.00	10.000	60.0	70.00	80.00	80.00	80.0
	ADA	5	56.00	26.077	20.0	40.00	60.00	80.00	80.0
	TOT	9	64.44	21.858	20.0	60.00	80.00	80.00	80.0
CHG FROM BEST*	PLO	4	-5.00	10.000	-20.0	-10.00	0.00	0.00	0.0
	ADA	5	-24.00	21.909	-60.0	-20.00	-20.00	-20.00	0.0
	TOT	9	-15.56	19.437	-60.0	-20.00	-20.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	4	81.25	16.137	62.5	68.75	81.25	93.75	100.0
	ADA	6	77.08	14.613	62.5	62.50	75.00	87.50	100.0
	TOT	10	78.75	14.494	62.5	62.50	75.00	87.50	100.0
FINAL/ET VALUE	PLO	4	81.25	23.936	50.0	62.50	87.50	100.00	100.0
	ADA	6	75.00	17.678	50.0	62.50	75.00	87.50	100.0
	TOT	10	77.50	19.365	50.0	62.50	75.00	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	10.206	-12.5	-6.25	0.00	6.25	12.5
	ADA	6	-2.08	14.613	-25.0	-12.50	0.00	12.50	12.5
	TOT	10	-1.25	12.430	-25.0	-12.50	0.00	12.50	12.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	4	87.50	14.434	75.0	75.00	87.50	100.00	100.0
	ADA	6	88.89	19.484	50.0	91.67	95.83	100.00	100.0
	TOT	10	88.33	16.759	50.0	75.00	95.83	100.00	100.0
FINAL/ET VALUE	PLO	4	87.50	19.837	58.3	75.00	95.83	100.00	100.0
	ADA	6	73.61	23.224	41.7	50.00	79.17	91.67	100.0
	TOT	10	79.17	21.960	41.7	58.33	87.50	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	18.002	-16.7	-12.50	-4.17	12.50	25.0
	ADA	6	-15.28	21.995	-58.3	-16.67	-8.33	0.00	0.0
	TOT	10	-9.17	20.953	-58.3	-16.67	-8.33	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	4	85.42	12.500	75.0	75.00	83.33	95.83	100.0
	ADA	6	79.86	13.544	62.5	66.67	83.33	83.33	100.0
	TOT	10	82.08	12.737	62.5	75.00	83.33	91.67	100.0
FINAL/ET VALUE	PLO	4	81.25	21.916	58.3	62.50	83.33	100.00	100.0
	ADA	6	69.79	26.801	33.3	43.75	75.00	91.67	100.0
	TOT	10	74.38	24.376	33.3	58.33	75.00	100.00	100.0
CHG FROM BEST*	PLO	4	-4.17	10.758	-16.7	-12.50	-4.17	4.17	8.3
	ADA	6	-10.07	21.506	-50.0	-18.75	0.00	0.00	8.3
	TOT	10	-7.71	17.459	-50.0	-16.67	0.00	0.00	8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	85.42	20.026	50.0	75.00	93.75	100.00	100.0
	TOT	10	88.75	17.129	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	87.50	11.180	75.0	75.00	87.50	100.00	100.0
	TOT	10	90.00	11.487	75.0	75.00	93.75	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	2.08	18.400	-12.5	-12.50	0.00	0.00	37.5
	TOT	10	1.25	13.756	-12.5	0.00	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	4	70.31	18.663	43.8	59.38	75.00	81.25	87.5
	ADA	6	58.33	17.078	31.3	50.00	59.38	68.75	81.3
	TOT	10	63.13	17.788	31.3	50.00	65.63	75.00	87.5
FINAL/ET VALUE	PLO	4	81.25	13.502	68.8	71.88	78.13	90.63	100.0
	ADA	6	53.13	26.146	18.8	37.50	50.00	68.75	93.8
	TOT	10	64.38	25.524	18.8	43.75	68.75	81.25	100.0
CHG FROM BEST*	PLO	4	10.94	16.437	-6.3	-3.13	12.50	25.00	25.0
	ADA	6	-5.21	23.524	-43.8	-12.50	-3.13	6.25	25.0
	TOT	10	1.25	21.611	-43.8	-12.50	3.13	25.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	4	68.75	23.936	50.0	50.00	62.50	87.50	100.0
	ADA	6	58.33	21.890	25.0	50.00	56.25	75.00	87.5
	TOT	10	62.50	22.048	25.0	50.00	56.25	75.00	100.0
FINAL/ET VALUE	PLO	4	81.25	23.936	50.0	62.50	87.50	100.00	100.0
	ADA	6	56.25	36.870	0.0	25.00	68.75	75.00	100.0
	TOT	10	66.25	33.359	0.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	4	12.50	25.000	0.0	0.00	0.00	25.00	50.0
	ADA	6	-2.08	34.836	-50.0	-37.50	6.25	25.00	37.5
	TOT	10	3.75	30.647	-50.0	0.00	0.00	25.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	4	87.50	19.837	58.3	75.00	95.83	100.00	100.0
	ADA	6	87.50	17.280	58.3	75.00	95.83	100.00	100.0
	TOT	10	87.50	17.236	58.3	75.00	95.83	100.00	100.0
FINAL/ET VALUE	PLO	4	96.88	6.250	87.5	93.75	100.00	100.00	100.0
	ADA	6	80.56	34.021	16.7	66.67	100.00	100.00	100.0
	TOT	10	87.08	26.964	16.7	87.50	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	9.38	13.767	0.0	0.00	4.17	18.75	29.2
	ADA	6	-6.94	34.728	-75.0	0.00	0.00	8.33	25.0
	TOT	10	-0.42	28.359	-75.0	0.00	0.00	8.33	29.2

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	2	83.33	0.000	83.3	83.33	83.33	83.33	83.3
	ADA	5	69.17	33.799	12.5	66.67	83.33	83.33	100.0
	TOT	7	73.21	28.449	12.5	66.67	83.33	83.33	100.0
FINAL/ET VALUE	PLO	2	75.00	11.785	66.7	66.67	75.00	83.33	83.3
	ADA	5	58.33	37.268	0.0	50.00	66.67	75.00	100.0
	TOT	7	63.10	31.862	0.0	50.00	66.67	83.33	100.0
CHG FROM BEST*	PLO	2	-8.33	11.785	-16.7	-16.67	-8.33	0.00	0.0
	ADA	5	-10.83	6.972	-16.7	-16.67	-12.50	-8.33	0.0
	TOT	7	-10.12	7.553	-16.7	-16.67	-12.50	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	95.83	10.206	75.0	100.00	100.00	100.00	100.0
	TOT	10	95.00	10.541	75.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	95.83	10.206	75.0	100.00	100.00	100.00	100.0
	TOT	10	95.00	10.541	75.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	TOT	10	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	83.33	12.910	75.0	75.00	75.00	100.00	100.0
	TOT	10	87.50	13.176	75.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	4	93.75	12.500	75.0	87.50	100.00	100.00	100.0
	ADA	6	66.67	20.412	50.0	50.00	62.50	75.00	100.0
	TOT	10	77.50	21.890	50.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	6	-16.67	20.412	-50.0	-25.00	-12.50	0.00	0.0
	TOT	10	-10.00	17.480	-50.0	-25.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.6.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	4	82.10	7.911	70.7	76.87	84.64	87.33	88.4
	ADA	6	76.62	14.294	57.5	60.79	81.65	85.04	93.1
	TOT	10	78.81	11.933	57.5	70.71	83.64	86.25	93.1
FINAL/ET VALUE	PLO	4	86.00	11.996	73.6	75.81	86.19	96.20	98.0
	ADA	6	69.44	18.532	45.9	60.64	64.04	84.36	97.6
	TOT	10	76.07	17.661	45.9	61.46	75.81	94.39	98.0
CHG FROM BEST*	PLO	4	3.90	6.612	-5.0	-1.06	5.53	8.86	9.6
	ADA	6	-7.18	16.428	-38.3	-12.42	-0.41	3.96	4.5
	TOT	10	-2.74	14.044	-38.3	-5.04	1.38	4.55	9.6

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	75.00		75.0	75.00	75.00	75.00	75.0
	TOT	2	87.50	17.678	75.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	75.00		75.0	75.00	75.00	75.00	75.0
	TOT	2	87.50	17.678	75.0	75.00	87.50	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	1	80.00		80.0	80.00	80.00	80.00	80.0
	ADA	1	80.00		80.0	80.00	80.00	80.00	80.0
	TOT	2	80.00	0.000	80.0	80.00	80.00	80.00	80.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	80.00		80.0	80.00	80.00	80.00	80.0
	TOT	2	90.00	14.142	80.0	80.00	90.00	100.00	100.0
CHG FROM BEST*	PLO	1	20.00		20.0	20.00	20.00	20.00	20.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	10.00	14.142	0.0	0.00	10.00	20.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	87.50		87.5	87.50	87.50	87.50	87.5
	TOT	2	93.75	8.839	87.5	87.50	93.75	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	81.25		81.3	81.25	81.25	81.25	81.3
	TOT	2	90.63	13.258	81.3	81.25	90.63	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	-6.25		-6.3	-6.25	-6.25	-6.25	-6.3
	TOT	2	-3.13	4.419	-6.3	-6.25	-3.13	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	100.00		100.0	100.00	100.00	100.00	100.0
	TOT	2	100.00	0.000	100.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	1	0.00		0.0	0.00	0.00	0.00	0.0
	ADA	1	0.00		0.0	0.00	0.00	0.00	0.0
	TOT	2	0.00	0.000	0.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.7.7.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: RACE=MULTI RACE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	1	98.18		98.2	98.18	98.18	98.18	98.2
	ADA	1	97.05		97.0	97.05	97.05	97.05	97.0
	TOT	2	97.61	0.804	97.0	97.05	97.61	98.18	98.2
FINAL/ET VALUE	PLO	1	100.00		100.0	100.00	100.00	100.00	100.0
	ADA	1	96.48		96.5	96.48	96.48	96.48	96.5
	TOT	2	98.24	2.491	96.5	96.48	98.24	100.00	100.0
CHG FROM BEST*	PLO	1	1.82		1.8	1.82	1.82	1.82	1.8
	ADA	1	-0.57		-0.6	-0.57	-0.57	-0.57	-0.6
	TOT	2	0.63	1.687	-0.6	-0.57	0.63	1.82	1.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	34	69.85	22.846	25.0	50.00	75.00	75.00	100.0			
	ADA	42	65.48	20.625	25.0	50.00	75.00	75.00	100.0			
	TOT	76	67.43	21.610	25.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	34	48.53	28.164	0.0	25.00	50.00	75.00	100.0			
	ADA	42	55.95	25.188	0.0	50.00	50.00	75.00	100.0			
	TOT	76	52.63	26.639	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	34	-21.32	24.720	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	42	-9.52	22.734	-75.0	-25.00	0.00	0.00	25.0			
	TOT	76	-14.80	24.214	-100.0	-25.00	0.00	0.00	25.0			
										11.80	(0.93, 22.67)	0.034A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	34	68.24	17.139	40.0	60.00	60.00	80.00	100.0			
	ADA	41	70.73	16.185	20.0	60.00	80.00	80.00	100.0			
	TOT	75	69.60	16.558	20.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	34	61.18	21.428	20.0	40.00	60.00	80.00	100.0			
	ADA	41	64.39	20.254	20.0	40.00	60.00	80.00	100.0			
	TOT	75	62.93	20.715	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	34	-7.06	18.994	-60.0	-20.00	0.00	0.00	20.0			
	ADA	41	-6.34	16.395	-60.0	-20.00	0.00	0.00	20.0			
	TOT	75	-6.67	17.502	-60.0	-20.00	0.00	0.00	20.0			
										0.72	(-7.43, 8.86)	0.861A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	34	84.56	17.693	37.5	75.00	87.50	100.00	100.0			
	ADA	42	81.55	18.362	25.0	75.00	81.25	100.00	100.0			
	TOT	76	82.89	18.010	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	34	76.10	23.308	25.0	62.50	75.00	100.00	100.0			
	ADA	42	81.85	20.697	25.0	62.50	87.50	100.00	100.0			
	TOT	76	79.28	21.942	25.0	62.50	87.50	100.00	100.0			
CHG FROM BEST*	PLO	34	-8.46	17.056	-50.0	-12.50	0.00	0.00	25.0			
	ADA	42	0.30	12.798	-37.5	0.00	0.00	0.00	25.0			
	TOT	76	-3.62	15.386	-50.0	-12.50	0.00	0.00	25.0			
										8.75	(1.93, 15.58)	0.013A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	34	74.75	21.269	25.0	58.33	75.00	91.67	100.0			
	ADA	42	72.82	24.697	16.7	50.00	75.00	100.00	100.0			
	TOT	76	73.68	23.096	16.7	58.33	75.00	95.83	100.0			
FINAL/ET VALUE	PLO	34	70.96	26.915	8.3	50.00	75.00	91.67	100.0			
	ADA	42	67.26	26.823	16.7	50.00	75.00	100.00	100.0			
	TOT	76	68.91	26.748	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	34	-3.80	20.576	-66.7	-8.33	0.00	0.00	41.7			
	ADA	42	-5.56	18.830	-66.7	-8.33	0.00	0.00	25.0			
	TOT	76	-4.77	19.516	-66.7	-8.33	0.00	0.00	41.7			
										-1.76	(-10.78, 7.27)	0.699A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	34	76.72	18.552	25.0	66.67	79.17	91.67	100.0			
	ADA	42	73.12	23.699	16.7	58.33	75.00	100.00	100.0			
	TOT	76	74.73	21.488	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	34	75.12	22.764	16.7	58.33	79.17	91.67	100.0			
	ADA	42	66.32	29.405	16.7	33.33	70.83	100.00	100.0			
	TOT	76	70.26	26.835	16.7	46.88	75.00	95.83	100.0			
CHG FROM BEST*	PLO	34	-1.59	15.146	-50.0	-8.33	0.00	0.00	41.7			
	ADA	42	-6.80	17.588	-66.7	-8.33	0.00	0.00	16.7			
	TOT	76	-4.47	16.638	-66.7	-8.33	0.00	0.00	41.7			
										-5.20	(-12.81, 2.40)	0.177A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	34	88.97	16.504	50.0	87.50	100.00	100.00	100.0			
	ADA	42	83.04	22.055	25.0	62.50	100.00	100.00	100.0			
	TOT	76	85.69	19.865	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	84.19	22.886	12.5	75.00	100.00	100.00	100.0			
	ADA	42	79.02	24.993	12.5	50.00	87.50	100.00	100.0			
	TOT	76	81.33	24.055	12.5	75.00	93.75	100.00	100.0			
CHG FROM BEST*	PLO	34	-4.78	16.859	-50.0	-12.50	0.00	0.00	37.5			
	ADA	42	-4.02	13.083	-50.0	-12.50	0.00	0.00	37.5			
	TOT	76	-4.36	14.791	-50.0	-12.50	0.00	0.00	37.5			
										0.76	(-6.08, 7.60)	0.825A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	34	67.28	20.474	6.3	50.00	68.75	81.25	100.0			
	ADA	42	65.03	23.951	0.0	50.00	71.88	81.25	100.0			
	TOT	76	66.04	22.345	0.0	50.00	68.75	81.25	100.0			
FINAL/ET VALUE	PLO	34	64.83	25.633	0.0	50.00	71.88	87.50	100.0			
	ADA	42	63.99	26.724	0.0	43.75	68.75	87.50	100.0			
	TOT	76	64.36	26.071	0.0	46.88	68.75	87.50	100.0			
CHG FROM BEST*	PLO	34	-2.45	17.199	-58.3	-12.50	0.00	6.25	31.3			
	ADA	42	-1.04	18.771	-43.8	-6.25	0.00	12.50	31.3			
	TOT	76	-1.67	17.980	-58.3	-9.38	0.00	9.38	31.3			
										1.41	(-6.90, 9.72)	0.737A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	34	69.85	22.216	25.0	50.00	75.00	87.50	100.0			
	ADA	42	66.37	26.978	0.0	50.00	62.50	100.00	100.0			
	TOT	76	67.93	24.861	0.0	50.00	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	34	64.34	28.560	12.5	37.50	75.00	75.00	100.0			
	ADA	42	66.96	29.454	0.0	37.50	62.50	100.00	100.0			
	TOT	76	65.79	28.894	0.0	37.50	75.00	93.75	100.0			
CHG FROM BEST*	PLO	34	-5.51	23.875	-75.0	-25.00	0.00	0.00	50.0			
	ADA	42	0.60	22.758	-50.0	0.00	0.00	12.50	50.0			
	TOT	76	-2.14	23.308	-75.0	-12.50	0.00	12.50	50.0			
										6.11	(-4.58, 16.80)	0.259A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	34	81.37	24.709	0.0	75.00	91.67	100.00	100.0			
	ADA	42	79.17	27.191	0.0	66.67	91.67	100.00	100.0			
	TOT	76	80.15	25.962	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	34	75.00	32.046	0.0	58.33	91.67	100.00	100.0			
	ADA	42	75.99	30.029	0.0	50.00	91.67	100.00	100.0			
	TOT	76	75.55	30.742	0.0	54.17	91.67	100.00	100.0			
CHG FROM BEST*	PLO	34	-6.37	19.469	-75.0	-8.33	0.00	0.00	16.7			
	ADA	42	-3.17	22.688	-75.0	0.00	0.00	0.00	50.0			
	TOT	76	-4.61	21.230	-75.0	0.00	0.00	0.00	50.0			
										3.20	(-6.60, 12.99)	0.517A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	32	65.36	30.166	0.0	50.00	75.00	83.33	100.0			
	ADA	39	60.26	34.846	0.0	25.00	66.67	91.67	100.0			
	TOT	71	62.56	32.691	0.0	41.67	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	32	60.55	28.200	0.0	39.58	70.83	83.33	100.0			
	ADA	39	57.26	37.277	0.0	16.67	75.00	83.33	100.0			
	TOT	71	58.74	33.305	0.0	33.33	75.00	83.33	100.0			
CHG FROM BEST*	PLO	32	-4.82	20.715	-58.3	-16.67	-8.33	0.00	50.0			
	ADA	39	-2.99	18.755	-66.7	-8.33	0.00	0.00	50.0			
	TOT	71	-3.81	19.540	-66.7	-12.50	0.00	0.00	50.0			
										1.83	(-7.53, 11.18)	0.698A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	34	91.91	14.720	50.0	75.00	100.00	100.00	100.0			
	ADA	42	92.26	15.109	25.0	75.00	100.00	100.00	100.0			
	TOT	76	92.11	14.838	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	88.97	19.648	25.0	75.00	100.00	100.00	100.0			
	ADA	42	89.88	17.513	50.0	75.00	100.00	100.00	100.0			
	TOT	76	89.47	18.377	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	34	-2.94	10.233	-25.0	0.00	0.00	0.00	25.0			
	ADA	42	-2.38	15.430	-50.0	0.00	0.00	0.00	25.0			
	TOT	76	-2.63	13.278	-50.0	0.00	0.00	0.00	25.0			
										0.56	(-5.58, 6.70)	0.856A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	34	83.09	19.189	25.0	75.00	75.00	100.00	100.0			
	ADA	41	76.22	24.969	25.0	50.00	75.00	100.00	100.0			
	TOT	75	79.33	22.651	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	34	78.68	18.599	25.0	75.00	75.00	100.00	100.0			
	ADA	41	73.78	26.781	25.0	50.00	75.00	100.00	100.0			
	TOT	75	76.00	23.409	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	34	-4.41	17.912	-50.0	-25.00	0.00	0.00	50.0			
	ADA	41	-2.44	18.375	-50.0	0.00	0.00	0.00	25.0			
	TOT	75	-3.33	18.071	-50.0	0.00	0.00	0.00	50.0			
										1.97	(-6.43, 10.37)	0.641A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.8.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS < 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	34	75.44	15.270	43.6	63.98	77.52	86.63	98.3			
	ADA	42	72.71	20.275	14.7	57.80	72.82	91.36	100.0			
	TOT	76	73.93	18.144	14.7	59.53	75.91	89.60	100.0			
FINAL/ET VALUE	PLO	34	72.70	19.519	27.6	62.92	76.63	87.20	100.0			
	ADA	42	71.33	22.125	18.5	51.10	74.45	92.77	99.2			
	TOT	76	71.94	20.874	18.5	54.58	76.40	88.50	100.0			
CHG FROM BEST*	PLO	34	-2.73	12.300	-48.0	-7.39	-1.33	4.36	20.6			
	ADA	42	-1.38	13.051	-38.7	-4.28	0.49	3.79	25.8			
	TOT	76	-1.99	12.654	-48.0	-5.68	-0.30	3.87	25.8			
										1.35	(-4.50, 7.19)	0.648A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	76	61.84	22.903	0.0	50.00	50.00	75.00	100.0			
	ADA	67	61.94	20.112	25.0	50.00	50.00	75.00	100.0			
	TOT	143	61.89	21.566	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	76	49.67	26.924	0.0	25.00	50.00	75.00	100.0			
	ADA	67	53.36	22.146	0.0	50.00	50.00	75.00	100.0			
	TOT	143	51.40	24.784	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	76	-12.17	19.362	-50.0	-25.00	0.00	0.00	25.0			
	ADA	67	-8.58	24.445	-100.0	-25.00	0.00	0.00	50.0			
	TOT	143	-10.49	21.886	-100.0	-25.00	0.00	0.00	50.0			
										3.59	(-3.66, 10.84)	0.330A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	76	73.16	14.442	40.0	60.00	80.00	80.00	100.0			
	ADA	67	68.51	13.735	40.0	60.00	60.00	80.00	100.0			
	TOT	143	70.98	14.257	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	76	62.11	20.805	20.0	40.00	60.00	80.00	100.0			
	ADA	67	65.22	18.697	20.0	60.00	60.00	80.00	100.0			
	TOT	143	63.57	19.838	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	76	-11.05	18.006	-60.0	-20.00	0.00	0.00	20.0			
	ADA	67	-3.28	17.002	-60.0	-20.00	0.00	0.00	40.0			
	TOT	143	-7.41	17.909	-60.0	-20.00	0.00	0.00	40.0			
										7.77	(1.96, 13.58)	0.009A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	76	85.03	15.682	37.5	75.00	87.50	100.00	100.0			
	ADA	67	85.63	17.442	25.0	75.00	87.50	100.00	100.0			
	TOT	143	85.31	16.474	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	76	70.89	24.697	12.5	50.00	75.00	93.75	100.0			
	ADA	67	79.66	19.804	25.0	62.50	75.00	100.00	100.0			
	TOT	143	75.00	22.886	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	76	-14.14	22.206	-87.5	-25.00	-12.50	0.00	12.5			
	ADA	67	-5.97	17.456	-75.0	-12.50	0.00	0.00	37.5			
	TOT	143	-10.31	20.465	-87.5	-12.50	0.00	0.00	37.5			
										8.17	(1.51, 14.84)	0.017A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	76	76.26	20.649	16.7	66.67	79.17	95.83	100.0			
	ADA	67	74.81	22.850	16.7	58.33	75.00	100.00	100.0			
	TOT	143	75.58	21.643	16.7	58.33	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	66.89	25.494	16.7	50.00	66.67	91.67	100.0			
	ADA	67	72.57	22.228	25.0	50.00	75.00	91.67	100.0			
	TOT	143	69.55	24.105	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	76	-9.38	16.275	-58.3	-16.67	-8.33	0.00	25.0			
	ADA	67	-2.24	14.853	-50.0	-8.33	0.00	0.00	50.0			
	TOT	143	-6.03	15.975	-58.3	-16.67	0.00	0.00	50.0			
										7.14	(1.96, 12.31)	0.007A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	76	76.26	22.163	16.7	58.33	83.33	100.00	100.0			
	ADA	67	76.31	21.087	12.5	58.33	83.33	91.67	100.0			
	TOT	143	76.28	21.590	12.5	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	76	68.70	27.843	8.3	45.83	75.00	91.67	100.0			
	ADA	67	73.38	22.531	25.0	58.33	75.00	91.67	100.0			
	TOT	143	70.89	25.513	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	76	-7.57	13.956	-50.0	-16.67	-8.33	0.00	25.0			
	ADA	67	-2.92	10.807	-25.0	-8.33	0.00	0.00	25.0			
	TOT	143	-5.39	12.750	-50.0	-16.67	0.00	0.00	25.0			
										4.64	(0.47, 8.81)	0.029A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	76	88.32	18.746	25.0	75.00	100.00	100.00	100.0			
	ADA	67	91.04	15.961	37.5	87.50	100.00	100.00	100.0			
	TOT	143	89.60	17.489	25.0	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	80.92	24.450	12.5	75.00	87.50	100.00	100.0			
	ADA	67	85.26	20.053	25.0	75.00	100.00	100.00	100.0			
	TOT	143	82.95	22.525	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	76	-7.40	15.163	-62.5	-12.50	0.00	0.00	25.0			
	ADA	67	-5.78	12.933	-50.0	-12.50	0.00	0.00	25.0			
	TOT	143	-6.64	14.136	-62.5	-12.50	0.00	0.00	25.0			
										1.62	(-3.07, 6.31)	0.497A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	76	69.65	25.955	0.0	50.00	75.00	87.50	100.0			
	ADA	67	68.50	23.516	12.5	50.00	68.75	87.50	100.0			
	TOT	143	69.11	24.762	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	76	63.10	30.571	0.0	40.63	68.75	93.75	100.0			
	ADA	67	68.63	25.965	6.3	43.75	75.00	93.75	100.0			
	TOT	143	65.69	28.541	0.0	43.75	68.75	93.75	100.0			
CHG FROM BEST*	PLO	76	-6.55	18.577	-75.0	-12.50	0.00	4.17	25.0			
	ADA	67	0.12	15.210	-62.5	-6.25	0.00	6.25	43.8			
	TOT	143	-3.42	17.349	-75.0	-12.50	0.00	6.25	43.8			
										6.68	(1.02, 12.34)	0.021A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	76	73.52	27.986	12.5	50.00	81.25	100.00	100.0			
	ADA	67	73.51	24.764	0.0	50.00	75.00	100.00	100.0			
	TOT	143	73.51	26.433	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	63.98	31.289	0.0	43.75	68.75	100.00	100.0			
	ADA	67	67.72	31.843	0.0	50.00	75.00	100.00	100.0			
	TOT	143	65.73	31.494	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	76	-9.54	17.305	-62.5	-25.00	0.00	0.00	25.0			
	ADA	67	-5.78	24.165	-87.5	-12.50	0.00	0.00	37.5			
	TOT	143	-7.78	20.811	-87.5	-25.00	0.00	0.00	37.5			
										3.76	(-3.13, 10.65)	0.283A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	76	82.68	25.341	0.0	70.83	95.83	100.00	100.0			
	ADA	67	84.20	23.216	0.0	66.67	100.00	100.00	100.0			
	TOT	143	83.39	24.296	0.0	66.67	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	74.18	30.467	0.0	50.00	85.42	100.00	100.0			
	ADA	67	81.22	26.565	0.0	58.33	100.00	100.00	100.0			
	TOT	143	77.48	28.822	0.0	58.33	91.67	100.00	100.0			
CHG FROM BEST*	PLO	76	-8.50	19.298	-75.0	-16.67	0.00	0.00	50.0			
	ADA	67	-2.99	14.844	-41.7	-8.33	0.00	0.00	58.3			
	TOT	143	-5.91	17.514	-75.0	-16.67	0.00	0.00	58.3			
										5.51	(-0.24, 11.26)	0.060A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	67	68.35	31.741	0.0	50.00	83.33	91.67	100.0			
	ADA	60	70.97	25.327	0.0	50.00	83.33	91.67	100.0			
	TOT	127	69.59	28.807	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	67	57.09	35.894	0.0	33.33	66.67	83.33	100.0			
	ADA	60	65.21	28.133	0.0	50.00	75.00	83.33	100.0			
	TOT	127	60.93	32.589	0.0	41.67	66.67	83.33	100.0			
CHG FROM BEST*	PLO	67	-11.26	20.153	-75.0	-25.00	0.00	0.00	33.3			
	ADA	60	-5.76	13.487	-50.0	-16.67	0.00	0.00	16.7			
	TOT	127	-8.66	17.479	-75.0	-16.67	0.00	0.00	33.3			
										5.49	(-0.60, 11.59)	0.077A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	76	95.39	11.336	50.0	100.00	100.00	100.00	100.0			
	ADA	67	94.03	11.588	50.0	100.00	100.00	100.00	100.0			
	TOT	143	94.76	11.435	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	92.60	14.603	50.0	100.00	100.00	100.00	100.0			
	ADA	67	89.18	17.529	25.0	75.00	100.00	100.00	100.0			
	TOT	143	91.00	16.074	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	76	-2.80	12.682	-50.0	0.00	0.00	0.00	25.0			
	ADA	67	-4.85	15.835	-75.0	0.00	0.00	0.00	25.0			
	TOT	143	-3.76	14.232	-75.0	0.00	0.00	0.00	25.0			
										-2.05	(-6.77, 2.66)	0.391A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	76	79.11	24.013	25.0	56.25	75.00	100.00	100.0			
	ADA	67	82.46	22.620	25.0	75.00	100.00	100.00	100.0			
	TOT	143	80.68	23.349	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	76	73.03	27.314	0.0	50.00	75.00	100.00	100.0			
	ADA	67	74.63	25.559	25.0	50.00	75.00	100.00	100.0			
	TOT	143	73.78	26.426	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	76	-6.09	16.007	-75.0	-12.50	0.00	0.00	50.0			
	ADA	67	-7.84	17.521	-50.0	-25.00	0.00	0.00	25.0			
	TOT	143	-6.91	16.697	-75.0	-25.00	0.00	0.00	50.0			
										-1.75	(-7.29, 3.79)	0.534A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.9.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF UVEITIS >= 1 YEAR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	76	77.03	18.532	25.7	66.34	82.73	93.35	98.7			
	ADA	67	76.60	16.711	31.5	63.03	82.73	91.17	99.4			
	TOT	143	76.83	17.642	25.7	63.22	82.73	91.93	99.4			
FINAL/ET VALUE	PLO	76	70.51	21.786	21.1	51.80	73.06	90.57	100.0			
	ADA	67	74.73	18.985	29.7	62.65	76.97	91.93	99.4			
	TOT	143	72.49	20.559	21.1	57.54	73.71	91.17	100.0			
CHG FROM BEST*	PLO	76	-6.51	11.607	-44.4	-10.81	-2.84	1.48	11.7			
	ADA	67	-1.86	9.454	-39.0	-5.04	-1.25	2.39	17.9			
	TOT	143	-4.33	10.868	-44.4	-8.64	-1.59	1.88	17.9			
										4.65	(1.12, 8.18)	0.010A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	23	69.57	26.064	0.0	50.00	75.00	100.00	100.0			
	ADA	23	68.48	21.608	25.0	50.00	75.00	75.00	100.0			
	TOT	46	69.02	23.679	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	56.52	22.885	0.0	50.00	50.00	75.00	100.0			
	ADA	23	55.43	26.064	0.0	50.00	50.00	75.00	100.0			
	TOT	46	55.98	24.258	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	23	-13.04	24.851	-75.0	-25.00	0.00	0.00	25.0			
	ADA	23	-13.04	24.851	-50.0	-25.00	0.00	0.00	50.0			
	TOT	46	-13.04	24.574	-75.0	-25.00	0.00	0.00	50.0			
										0.00	(-14.77, 14.77)	1.000A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	23	74.78	16.200	40.0	60.00	80.00	80.00	100.0			
	ADA	23	67.83	18.819	20.0	60.00	60.00	80.00	100.0			
	TOT	46	71.30	17.715	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	23	62.61	22.807	20.0	40.00	60.00	80.00	100.0			
	ADA	23	60.00	21.742	20.0	40.00	60.00	80.00	100.0			
	TOT	46	61.30	22.071	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	23	-12.17	19.761	-40.0	-20.00	-20.00	0.00	20.0			
	ADA	23	-7.83	11.661	-20.0	-20.00	0.00	0.00	20.0			
	TOT	46	-10.00	16.193	-40.0	-20.00	0.00	0.00	20.0			
										4.35	(-5.29, 13.99)	0.368A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	23	89.67	16.708	50.0	75.00	100.00	100.00	100.0			
	ADA	23	82.07	19.153	25.0	62.50	87.50	100.00	100.0			
	TOT	46	85.87	18.183	25.0	75.00	93.75	100.00	100.0			
FINAL/ET VALUE	PLO	23	79.35	22.490	25.0	75.00	87.50	100.00	100.0			
	ADA	23	76.09	20.613	37.5	62.50	75.00	100.00	100.0			
	TOT	46	77.72	21.395	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	23	-10.33	18.713	-75.0	-12.50	0.00	0.00	12.5			
	ADA	23	-5.98	14.036	-37.5	-12.50	0.00	0.00	12.5			
	TOT	46	-8.15	16.503	-75.0	-12.50	0.00	0.00	12.5			
										4.35	(-5.48, 14.18)	0.378A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	23	79.35	19.114	50.0	58.33	83.33	100.00	100.0			
	ADA	23	76.45	25.704	16.7	58.33	83.33	100.00	100.0			
	TOT	46	77.90	22.445	16.7	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	23	67.57	29.408	8.3	50.00	75.00	91.67	100.0			
	ADA	23	70.29	25.848	25.0	50.00	75.00	91.67	100.0			
	TOT	46	68.93	27.410	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	23	-11.78	19.244	-66.7	-12.50	-8.33	0.00	8.3			
	ADA	23	-6.16	15.934	-50.0	-16.67	-8.33	0.00	25.0			
	TOT	46	-8.97	17.699	-66.7	-12.50	-8.33	0.00	25.0			
										5.62	(-4.88, 16.12)	0.287A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	23	79.35	21.448	33.3	75.00	83.33	91.67	100.0			
	ADA	23	68.84	27.862	12.5	41.67	75.00	91.67	100.0			
	TOT	46	74.09	25.153	12.5	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	23	74.64	25.060	16.7	66.67	83.33	91.67	100.0			
	ADA	23	66.39	27.612	16.7	41.67	75.00	91.67	100.0			
	TOT	46	70.52	26.403	16.7	50.00	83.33	91.67	100.0			
CHG FROM BEST*	PLO	23	-4.71	12.004	-33.3	-8.33	-8.33	0.00	25.0			
	ADA	23	-2.45	12.975	-33.3	-8.33	0.00	8.33	25.0			
	TOT	46	-3.58	12.412	-33.3	-8.33	0.00	0.00	25.0			
										2.26	(-5.16, 9.69)	0.542A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	23	91.30	16.182	37.5	87.50	100.00	100.00	100.0			
	ADA	23	82.61	24.639	25.0	62.50	100.00	100.00	100.0			
	TOT	46	86.96	21.075	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	86.41	19.552	37.5	75.00	100.00	100.00	100.0			
	ADA	23	79.35	25.730	12.5	62.50	87.50	100.00	100.0			
	TOT	46	82.88	22.876	12.5	75.00	93.75	100.00	100.0			
CHG FROM BEST*	PLO	23	-4.89	11.142	-37.5	-12.50	0.00	0.00	12.5			
	ADA	23	-3.26	13.174	-25.0	-12.50	0.00	0.00	37.5			
	TOT	46	-4.08	12.092	-37.5	-12.50	0.00	0.00	37.5			
										1.63	(-5.62, 8.88)	0.653A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	23	70.65	24.165	12.5	50.00	75.00	93.75	100.0			
	ADA	23	66.85	26.878	0.0	56.25	81.25	87.50	93.8			
	TOT	46	68.75	25.345	0.0	56.25	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	23	65.85	30.778	0.0	37.50	75.00	87.50	100.0			
	ADA	23	61.05	27.989	0.0	37.50	66.67	81.25	100.0			
	TOT	46	63.45	29.189	0.0	37.50	75.00	87.50	100.0			
CHG FROM BEST*	PLO	23	-4.80	20.056	-75.0	-12.50	0.00	12.50	18.8			
	ADA	23	-5.80	15.841	-62.5	-12.50	0.00	6.25	18.8			
	TOT	46	-5.30	17.877	-75.0	-12.50	0.00	6.25	18.8			
										-1.00	(-11.74, 9.74)	0.853A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	23	72.83	27.348	25.0	50.00	75.00	100.00	100.0			
	ADA	23	68.48	28.422	0.0	50.00	75.00	100.00	100.0			
	TOT	46	70.65	27.666	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	63.59	33.053	0.0	37.50	75.00	100.00	100.0			
	ADA	23	62.50	32.640	0.0	37.50	62.50	100.00	100.0			
	TOT	46	63.04	32.485	0.0	37.50	68.75	100.00	100.0			
CHG FROM BEST*	PLO	23	-9.24	17.765	-50.0	-25.00	0.00	0.00	12.5			
	ADA	23	-5.98	21.277	-50.0	-12.50	0.00	0.00	37.5			
	TOT	46	-7.61	19.450	-50.0	-25.00	0.00	0.00	37.5			
										3.26	(-8.39, 14.91)	0.575A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	23	85.14	22.607	25.0	66.67	100.00	100.00	100.0			
	ADA	23	81.16	25.773	0.0	66.67	91.67	100.00	100.0			
	TOT	46	83.15	24.056	0.0	66.67	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	80.07	29.595	8.3	66.67	100.00	100.00	100.0			
	ADA	23	75.72	28.967	0.0	58.33	91.67	100.00	100.0			
	TOT	46	77.90	29.039	0.0	58.33	95.83	100.00	100.0			
CHG FROM BEST*	PLO	23	-5.07	16.993	-50.0	0.00	0.00	0.00	16.7			
	ADA	23	-5.43	15.612	-33.3	-16.67	0.00	0.00	33.3			
	TOT	46	-5.25	16.136	-50.0	-8.33	0.00	0.00	33.3			
										-0.36	(-10.06, 9.33)	0.940A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	20	75.83	28.214	0.0	62.50	83.33	100.00	100.0			
	ADA	21	61.71	27.437	0.0	41.67	66.67	83.33	100.0			
	TOT	41	68.60	28.384	0.0	50.00	79.17	91.67	100.0			
FINAL/ET VALUE	PLO	20	60.42	39.447	0.0	20.83	83.33	91.67	100.0			
	ADA	21	54.96	32.049	0.0	25.00	66.67	83.33	100.0			
	TOT	41	57.62	35.501	0.0	25.00	75.00	83.33	100.0			
CHG FROM BEST*	PLO	20	-15.42	22.826	-75.0	-29.17	-4.17	0.00	8.3			
	ADA	21	-6.75	13.912	-41.7	-16.67	-8.33	0.00	16.7			
	TOT	41	-10.98	19.066	-75.0	-16.67	-8.33	0.00	16.7			
										8.67	(-3.20, 20.55)	0.148A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	23	100.00	0.000	100.0	100.00	100.00	100.00	100.0			
	ADA	23	93.48	17.218	25.0	100.00	100.00	100.00	100.0			
	TOT	46	96.74	12.482	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	23	97.83	7.203	75.0	100.00	100.00	100.00	100.0			
	ADA	23	93.48	13.521	50.0	100.00	100.00	100.00	100.0			
	TOT	46	95.65	10.935	50.0	100.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	23	-2.17	7.203	-25.0	0.00	0.00	0.00	0.0			
	ADA	23	0.00	10.660	-25.0	0.00	0.00	0.00	25.0			
	TOT	46	-1.09	9.062	-25.0	0.00	0.00	0.00	25.0			
										2.17	(-3.23, 7.58)	0.422A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	23	83.70	22.116	25.0	75.00	100.00	100.00	100.0			
	ADA	23	72.83	29.109	25.0	50.00	75.00	100.00	100.0			
	TOT	46	78.26	26.145	25.0	50.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	23	82.61	23.153	25.0	75.00	100.00	100.00	100.0			
	ADA	23	67.39	29.614	25.0	50.00	75.00	100.00	100.0			
	TOT	46	75.00	27.386	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	23	-1.09	9.165	-25.0	0.00	0.00	0.00	25.0			
	ADA	23	-5.43	16.782	-50.0	-25.00	0.00	0.00	25.0			
	TOT	46	-3.26	13.549	-50.0	0.00	0.00	0.00	25.0			
										-4.35	(-12.38, 3.69)	0.281A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.10.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=INTERMEDIATE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	23	80.19	17.561	48.1	61.63	86.52	96.21	98.7			
	ADA	23	72.38	20.963	14.7	60.79	74.49	92.42	95.3			
	TOT	46	76.29	19.524	14.7	61.63	82.14	93.07	98.7			
FINAL/ET VALUE	PLO	23	74.94	20.198	37.2	51.74	78.08	93.42	100.0			
	ADA	23	69.31	21.667	18.5	51.10	65.49	91.17	96.2			
	TOT	46	72.13	20.906	18.5	51.74	75.76	91.17	100.0			
CHG FROM BEST*	PLO	23	-5.25	10.096	-34.8	-9.58	-1.70	2.65	5.3			
	ADA	23	-3.07	8.767	-26.4	-5.42	-1.70	1.52	17.9			
	TOT	46	-4.16	9.414	-34.8	-9.02	-1.70	1.82	17.9			
										2.18	(-3.44, 7.80)	0.438A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	33	62.88	20.843	25.0	50.00	50.00	75.00	100.0			
	ADA	37	60.14	22.407	25.0	50.00	50.00	75.00	100.0			
	TOT	70	61.43	21.571	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	33	47.73	21.976	0.0	25.00	50.00	50.00	100.0			
	ADA	37	48.65	26.968	0.0	25.00	50.00	50.00	100.0			
	TOT	70	48.21	24.569	0.0	25.00	50.00	50.00	100.0			
CHG FROM BEST*	PLO	33	-15.15	18.687	-50.0	-25.00	-25.00	0.00	25.0			
	ADA	37	-11.49	30.388	-100.0	-25.00	0.00	0.00	50.0			
	TOT	70	-13.21	25.439	-100.0	-25.00	0.00	0.00	50.0			
										3.67	(-8.55, 15.88)	0.551A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	33	72.73	13.056	40.0	60.00	80.00	80.00	100.0			
	ADA	37	68.38	13.232	40.0	60.00	60.00	80.00	100.0			
	TOT	70	70.43	13.235	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	33	66.06	16.945	40.0	60.00	60.00	80.00	100.0			
	ADA	37	69.46	18.249	20.0	60.00	80.00	80.00	100.0			
	TOT	70	67.86	17.602	20.0	60.00	80.00	80.00	100.0			
CHG FROM BEST*	PLO	33	-6.67	13.844	-40.0	-20.00	0.00	0.00	20.0			
	ADA	37	1.08	16.463	-40.0	0.00	0.00	20.00	30.0			
	TOT	70	-2.57	15.667	-40.0	-20.00	0.00	0.00	30.0			
										7.75	(0.44, 15.05)	0.038A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	33	87.12	12.688	62.5	75.00	87.50	100.00	100.0			
	ADA	37	79.73	18.246	50.0	62.50	75.00	100.00	100.0			
	TOT	70	83.21	16.191	50.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	33	75.76	23.991	25.0	75.00	75.00	100.00	100.0			
	ADA	37	78.04	20.709	25.0	62.50	75.00	100.00	100.0			
	TOT	70	76.96	22.181	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-11.36	22.396	-62.5	-25.00	0.00	0.00	12.5			
	ADA	37	-1.69	15.070	-37.5	0.00	0.00	0.00	25.0			
	TOT	70	-6.25	19.359	-62.5	-12.50	0.00	0.00	25.0			
										9.67	(0.66, 18.69)	0.036A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	33	80.93	15.556	50.0	66.67	83.33	91.67	100.0			
	ADA	37	72.86	21.508	29.2	66.67	75.00	91.67	100.0			
	TOT	70	76.67	19.237	29.2	66.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	33	70.45	24.214	25.0	50.00	75.00	91.67	100.0			
	ADA	37	71.62	25.266	16.7	50.00	75.00	100.00	100.0			
	TOT	70	71.07	24.603	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	33	-10.48	17.309	-50.0	-25.00	-8.33	0.00	25.0			
	ADA	37	-1.24	16.978	-66.7	0.00	0.00	8.33	25.0			
	TOT	70	-5.60	17.633	-66.7	-16.67	0.00	4.17	25.0			
										9.24	(1.05, 17.43)	0.028A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	33	82.20	16.837	37.5	75.00	83.33	100.00	100.0			
	ADA	37	79.39	18.054	41.7	66.67	83.33	100.00	100.0			
	TOT	70	80.71	17.422	37.5	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	33	75.63	24.697	16.7	58.33	83.33	91.67	100.0			
	ADA	37	73.87	24.858	16.7	58.33	75.00	91.67	100.0			
	TOT	70	74.70	24.618	16.7	58.33	83.33	91.67	100.0			
CHG FROM BEST*	PLO	33	-6.57	16.405	-50.0	-16.67	0.00	0.00	41.7			
	ADA	37	-5.52	16.668	-66.7	-8.33	0.00	0.00	16.7			
	TOT	70	-6.01	16.433	-66.7	-8.33	0.00	0.00	41.7			
										1.05	(-6.86, 8.95)	0.792A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	33	93.94	11.320	50.0	87.50	100.00	100.00	100.0			
	ADA	37	92.91	13.988	37.5	87.50	100.00	100.00	100.0			
	TOT	70	93.39	12.719	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	86.74	19.995	25.0	75.00	100.00	100.00	100.0			
	ADA	37	86.49	20.493	37.5	75.00	100.00	100.00	100.0			
	TOT	70	86.61	20.113	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-7.20	14.331	-50.0	-12.50	0.00	0.00	25.0			
	ADA	37	-6.42	14.320	-50.0	-12.50	0.00	0.00	12.5			
	TOT	70	-6.79	14.226	-50.0	-12.50	0.00	0.00	25.0			
										0.78	(-6.07, 7.62)	0.821A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	33	74.24	19.625	18.8	68.75	75.00	87.50	100.0			
	ADA	37	67.45	23.382	18.8	50.00	75.00	87.50	100.0			
	TOT	70	70.65	21.806	18.8	62.50	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	33	67.74	24.496	16.7	56.25	68.75	87.50	100.0			
	ADA	37	68.92	25.790	6.3	56.25	75.00	87.50	100.0			
	TOT	70	68.36	25.013	6.3	56.25	71.88	87.50	100.0			
CHG FROM BEST*	PLO	33	-6.50	18.828	-58.3	-12.50	0.00	6.25	25.0			
	ADA	37	1.46	16.062	-43.8	-6.25	0.00	12.50	31.3			
	TOT	70	-2.29	17.749	-58.3	-6.25	0.00	6.25	31.3			
										7.97	(-0.36, 16.29)	0.060A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	33	77.65	24.756	25.0	75.00	87.50	100.00	100.0			
	ADA	37	69.59	25.094	12.5	50.00	62.50	100.00	100.0			
	TOT	70	73.39	25.083	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	69.70	28.303	12.5	50.00	75.00	100.00	100.0			
	ADA	37	66.22	29.590	0.0	50.00	75.00	100.00	100.0			
	TOT	70	67.86	28.834	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-7.95	20.449	-75.0	-12.50	0.00	0.00	12.5			
	ADA	37	-3.38	25.962	-75.0	0.00	0.00	12.50	37.5			
	TOT	70	-5.54	23.471	-75.0	-12.50	0.00	12.50	37.5			
										4.58	(-6.67, 15.82)	0.419A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	33	88.64	17.157	25.0	83.33	91.67	100.00	100.0			
	ADA	37	84.01	25.259	16.7	75.00	100.00	100.00	100.0			
	TOT	70	86.19	21.790	16.7	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	76.52	27.986	8.3	66.67	83.33	100.00	100.0			
	ADA	37	83.56	25.871	16.7	75.00	100.00	100.00	100.0			
	TOT	70	80.24	26.926	8.3	75.00	91.67	100.00	100.0			
CHG FROM BEST*	PLO	33	-12.12	20.947	-75.0	-16.67	0.00	0.00	16.7			
	ADA	37	-0.45	18.315	-66.7	0.00	0.00	0.00	50.0			
	TOT	70	-5.95	20.321	-75.0	-8.33	0.00	0.00	50.0			
										11.67	(2.31, 21.03)	0.015A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	28	76.49	21.879	25.0	70.83	83.33	91.67	100.0			
	ADA	34	70.10	29.310	0.0	50.00	79.17	91.67	100.0			
	TOT	62	72.98	26.209	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	28	65.92	24.691	8.3	54.17	75.00	83.33	100.0			
	ADA	34	66.91	31.281	0.0	50.00	75.00	91.67	100.0			
	TOT	62	66.47	28.274	0.0	50.00	75.00	83.33	100.0			
CHG FROM BEST*	PLO	28	-10.57	19.261	-50.0	-25.00	-8.33	0.00	33.3			
	ADA	34	-3.19	16.542	-66.7	-8.33	0.00	0.00	33.3			
	TOT	62	-6.52	18.054	-66.7	-8.33	0.00	0.00	33.3			
										7.38	(-1.72, 16.47)	0.110A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	33	94.70	10.379	75.0	100.00	100.00	100.00	100.0			
	ADA	37	93.92	10.874	75.0	100.00	100.00	100.00	100.0			
	TOT	70	94.29	10.574	75.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	90.15	17.611	50.0	75.00	100.00	100.00	100.0			
	ADA	37	89.19	19.131	25.0	75.00	100.00	100.00	100.0			
	TOT	70	89.64	18.303	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-4.55	13.191	-50.0	0.00	0.00	0.00	25.0			
	ADA	37	-4.73	18.482	-75.0	0.00	0.00	0.00	25.0			
	TOT	70	-4.64	16.091	-75.0	0.00	0.00	0.00	25.0			
										-0.18	(-7.93, 7.56)	0.962A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	33	81.06	23.411	25.0	75.00	75.00	100.00	100.0			
	ADA	37	84.46	19.853	25.0	75.00	100.00	100.00	100.0			
	TOT	70	82.86	21.511	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	74.24	23.787	0.0	75.00	75.00	100.00	100.0			
	ADA	37	75.00	26.352	25.0	50.00	75.00	100.00	100.0			
	TOT	70	74.64	24.997	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-6.82	20.984	-50.0	-25.00	0.00	0.00	50.0			
	ADA	37	-9.46	18.958	-50.0	-25.00	0.00	0.00	25.0			
	TOT	70	-8.21	19.837	-50.0	-25.00	0.00	0.00	50.0			
										-2.64	(-12.17, 6.88)	0.582A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.11.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=POSTERIOR)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	33	81.07	13.865	39.1	75.83	85.30	90.11	98.3			
	ADA	37	76.11	16.163	35.6	63.03	82.08	89.17	100.0			
	TOT	70	78.45	15.221	35.6	69.02	83.11	89.85	100.0			
FINAL/ET VALUE	PLO	33	74.74	18.598	28.4	64.05	75.64	90.42	98.0			
	ADA	37	75.31	19.814	29.6	64.09	81.02	92.12	99.4			
	TOT	70	75.04	19.113	28.4	64.05	78.58	91.25	99.4			
CHG FROM BEST*	PLO	33	-6.33	12.778	-48.0	-12.01	-2.46	1.70	19.7			
	ADA	37	-0.80	11.576	-38.7	-1.70	0.49	6.74	13.9			
	TOT	70	-3.41	12.385	-48.0	-8.14	-1.10	2.46	19.7			
										5.53	(-0.27, 11.34)	0.061A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	54	62.96	23.159	25.0	50.00	75.00	75.00	100.0			
	ADA	49	63.27	17.753	25.0	50.00	50.00	75.00	100.0			
	TOT	103	63.11	20.664	25.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	54	47.22	31.348	0.0	25.00	50.00	75.00	100.0			
	ADA	49	58.16	17.961	25.0	50.00	50.00	75.00	100.0			
	TOT	103	52.43	26.317	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	54	-15.74	21.879	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	49	-5.10	16.121	-50.0	-25.00	0.00	0.00	25.0			
	TOT	103	-10.68	19.988	-100.0	-25.00	0.00	0.00	25.0			
										10.64	(3.06, 18.21)	0.006A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	54	69.63	16.364	40.0	60.00	80.00	80.00	100.0			
	ADA	48	70.83	13.657	40.0	60.00	80.00	80.00	100.0			
	TOT	102	70.20	15.089	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	54	58.89	22.120	20.0	40.00	60.00	80.00	100.0			
	ADA	48	63.75	18.291	20.0	60.00	60.00	80.00	100.0			
	TOT	102	61.18	20.455	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	54	-10.74	20.080	-60.0	-20.00	0.00	0.00	20.0			
	ADA	48	-7.08	18.214	-60.0	-20.00	0.00	0.00	40.0			
	TOT	102	-9.02	19.218	-60.0	-20.00	0.00	0.00	40.0			
										3.66	(-3.91, 11.22)	0.340A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	54	81.48	17.466	37.5	62.50	87.50	100.00	100.0			
	ADA	49	88.27	16.220	25.0	75.00	100.00	100.00	100.0			
	TOT	103	84.71	17.144	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	54	67.59	24.586	12.5	50.00	62.50	87.50	100.0			
	ADA	49	84.44	19.014	25.0	75.00	87.50	100.00	100.0			
	TOT	103	75.61	23.573	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-13.89	20.982	-87.5	-25.00	-12.50	0.00	25.0			
	ADA	49	-3.83	17.715	-75.0	-12.50	0.00	0.00	37.5			
	TOT	103	-9.10	20.049	-87.5	-12.50	0.00	0.00	37.5			
										10.06	(2.43, 17.69)	0.010A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	54	71.14	23.331	16.7	58.33	75.00	91.67	100.0			
	ADA	49	73.81	24.236	16.7	50.00	75.00	100.00	100.0			
	TOT	103	72.41	23.686	16.7	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	66.98	25.696	8.3	50.00	66.67	91.67	100.0			
	ADA	49	69.81	22.862	25.0	50.00	75.00	91.67	100.0			
	TOT	103	68.33	24.312	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	54	-4.17	17.113	-50.0	-16.67	0.00	0.00	41.7			
	ADA	49	-4.00	16.491	-58.3	-8.33	0.00	0.00	50.0			
	TOT	103	-4.09	16.738	-58.3	-8.33	0.00	0.00	50.0			
										0.17	(-6.41, 6.75)	0.959A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	54	71.60	22.344	16.7	50.00	75.00	91.67	100.0			
	ADA	49	74.74	21.523	33.3	58.33	75.00	91.67	100.0			
	TOT	103	73.10	21.907	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	54	65.97	27.647	8.3	41.67	68.75	91.67	100.0			
	ADA	49	70.24	25.173	25.0	50.00	75.00	91.67	100.0			
	TOT	103	68.00	26.457	8.3	41.67	70.83	91.67	100.0			
CHG FROM BEST*	PLO	54	-5.63	14.528	-50.0	-8.33	0.00	0.00	25.0			
	ADA	49	-4.51	12.023	-50.0	-8.33	0.00	0.00	16.7			
	TOT	103	-5.10	13.342	-50.0	-8.33	0.00	0.00	25.0			
										1.13	(-4.12, 6.37)	0.671A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	54	84.03	20.947	25.0	75.00	100.00	100.00	100.0			
	ADA	49	86.73	18.472	37.5	75.00	100.00	100.00	100.0			
	TOT	103	85.32	19.759	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	77.08	27.012	12.5	62.50	87.50	100.00	100.0			
	ADA	49	81.76	21.720	25.0	75.00	87.50	100.00	100.0			
	TOT	103	79.31	24.630	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	54	-6.94	18.117	-62.5	-12.50	0.00	0.00	37.5			
	ADA	49	-4.97	11.898	-50.0	-12.50	0.00	0.00	25.0			
	TOT	103	-6.01	15.432	-62.5	-12.50	0.00	0.00	37.5			
										1.97	(-4.09, 8.03)	0.520A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	54	64.93	26.584	0.0	50.00	68.75	87.50	100.0			
	ADA	49	67.09	22.706	25.0	50.00	68.75	87.50	100.0			
	TOT	103	65.96	24.719	0.0	50.00	68.75	87.50	100.0			
FINAL/ET VALUE	PLO	54	60.19	30.865	0.0	37.50	62.50	87.50	100.0			
	ADA	49	67.98	25.884	18.8	43.75	68.75	93.75	100.0			
	TOT	103	63.90	28.734	0.0	43.75	68.75	93.75	100.0			
CHG FROM BEST*	PLO	54	-4.75	17.253	-56.3	-12.50	0.00	6.25	31.3			
	ADA	49	0.89	17.116	-43.8	-6.25	0.00	12.50	43.8			
	TOT	103	-2.06	17.336	-56.3	-6.25	0.00	6.25	43.8			
										5.64	(-1.09, 12.37)	0.099A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	54	68.98	26.682	12.5	50.00	75.00	100.00	100.0			
	ADA	49	72.70	25.346	0.0	50.00	75.00	100.00	100.0			
	TOT	103	70.75	25.995	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	60.88	30.430	0.0	37.50	75.00	87.50	100.0			
	ADA	49	70.66	31.099	0.0	50.00	87.50	100.00	100.0			
	TOT	103	65.53	30.990	0.0	37.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-8.10	20.047	-50.0	-25.00	0.00	0.00	50.0			
	ADA	49	-2.04	23.434	-87.5	-12.50	0.00	0.00	50.0			
	TOT	103	-5.22	21.829	-87.5	-25.00	0.00	0.00	50.0			
										6.06	(-2.44, 14.56)	0.160A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	54	77.16	29.057	0.0	58.33	91.67	100.00	100.0			
	ADA	49	81.46	24.489	0.0	66.67	91.67	100.00	100.0			
	TOT	103	79.21	26.937	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	54	70.76	32.963	0.0	41.67	89.58	100.00	100.0			
	ADA	49	77.55	29.077	0.0	58.33	91.67	100.00	100.0			
	TOT	103	73.99	31.210	0.0	50.00	91.67	100.00	100.0			
CHG FROM BEST*	PLO	54	-6.40	19.063	-66.7	-16.67	0.00	0.00	50.0			
	ADA	49	-3.91	19.253	-75.0	-8.33	0.00	0.00	58.3			
	TOT	103	-5.22	19.100	-75.0	-16.67	0.00	0.00	58.3			
										2.49	(-5.00, 9.99)	0.511A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	51	59.07	34.518	0.0	41.67	62.50	83.33	100.0			
	ADA	44	66.57	31.393	0.0	45.83	75.00	91.67	100.0			
	TOT	95	62.54	33.147	0.0	41.67	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	51	53.10	34.879	0.0	33.33	50.00	83.33	100.0			
	ADA	44	61.74	32.812	0.0	41.67	70.83	83.33	100.0			
	TOT	95	57.11	34.034	0.0	33.33	66.67	83.33	100.0			
CHG FROM BEST*	PLO	51	-5.96	19.865	-58.3	-16.67	0.00	0.00	50.0			
	ADA	44	-4.83	16.149	-50.0	-14.58	0.00	0.00	50.0			
	TOT	95	-5.44	18.153	-58.3	-16.67	0.00	0.00	50.0			
										1.13	(-6.32, 8.59)	0.763A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	54	91.67	15.357	50.0	75.00	100.00	100.00	100.0			
	ADA	49	92.86	12.500	50.0	75.00	100.00	100.00	100.0			
	TOT	103	92.23	14.016	50.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	89.58	17.802	25.0	75.00	100.00	100.00	100.0			
	ADA	49	87.76	17.768	50.0	75.00	100.00	100.00	100.0			
	TOT	103	88.71	17.722	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-2.08	12.791	-50.0	0.00	0.00	0.00	25.0			
	ADA	49	-5.10	15.292	-50.0	-25.00	0.00	0.00	25.0			
	TOT	103	-3.52	14.048	-50.0	0.00	0.00	0.00	25.0			
										-3.02	(-8.51, 2.47)	0.278A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	54	78.47	22.573	25.0	50.00	75.00	100.00	100.0			
	ADA	48	80.21	23.039	25.0	75.00	100.00	100.00	100.0			
	TOT	102	79.29	22.697	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	71.76	26.174	25.0	50.00	75.00	100.00	100.0			
	ADA	48	77.08	23.539	25.0	50.00	75.00	100.00	100.0			
	TOT	102	74.26	24.989	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-6.71	15.870	-75.0	-25.00	0.00	0.00	25.0			
	ADA	48	-3.13	17.583	-50.0	0.00	0.00	0.00	25.0			
	TOT	102	-5.02	16.711	-75.0	-25.00	0.00	0.00	25.0			
										3.59	(-2.98, 10.16)	0.281A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.12.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TYPE OF UVEITIS=PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	54	72.21	18.723	25.7	58.48	72.71	90.38	98.2			
	ADA	49	75.62	18.474	31.5	59.81	79.54	91.82	99.4			
	TOT	103	73.83	18.592	25.7	58.94	73.71	91.36	99.4			
FINAL/ET VALUE	PLO	54	67.43	22.461	21.1	48.64	72.30	87.65	100.0			
	ADA	49	73.92	19.981	31.2	56.48	76.21	92.77	99.4			
	TOT	103	70.52	21.463	21.1	50.91	73.63	90.30	100.0			
CHG FROM BEST*	PLO	54	-4.78	12.220	-44.4	-8.71	-2.77	3.22	20.6			
	ADA	49	-1.69	11.456	-39.0	-5.04	-0.68	2.92	25.8			
	TOT	103	-3.31	11.906	-44.4	-7.42	-1.33	3.22	25.8			
										3.09	(-1.55, 7.73)	0.190A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	61	63.93	23.507	0.0	50.00	50.00	75.00	100.0			
	ADA	43	68.60	21.194	25.0	50.00	75.00	75.00	100.0			
	TOT	104	65.87	22.592	0.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	61	47.54	27.653	0.0	25.00	50.00	75.00	100.0			
	ADA	43	55.23	25.911	0.0	50.00	50.00	75.00	100.0			
	TOT	104	50.72	27.087	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	61	-16.39	22.769	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	43	-13.37	25.207	-100.0	-25.00	0.00	0.00	50.0			
	TOT	104	-15.14	23.735	-100.0	-25.00	-25.00	0.00	50.0			
										3.02	(-6.38, 12.42)	0.525A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	61	71.80	16.074	40.0	60.00	80.00	80.00	100.0			
	ADA	43	70.23	15.960	20.0	60.00	80.00	80.00	100.0			
	TOT	104	71.15	15.968	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	61	58.03	21.511	20.0	40.00	60.00	80.00	100.0			
	ADA	43	63.26	18.989	20.0	60.00	60.00	80.00	100.0			
	TOT	104	60.19	20.573	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	61	-13.77	20.507	-60.0	-20.00	-20.00	0.00	20.0			
	ADA	43	-6.98	13.721	-40.0	-20.00	0.00	0.00	20.0			
	TOT	104	-10.96	18.250	-60.0	-20.00	0.00	0.00	20.0			
										6.79	(-0.33, 13.91)	0.061A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	61	83.81	18.020	37.5	75.00	87.50	100.00	100.0			
	ADA	43	86.05	17.510	25.0	75.00	87.50	100.00	100.0			
	TOT	104	84.74	17.760	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	61	69.88	24.620	12.5	50.00	75.00	87.50	100.0			
	ADA	43	81.69	19.355	37.5	62.50	87.50	100.00	100.0			
	TOT	104	74.76	23.238	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	61	-13.93	19.378	-75.0	-25.00	-12.50	0.00	25.0			
	ADA	43	-4.36	12.760	-37.5	-12.50	0.00	0.00	25.0			
	TOT	104	-9.98	17.538	-75.0	-12.50	-6.25	0.00	25.0			
										9.57	(2.87, 16.28)	0.006A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	61	74.59	20.437	25.0	58.33	75.00	91.67	100.0			
	ADA	43	75.78	24.112	16.7	50.00	83.33	100.00	100.0			
	TOT	104	75.08	21.925	16.7	58.33	75.00	95.83	100.0			
FINAL/ET VALUE	PLO	61	65.98	25.060	8.3	50.00	66.67	83.33	100.0			
	ADA	43	72.67	23.169	25.0	58.33	75.00	91.67	100.0			
	TOT	104	68.75	24.406	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	61	-8.61	18.756	-66.7	-16.67	-8.33	0.00	41.7			
	ADA	43	-3.10	14.436	-50.0	-8.33	0.00	0.00	25.0			
	TOT	104	-6.33	17.243	-66.7	-12.50	0.00	0.00	41.7			
										5.51	(-1.25, 12.26)	0.109A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	61	75.96	21.842	16.7	58.33	83.33	91.67	100.0			
	ADA	43	74.22	22.608	16.7	58.33	75.00	91.67	100.0			
	TOT	104	75.24	22.070	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	61	69.40	26.894	8.3	50.00	75.00	91.67	100.0			
	ADA	43	69.82	25.277	16.7	50.00	75.00	91.67	100.0			
	TOT	104	69.57	26.114	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	61	-6.56	15.204	-50.0	-16.67	0.00	0.00	25.0			
	ADA	43	-4.41	10.856	-33.3	-8.33	0.00	0.00	25.0			
	TOT	104	-5.67	13.559	-50.0	-16.67	0.00	0.00	25.0			
										2.15	(-3.22, 7.51)	0.429A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	61	87.30	19.025	37.5	75.00	100.00	100.00	100.0			
	ADA	43	87.50	20.594	25.0	75.00	100.00	100.00	100.0			
	TOT	104	87.38	19.590	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	61	81.15	24.112	12.5	75.00	87.50	100.00	100.0			
	ADA	43	83.58	22.328	12.5	75.00	87.50	100.00	100.0			
	TOT	104	82.15	23.311	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	61	-6.15	17.021	-62.5	-12.50	0.00	0.00	37.5			
	ADA	43	-3.92	11.082	-25.0	-12.50	0.00	0.00	37.5			
	TOT	104	-5.23	14.834	-62.5	-12.50	0.00	0.00	37.5			
										2.22	(-3.65, 8.09)	0.454A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	61	67.42	24.047	6.3	50.00	75.00	87.50	100.0			
	ADA	43	69.04	24.396	0.0	56.25	81.25	87.50	100.0			
	TOT	104	68.09	24.087	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	61	59.87	28.769	0.0	37.50	62.50	87.50	100.0			
	ADA	43	64.05	27.478	0.0	37.50	68.75	87.50	100.0			
	TOT	104	61.60	28.183	0.0	37.50	62.50	87.50	100.0			
CHG FROM BEST*	PLO	61	-7.55	20.142	-75.0	-18.75	-6.25	6.25	31.3			
	ADA	43	-4.99	15.749	-62.5	-12.50	-2.08	6.25	25.0			
	TOT	104	-6.49	18.414	-75.0	-12.50	-6.25	6.25	31.3			
										2.56	(-4.73, 9.85)	0.488A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	61	69.88	25.958	12.5	50.00	75.00	100.00	100.0			
	ADA	43	70.93	27.102	0.0	50.00	75.00	100.00	100.0			
	TOT	104	70.31	26.312	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	61	60.04	29.828	0.0	37.50	75.00	75.00	100.0			
	ADA	43	68.02	31.729	0.0	37.50	75.00	100.00	100.0			
	TOT	104	63.34	30.731	0.0	37.50	75.00	87.50	100.0			
CHG FROM BEST*	PLO	61	-9.84	20.170	-62.5	-25.00	0.00	0.00	37.5			
	ADA	43	-2.91	23.280	-62.5	-12.50	0.00	12.50	37.5			
	TOT	104	-6.97	21.674	-62.5	-25.00	0.00	0.00	37.5			
										6.93	(-1.56, 15.42)	0.109A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	61	81.28	24.136	16.7	66.67	91.67	100.00	100.0			
	ADA	43	83.14	23.674	0.0	66.67	91.67	100.00	100.0			
	TOT	104	82.05	23.848	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	61	72.40	31.385	0.0	50.00	83.33	100.00	100.0			
	ADA	43	79.26	27.300	0.0	58.33	91.67	100.00	100.0			
	TOT	104	75.24	29.820	0.0	54.17	91.67	100.00	100.0			
CHG FROM BEST*	PLO	61	-8.88	20.854	-75.0	-16.67	0.00	0.00	50.0			
	ADA	43	-3.88	18.397	-50.0	-16.67	0.00	0.00	58.3			
	TOT	104	-6.81	19.937	-75.0	-16.67	0.00	0.00	58.3			
										5.00	(-2.85, 12.86)	0.209A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	54	68.60	30.119	0.0	50.00	75.00	91.67	100.0			
	ADA	40	65.52	27.815	0.0	41.67	75.00	83.33	100.0			
	TOT	94	67.29	29.048	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	54	55.86	33.122	0.0	33.33	58.33	83.33	100.0			
	ADA	40	59.48	31.137	0.0	37.50	70.83	83.33	100.0			
	TOT	94	57.40	32.171	0.0	33.33	66.67	83.33	100.0			
CHG FROM BEST*	PLO	54	-12.73	21.113	-75.0	-25.00	-8.33	0.00	33.3			
	ADA	40	-6.04	12.118	-41.7	-8.33	0.00	0.00	16.7			
	TOT	94	-9.88	18.074	-75.0	-16.67	-2.08	0.00	33.3			
										6.69	(-0.71, 14.09)	0.076A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	61	95.49	12.507	50.0	100.00	100.00	100.00	100.0			
	ADA	43	94.19	14.265	25.0	100.00	100.00	100.00	100.0			
	TOT	104	94.95	13.210	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	61	93.03	13.015	50.0	100.00	100.00	100.00	100.0			
	ADA	43	92.44	14.975	50.0	100.00	100.00	100.00	100.0			
	TOT	104	92.79	13.792	50.0	100.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	61	-2.46	11.819	-50.0	0.00	0.00	0.00	25.0			
	ADA	43	-1.74	11.437	-25.0	0.00	0.00	0.00	25.0			
	TOT	104	-2.16	11.612	-50.0	0.00	0.00	0.00	25.0			
										0.71	(-3.89, 5.32)	0.759A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	61	78.69	22.747	25.0	75.00	75.00	100.00	100.0			
	ADA	43	79.65	24.553	25.0	75.00	75.00	100.00	100.0			
	TOT	104	79.09	23.398	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	61	71.72	27.186	0.0	50.00	75.00	100.00	100.0			
	ADA	43	75.58	26.440	25.0	50.00	75.00	100.00	100.0			
	TOT	104	73.32	26.818	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	61	-6.97	15.898	-75.0	-25.00	0.00	0.00	25.0			
	ADA	43	-4.07	15.363	-50.0	0.00	0.00	0.00	25.0			
	TOT	104	-5.77	15.669	-75.0	-12.50	0.00	0.00	25.0			
										2.90	(-3.30, 9.09)	0.356A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.13.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=IDIOPATHIC/OTHER)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	61	75.42	17.353	39.2	61.63	79.24	89.85	98.7			
	ADA	43	75.32	18.650	14.7	60.79	81.40	91.36	97.0			
	TOT	104	75.38	17.811	14.7	61.21	80.32	90.78	98.7			
FINAL/ET VALUE	PLO	61	69.03	20.181	27.0	51.74	70.72	86.89	100.0			
	ADA	43	73.44	19.738	18.5	59.51	81.02	91.93	99.2			
	TOT	104	70.85	20.022	18.5	56.16	71.69	88.50	100.0			
CHG FROM BEST*	PLO	61	-6.39	12.568	-44.4	-9.85	-5.04	2.46	20.6			
	ADA	43	-1.88	8.338	-26.4	-5.42	-1.70	1.82	17.9			
	TOT	104	-4.53	11.196	-44.4	-8.67	-3.09	2.46	20.6			
										4.51	(0.16, 8.86)	0.042A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	18	63.89	21.390	25.0	50.00	75.00	75.00	100.0			
	ADA	23	59.78	20.970	25.0	50.00	50.00	75.00	100.0			
	TOT	41	61.59	20.989	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	18	52.78	26.965	0.0	50.00	50.00	75.00	100.0			
	ADA	23	51.09	24.400	0.0	25.00	50.00	75.00	100.0			
	TOT	41	51.83	25.243	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	18	-11.11	17.620	-50.0	-25.00	0.00	0.00	0.0			
	ADA	23	-8.70	28.810	-75.0	-25.00	0.00	0.00	50.0			
	TOT	41	-9.76	24.289	-75.0	-25.00	0.00	0.00	50.0			
										2.42	(-13.22, 18.05)	0.756A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	18	74.44	13.382	60.0	60.00	80.00	80.00	100.0			
	ADA	23	68.26	12.304	50.0	60.00	60.00	80.00	100.0			
	TOT	41	70.98	13.001	50.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	18	66.67	18.150	40.0	60.00	70.00	80.00	100.0			
	ADA	23	70.00	16.237	40.0	60.00	80.00	80.00	100.0			
	TOT	41	68.54	16.965	40.0	60.00	80.00	80.00	100.0			
CHG FROM BEST*	PLO	18	-7.78	15.551	-40.0	-20.00	0.00	0.00	20.0			
	ADA	23	1.74	14.970	-20.0	0.00	0.00	20.00	30.0			
	TOT	41	-2.44	15.777	-40.0	-20.00	0.00	0.00	30.0			
										9.52	(-0.18, 19.21)	0.054A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	18	84.03	13.426	62.5	75.00	81.25	100.00	100.0			
	ADA	23	81.52	16.372	50.0	62.50	75.00	100.00	100.0			
	TOT	41	82.62	15.020	50.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	77.08	20.224	25.0	75.00	75.00	87.50	100.0			
	ADA	23	79.89	20.553	25.0	62.50	87.50	100.00	100.0			
	TOT	41	78.66	20.203	25.0	75.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-6.94	20.211	-62.5	-12.50	0.00	0.00	12.5			
	ADA	23	-1.63	13.747	-37.5	0.00	0.00	0.00	25.0			
	TOT	41	-3.96	16.872	-62.5	0.00	0.00	0.00	25.0			
										5.31	(-5.43, 16.05)	0.323A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	18	76.39	15.192	50.0	66.67	75.00	83.33	100.0			
	ADA	23	72.28	23.288	25.0	50.00	75.00	91.67	100.0			
	TOT	41	74.09	20.015	25.0	66.67	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	18	65.97	21.780	25.0	50.00	75.00	75.00	100.0			
	ADA	23	70.65	27.851	16.7	50.00	75.00	100.00	100.0			
	TOT	41	68.60	25.175	16.7	50.00	75.00	87.50	100.0			
CHG FROM BEST*	PLO	18	-10.42	17.045	-50.0	-16.67	-8.33	0.00	16.7			
	ADA	23	-1.63	14.691	-33.3	-8.33	0.00	8.33	25.0			
	TOT	41	-5.49	16.176	-50.0	-16.67	0.00	0.00	25.0			
										8.79	(-1.25, 18.82)	0.084A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	18	76.16	17.019	37.5	66.67	83.33	83.33	100.0			
	ADA	23	77.90	20.506	33.3	66.67	83.33	100.00	100.0			
	TOT	41	77.13	18.845	33.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	18	71.06	24.525	16.7	58.33	79.17	91.67	100.0			
	ADA	23	75.72	23.957	16.7	58.33	83.33	100.00	100.0			
	TOT	41	73.68	24.016	16.7	58.33	83.33	91.67	100.0			
CHG FROM BEST*	PLO	18	-5.09	19.150	-50.0	-16.67	-2.08	0.00	41.7			
	ADA	23	-2.17	11.298	-33.3	-8.33	0.00	0.00	16.7			
	TOT	41	-3.46	15.107	-50.0	-8.33	0.00	0.00	41.7			
										2.92	(-6.77, 12.61)	0.546A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	18	92.36	8.723	75.0	87.50	93.75	100.00	100.0			
	ADA	23	90.76	18.926	37.5	87.50	100.00	100.00	100.0			
	TOT	41	91.46	15.165	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	82.64	19.712	37.5	75.00	87.50	100.00	100.0			
	ADA	23	86.96	22.130	37.5	75.00	100.00	100.00	100.0			
	TOT	41	85.06	20.957	37.5	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-9.72	15.192	-50.0	-12.50	-6.25	0.00	12.5			
	ADA	23	-3.80	14.807	-50.0	0.00	0.00	0.00	12.5			
	TOT	41	-6.40	15.084	-50.0	-12.50	0.00	0.00	12.5			
										5.92	(-3.61, 15.45)	0.217A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	18	71.18	19.429	18.8	62.50	75.00	81.25	100.0			
	ADA	23	71.29	23.486	18.8	50.00	81.25	87.50	100.0			
	TOT	41	71.24	21.536	18.8	62.50	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	18	65.51	24.704	16.7	50.00	71.88	87.50	100.0			
	ADA	23	70.65	26.679	12.5	43.75	81.25	93.75	100.0			
	TOT	41	68.39	25.642	12.5	50.00	75.00	87.50	100.0			
CHG FROM BEST*	PLO	18	-5.67	19.723	-58.3	-12.50	0.00	6.25	18.8			
	ADA	23	-0.63	13.361	-43.8	-6.25	0.00	12.50	18.8			
	TOT	41	-2.85	16.429	-58.3	-6.25	0.00	6.25	18.8			
										5.04	(-5.43, 15.50)	0.336A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	18	71.53	29.017	25.0	62.50	75.00	100.00	100.0			
	ADA	23	70.65	24.602	12.5	50.00	75.00	100.00	100.0			
	TOT	41	71.04	26.286	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	64.58	28.841	12.5	37.50	68.75	87.50	100.0			
	ADA	23	65.76	32.028	0.0	37.50	75.00	100.00	100.0			
	TOT	41	65.24	30.300	0.0	37.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-6.94	20.211	-75.0	-12.50	0.00	0.00	12.5			
	ADA	23	-4.89	24.639	-75.0	-12.50	0.00	12.50	37.5			
	TOT	41	-5.79	22.552	-75.0	-12.50	0.00	0.00	37.5			
										2.05	(-12.47, 16.58)	0.776A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	18	86.11	20.008	25.0	83.33	91.67	100.00	100.0			
	ADA	23	88.04	21.879	16.7	75.00	100.00	100.00	100.0			
	TOT	41	87.20	20.841	16.7	83.33	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	75.00	26.507	8.3	66.67	83.33	91.67	100.0			
	ADA	23	86.59	24.327	16.7	83.33	100.00	100.00	100.0			
	TOT	41	81.50	25.652	8.3	75.00	91.67	100.00	100.0			
CHG FROM BEST*	PLO	18	-11.11	21.198	-75.0	-16.67	-8.33	0.00	16.7			
	ADA	23	-1.45	16.790	-66.7	0.00	0.00	0.00	33.3			
	TOT	41	-5.69	19.224	-75.0	-8.33	0.00	0.00	33.3			
										9.66	(-2.33, 21.65)	0.111A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	18	71.30	24.122	25.0	50.00	75.00	83.33	100.0			
	ADA	22	71.21	25.938	25.0	41.67	79.17	91.67	100.0			
	TOT	40	71.25	24.818	25.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	18	59.49	24.329	16.7	41.67	62.50	83.33	91.7			
	ADA	22	67.42	30.091	0.0	41.67	75.00	91.67	100.0			
	TOT	40	63.85	27.596	0.0	41.67	75.00	83.33	100.0			
CHG FROM BEST*	PLO	18	-11.81	17.978	-41.7	-25.00	-8.33	-8.33	33.3			
	ADA	22	-3.79	13.295	-41.7	-8.33	0.00	0.00	33.3			
	TOT	40	-7.40	15.887	-41.7	-16.67	-8.33	0.00	33.3			
										8.02	(-2.00, 18.03)	0.113A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	18	91.67	12.127	75.0	75.00	100.00	100.00	100.0			
	ADA	23	93.48	11.224	75.0	75.00	100.00	100.00	100.0			
	TOT	41	92.68	11.516	75.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	88.89	19.596	50.0	75.00	100.00	100.00	100.0			
	ADA	23	88.04	21.146	25.0	75.00	100.00	100.00	100.0			
	TOT	41	88.41	20.231	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-2.78	11.785	-25.0	0.00	0.00	0.00	25.0			
	ADA	23	-5.43	22.559	-75.0	0.00	0.00	0.00	25.0			
	TOT	41	-4.27	18.458	-75.0	0.00	0.00	0.00	25.0			
										-2.66	(-14.52, 9.21)	0.653A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	18	80.56	25.082	25.0	75.00	87.50	100.00	100.0			
	ADA	22	85.23	19.909	50.0	75.00	100.00	100.00	100.0			
	TOT	40	83.13	22.208	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	75.00	19.174	50.0	50.00	75.00	100.00	100.0			
	ADA	22	78.41	27.053	25.0	75.00	87.50	100.00	100.0			
	TOT	40	76.88	23.607	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-5.56	26.507	-50.0	-25.00	0.00	0.00	50.0			
	ADA	22	-6.82	19.182	-50.0	-25.00	0.00	0.00	25.0			
	TOT	40	-6.25	22.468	-50.0	-25.00	0.00	0.00	50.0			
										-1.26	(-15.90, 13.38)	0.862A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.14.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BIRDSHOT CHOROIDOPATHY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	18	77.42	15.455	39.1	69.02	77.61	90.98	98.3			
	ADA	23	77.03	15.377	48.8	61.70	80.19	89.47	100.0			
	TOT	41	77.20	15.218	39.1	67.58	77.80	89.47	100.0			
FINAL/ET VALUE	PLO	18	71.99	18.330	29.8	63.41	75.17	84.36	97.2			
	ADA	23	76.18	20.524	29.6	63.98	83.86	92.77	98.5			
	TOT	41	74.34	19.466	29.6	63.98	79.24	91.17	98.5			
CHG FROM BEST*	PLO	18	-5.43	14.110	-48.0	-9.58	-2.97	-0.19	19.7			
	ADA	23	-0.85	10.202	-38.0	-4.09	-0.38	6.74	12.0			
	TOT	41	-2.86	12.131	-48.0	-8.26	-1.14	3.79	19.7			
										4.58	(-3.10, 12.26)	0.235A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	3	50.00	0.000	50.0	50.00	50.00	50.00	50.0
	ADA	7	53.57	9.449	50.0	50.00	50.00	50.00	75.0
	TOT	10	52.50	7.906	50.0	50.00	50.00	50.00	75.0
FINAL/ET VALUE	PLO	3	50.00	25.000	25.0	25.00	50.00	75.00	75.0
	ADA	7	53.57	9.449	50.0	50.00	50.00	50.00	75.0
	TOT	10	52.50	14.191	25.0	50.00	50.00	50.00	75.0
CHG FROM BEST*	PLO	3	0.00	25.000	-25.0	-25.00	0.00	25.00	25.0
	ADA	7	0.00	14.434	-25.0	0.00	0.00	0.00	25.0
	TOT	10	0.00	16.667	-25.0	0.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	3	73.33	11.547	60.0	60.00	80.00	80.00	80.0
	ADA	7	60.00	0.000	60.0	60.00	60.00	60.00	60.0
	TOT	10	64.00	8.433	60.0	60.00	60.00	60.00	80.0
FINAL/ET VALUE	PLO	3	80.00	0.000	80.0	80.00	80.00	80.00	80.0
	ADA	7	57.14	13.801	40.0	40.00	60.00	60.00	80.0
	TOT	10	64.00	15.776	40.0	60.00	60.00	80.00	80.0
CHG FROM BEST*	PLO	3	6.67	11.547	0.0	0.00	0.00	20.00	20.0
	ADA	7	-2.86	13.801	-20.0	-20.00	0.00	0.00	20.0
	TOT	10	0.00	13.333	-20.0	0.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	3	91.67	7.217	87.5	87.50	87.50	100.00	100.0
	ADA	7	71.43	6.099	62.5	62.50	75.00	75.00	75.0
	TOT	10	77.50	11.487	62.5	75.00	75.00	87.50	100.0
FINAL/ET VALUE	PLO	3	95.83	7.217	87.5	87.50	100.00	100.00	100.0
	ADA	7	78.57	21.304	50.0	62.50	75.00	100.00	100.0
	TOT	10	83.75	19.588	50.0	62.50	93.75	100.00	100.0
CHG FROM BEST*	PLO	3	4.17	7.217	0.0	0.00	0.00	12.50	12.5
	ADA	7	7.14	17.466	-12.5	-12.50	0.00	25.00	25.0
	TOT	10	6.25	14.731	-12.5	0.00	0.00	25.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	3	94.44	4.811	91.7	91.67	91.67	100.00	100.0
	ADA	7	55.95	14.203	41.7	41.67	50.00	75.00	75.0
	TOT	10	67.50	22.030	41.7	50.00	66.67	91.67	100.0
FINAL/ET VALUE	PLO	3	88.89	4.811	83.3	83.33	91.67	91.67	91.7
	ADA	7	55.95	17.156	41.7	41.67	50.00	75.00	83.3
	TOT	10	65.83	21.318	41.7	41.67	66.67	83.33	91.7
CHG FROM BEST*	PLO	3	-5.56	4.811	-8.3	-8.33	-8.33	0.00	0.0
	ADA	7	0.00	10.758	-16.7	-8.33	0.00	8.33	16.7
	TOT	10	-1.67	9.461	-16.7	-8.33	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	3	88.89	12.729	75.0	75.00	91.67	100.00	100.0
	ADA	7	49.40	22.622	12.5	33.33	50.00	75.00	75.0
	TOT	10	61.25	27.220	12.5	41.67	66.67	75.00	100.0
FINAL/ET VALUE	PLO	3	88.89	12.729	75.0	75.00	91.67	100.00	100.0
	ADA	7	54.76	19.754	25.0	33.33	58.33	75.00	75.0
	TOT	10	65.00	23.831	25.0	50.00	70.83	75.00	100.0
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	5.36	7.101	0.0	0.00	0.00	12.50	16.7
	TOT	10	3.75	6.350	0.0	0.00	0.00	8.33	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	3	95.83	7.217	87.5	87.50	100.00	100.00	100.0
	ADA	7	75.00	23.936	37.5	50.00	75.00	100.00	100.0
	TOT	10	81.25	22.244	37.5	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	3	95.83	7.217	87.5	87.50	100.00	100.00	100.0
	ADA	7	71.43	23.623	25.0	62.50	75.00	87.50	100.0
	TOT	10	78.75	22.860	25.0	75.00	81.25	100.00	100.0
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	-3.57	17.252	-25.0	-12.50	-12.50	12.50	25.0
	TOT	10	-2.50	14.191	-25.0	-12.50	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	3	93.75	0.000	93.8	93.75	93.75	93.75	93.8
	ADA	7	53.57	7.087	43.8	50.00	50.00	62.50	62.5
	TOT	10	65.63	20.252	43.8	50.00	59.38	93.75	93.8
FINAL/ET VALUE	PLO	3	93.75	0.000	93.8	93.75	93.75	93.75	93.8
	ADA	7	66.07	9.449	56.3	56.25	62.50	75.00	81.3
	TOT	10	74.38	15.436	56.3	62.50	71.88	93.75	93.8
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	12.50	7.217	0.0	6.25	12.50	18.75	18.8
	TOT	10	8.75	8.437	0.0	0.00	9.38	18.75	18.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	7	55.36	20.229	37.5	50.00	50.00	50.00	100.0
	TOT	10	66.25	25.035	37.5	50.00	50.00	100.00	100.0
FINAL/ET VALUE	PLO	3	83.33	28.868	50.0	50.00	100.00	100.00	100.0
	ADA	7	60.71	23.306	37.5	50.00	50.00	87.50	100.0
	TOT	10	67.50	25.820	37.5	50.00	50.00	100.00	100.0
CHG FROM BEST*	PLO	3	-8.33	14.434	-25.0	-25.00	0.00	0.00	0.0
	ADA	7	5.36	14.174	0.0	0.00	0.00	0.00	37.5
	TOT	10	1.25	14.965	-25.0	0.00	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	7	66.67	20.972	41.7	41.67	66.67	83.33	100.0
	TOT	10	76.67	23.505	41.7	66.67	75.00	100.00	100.0
FINAL/ET VALUE	PLO	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	7	63.10	26.726	25.0	33.33	66.67	83.33	100.0
	TOT	10	74.17	28.178	25.0	58.33	79.17	100.00	100.0
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	-3.57	17.252	-16.7	-16.67	-8.33	0.00	33.3
	TOT	10	-2.50	14.191	-16.7	-8.33	-4.17	0.00	33.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	3	88.89	4.811	83.3	83.33	91.67	91.67	91.7
	ADA	7	34.52	33.134	0.0	0.00	50.00	58.33	75.0
	TOT	10	50.83	37.772	0.0	0.00	58.33	83.33	91.7
FINAL/ET VALUE	PLO	3	86.11	9.623	75.0	75.00	91.67	91.67	91.7
	ADA	7	47.62	34.263	0.0	0.00	58.33	75.00	83.3
	TOT	10	59.17	33.896	0.0	50.00	70.83	83.33	91.7
CHG FROM BEST*	PLO	3	-2.78	4.811	-8.3	-8.33	0.00	0.00	0.0
	ADA	7	13.10	17.252	0.0	0.00	8.33	16.67	50.0
	TOT	10	8.33	16.197	-8.3	0.00	4.17	8.33	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	7	92.86	12.199	75.0	75.00	100.00	100.00	100.0
	TOT	10	95.00	10.541	75.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	3	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	7	92.86	18.898	50.0	100.00	100.00	100.00	100.0
	TOT	10	95.00	15.811	50.0	100.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	0.00	14.434	-25.0	0.00	0.00	0.00	25.0
	TOT	10	0.00	11.785	-25.0	0.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	7	60.71	28.347	25.0	25.00	75.00	75.00	100.0
	TOT	10	70.00	28.382	25.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	3	91.67	14.434	75.0	75.00	100.00	100.00	100.0
	ADA	7	57.14	23.780	25.0	25.00	75.00	75.00	75.0
	TOT	10	67.50	26.484	25.0	50.00	75.00	75.00	100.0
CHG FROM BEST*	PLO	3	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	7	-3.57	9.449	-25.0	0.00	0.00	0.00	0.0
	TOT	10	-2.50	7.906	-25.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.15.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=MULTIFOCAL CHOROIDITIS AND PANUVEITIS)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	3	90.82	0.641	90.1	90.11	90.98	91.36	91.4
	ADA	7	58.33	11.825	42.6	45.42	64.55	69.85	70.2
	TOT	10	68.08	18.428	42.6	50.42	67.58	90.11	91.4
FINAL/ET VALUE	PLO	3	91.30	1.157	90.0	90.04	91.55	92.31	92.3
	ADA	7	64.12	14.808	41.7	44.55	71.55	76.21	76.5
	TOT	10	72.28	17.856	41.7	65.68	74.45	90.04	92.3
CHG FROM BEST*	PLO	3	0.48	1.763	-1.3	-1.33	0.57	2.20	2.2
	ADA	7	5.79	9.869	-3.7	1.14	1.97	11.17	25.8
	TOT	10	4.20	8.497	-3.7	0.57	1.65	2.84	25.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	13	71.15	20.016	25.0	75.00	75.00	75.00	100.0
	ADA	11	68.18	11.677	50.0	50.00	75.00	75.00	75.0
	TOT	24	69.79	16.450	25.0	62.50	75.00	75.00	100.0
FINAL/ET VALUE	PLO	13	61.54	24.185	25.0	50.00	50.00	75.00	100.0
	ADA	11	59.09	20.226	25.0	50.00	75.00	75.00	75.0
	TOT	24	60.42	22.014	25.0	50.00	62.50	75.00	100.0
CHG FROM BEST*	PLO	13	-9.62	21.743	-50.0	-25.00	0.00	0.00	25.0
	ADA	11	-9.09	23.110	-50.0	-25.00	0.00	0.00	25.0
	TOT	24	-9.38	21.885	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	13	69.23	15.525	40.0	60.00	80.00	80.00	80.0
	ADA	10	80.00	9.428	60.0	80.00	80.00	80.00	100.0
	TOT	23	73.91	14.058	40.0	60.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	13	67.69	20.878	20.0	60.00	80.00	80.00	100.0
	ADA	10	68.00	23.476	20.0	60.00	80.00	80.00	100.0
	TOT	23	67.83	21.523	20.0	60.00	80.00	80.00	100.0
CHG FROM BEST*	PLO	13	-1.54	9.871	-20.0	0.00	0.00	0.00	20.0
	ADA	10	-12.00	21.499	-60.0	-20.00	0.00	0.00	0.0
	TOT	23	-6.09	16.442	-60.0	0.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	13	81.73	16.627	62.5	62.50	75.00	100.00	100.0
	ADA	11	84.09	19.438	50.0	62.50	100.00	100.00	100.0
	TOT	24	82.81	17.605	50.0	62.50	81.25	100.00	100.0
FINAL/ET VALUE	PLO	13	68.27	25.318	25.0	50.00	75.00	87.50	100.0
	ADA	11	79.55	19.584	50.0	62.50	75.00	100.00	100.0
	TOT	24	73.44	23.111	25.0	56.25	75.00	100.00	100.0
CHG FROM BEST*	PLO	13	-13.46	22.512	-75.0	-25.00	0.00	0.00	0.0
	ADA	11	-4.55	14.001	-25.0	-12.50	0.00	0.00	25.0
	TOT	24	-9.38	19.242	-75.0	-18.75	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	13	72.12	25.310	16.7	58.33	75.00	87.50	100.0
	ADA	11	78.79	18.395	50.0	66.67	75.00	100.00	100.0
	TOT	24	75.17	22.201	16.7	62.50	75.00	95.83	100.0
FINAL/ET VALUE	PLO	13	75.00	25.909	33.3	50.00	91.67	91.67	100.0
	ADA	11	67.42	21.875	41.7	50.00	58.33	91.67	100.0
	TOT	24	71.53	23.941	33.3	50.00	75.00	91.67	100.0
CHG FROM BEST*	PLO	13	2.88	16.438	-25.0	-8.33	0.00	16.67	33.3
	ADA	11	-11.36	18.361	-58.3	-25.00	0.00	0.00	0.0
	TOT	24	-3.65	18.443	-58.3	-8.33	0.00	0.00	33.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	13	73.72	21.743	25.0	66.67	75.00	83.33	100.0
	ADA	11	79.92	18.335	50.0	62.50	83.33	100.00	100.0
	TOT	24	76.56	20.070	25.0	64.58	79.17	91.67	100.0
FINAL/ET VALUE	PLO	13	68.59	25.944	16.7	58.33	75.00	83.33	100.0
	ADA	11	70.45	25.376	25.0	58.33	66.67	100.00	100.0
	TOT	24	69.44	25.141	16.7	58.33	70.83	87.50	100.0
CHG FROM BEST*	PLO	13	-5.13	8.699	-25.0	-8.33	0.00	0.00	8.3
	ADA	11	-9.47	23.577	-50.0	-25.00	0.00	8.33	16.7
	TOT	24	-7.12	16.913	-50.0	-12.50	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	13	85.58	23.852	25.0	75.00	100.00	100.00	100.0
	ADA	11	85.23	15.631	62.5	75.00	87.50	100.00	100.0
	TOT	24	85.42	20.077	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	13	82.69	27.735	12.5	75.00	100.00	100.00	100.0
	ADA	11	78.41	17.758	50.0	75.00	75.00	100.00	100.0
	TOT	24	80.73	23.307	12.5	75.00	87.50	100.00	100.0
CHG FROM BEST*	PLO	13	-2.88	13.649	-37.5	0.00	0.00	0.00	25.0
	ADA	11	-6.82	11.677	-25.0	-12.50	0.00	0.00	12.5
	TOT	24	-4.69	12.669	-37.5	-12.50	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	13	58.65	32.329	0.0	43.75	68.75	87.50	93.8
	ADA	11	65.91	24.103	25.0	43.75	68.75	87.50	93.8
	TOT	24	61.98	28.487	0.0	43.75	68.75	87.50	93.8
FINAL/ET VALUE	PLO	13	63.46	35.249	0.0	50.00	75.00	87.50	100.0
	ADA	11	67.05	25.014	18.8	56.25	68.75	93.75	93.8
	TOT	24	65.10	30.391	0.0	53.13	75.00	90.63	100.0
CHG FROM BEST*	PLO	13	4.81	8.895	-6.3	0.00	6.25	6.25	25.0
	ADA	11	1.14	20.120	-43.8	-6.25	0.00	6.25	31.3
	TOT	24	3.13	14.859	-43.8	-3.13	0.00	6.25	31.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	13	69.23	25.828	12.5	50.00	75.00	87.50	100.0
	ADA	11	72.73	22.233	50.0	50.00	62.50	100.00	100.0
	TOT	24	70.83	23.793	12.5	50.00	75.00	93.75	100.0
FINAL/ET VALUE	PLO	13	66.35	32.430	0.0	50.00	75.00	87.50	100.0
	ADA	11	70.45	24.541	25.0	50.00	62.50	100.00	100.0
	TOT	24	68.23	28.547	0.0	50.00	75.00	93.75	100.0
CHG FROM BEST*	PLO	13	-2.88	19.865	-37.5	-12.50	0.00	0.00	50.0
	ADA	11	-2.27	19.218	-37.5	0.00	0.00	12.50	25.0
	TOT	24	-2.60	19.146	-37.5	-6.25	0.00	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	13	73.72	36.459	0.0	58.33	91.67	100.00	100.0
	ADA	11	78.79	29.431	25.0	58.33	91.67	100.00	100.0
	TOT	24	76.04	32.814	0.0	58.33	91.67	100.00	100.0
FINAL/ET VALUE	PLO	13	72.76	38.961	0.0	58.33	91.67	100.00	100.0
	ADA	11	75.76	29.215	16.7	66.67	83.33	100.00	100.0
	TOT	24	74.13	34.138	0.0	62.50	89.58	100.00	100.0
CHG FROM BEST*	PLO	13	-0.96	13.411	-25.0	0.00	0.00	0.00	29.2
	ADA	11	-3.03	29.172	-75.0	-8.33	0.00	8.33	50.0
	TOT	24	-1.91	21.563	-75.0	0.00	0.00	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	11	47.73	39.632	0.0	0.00	75.00	83.33	83.3
	ADA	8	63.02	37.760	0.0	35.42	75.00	91.67	100.0
	TOT	19	54.17	38.565	0.0	0.00	75.00	83.33	100.0
FINAL/ET VALUE	PLO	11	53.03	36.945	0.0	0.00	66.67	83.33	100.0
	ADA	8	54.17	39.340	0.0	20.83	58.33	87.50	100.0
	TOT	19	53.51	36.884	0.0	0.00	66.67	83.33	100.0
CHG FROM BEST*	PLO	11	5.30	16.780	-16.7	0.00	0.00	8.33	50.0
	ADA	8	-8.85	16.732	-41.7	-16.67	-6.25	4.17	8.3
	TOT	19	-0.66	17.801	-41.7	-12.50	0.00	8.33	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	13	90.38	12.659	75.0	75.00	100.00	100.00	100.0
	ADA	11	90.91	12.613	75.0	75.00	100.00	100.00	100.0
	TOT	24	90.63	12.363	75.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	13	88.46	19.406	50.0	75.00	100.00	100.00	100.0
	ADA	11	84.09	16.855	50.0	75.00	75.00	100.00	100.0
	TOT	24	86.46	18.027	50.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	13	-1.92	12.339	-25.0	0.00	0.00	0.00	25.0
	ADA	11	-6.82	16.167	-25.0	-25.00	0.00	0.00	25.0
	TOT	24	-4.17	14.116	-25.0	-12.50	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	13	78.85	22.468	25.0	75.00	75.00	100.00	100.0
	ADA	11	77.27	20.780	50.0	50.00	75.00	100.00	100.0
	TOT	24	78.13	21.255	25.0	75.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	13	75.00	22.822	25.0	75.00	75.00	100.00	100.0
	ADA	11	72.73	20.780	50.0	50.00	75.00	100.00	100.0
	TOT	24	73.96	21.467	25.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	13	-3.85	9.388	-25.0	0.00	0.00	0.00	0.0
	ADA	11	-4.55	24.541	-50.0	-25.00	0.00	25.00	25.0
	TOT	24	-4.17	17.549	-50.0	-12.50	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.16.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=VOGT KOYANAGI HARADA)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	13	72.21	20.629	25.7	70.71	77.23	85.50	95.5
	ADA	11	77.53	17.747	54.3	57.50	84.25	95.34	99.4
	TOT	24	74.65	19.139	25.7	60.13	78.56	88.43	99.4
FINAL/ET VALUE	PLO	13	71.41	24.583	21.1	70.98	76.59	87.79	100.0
	ADA	11	72.19	19.507	42.8	61.46	69.47	94.96	99.4
	TOT	24	71.77	21.929	21.1	62.34	74.58	90.43	100.0
CHG FROM BEST*	PLO	13	-0.80	6.380	-17.1	-4.47	-0.45	3.22	8.1
	ADA	11	-5.35	14.760	-38.3	-13.30	0.00	4.36	11.5
	TOT	24	-2.88	11.014	-38.3	-4.82	-0.23	3.87	11.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	11	61.36	30.339	25.0	25.00	50.00	100.00	100.0
	ADA	12	60.42	16.714	25.0	50.00	62.50	75.00	75.0
	TOT	23	60.87	23.628	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	11	40.91	30.151	0.0	25.00	50.00	50.00	100.0
	ADA	12	56.25	26.382	0.0	50.00	50.00	75.00	100.0
	TOT	23	48.91	28.682	0.0	25.00	50.00	75.00	100.0
CHG FROM BEST*	PLO	11	-20.45	18.769	-50.0	-25.00	-25.00	0.00	0.0
	ADA	12	-4.17	17.944	-25.0	-25.00	0.00	0.00	25.0
	TOT	23	-11.96	19.756	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	11	67.27	18.488	40.0	60.00	60.00	80.00	100.0
	ADA	12	66.67	13.027	40.0	60.00	60.00	80.00	80.0
	TOT	23	66.96	15.502	40.0	60.00	60.00	80.00	100.0
FINAL/ET VALUE	PLO	11	61.82	22.724	20.0	40.00	60.00	80.00	100.0
	ADA	12	61.67	21.672	20.0	50.00	60.00	80.00	100.0
	TOT	23	61.74	21.669	20.0	40.00	60.00	80.00	100.0
CHG FROM BEST*	PLO	11	-5.45	12.933	-40.0	0.00	0.00	0.00	0.0
	ADA	12	-5.00	17.321	-40.0	-20.00	0.00	0.00	20.0
	TOT	23	-5.22	15.036	-40.0	-20.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	11	93.18	10.252	75.0	87.50	100.00	100.00	100.0
	ADA	12	91.67	15.386	50.0	87.50	100.00	100.00	100.0
	TOT	23	92.39	12.913	50.0	87.50	100.00	100.00	100.0
FINAL/ET VALUE	PLO	11	73.86	30.850	12.5	50.00	87.50	100.00	100.0
	ADA	12	82.29	20.267	50.0	68.75	87.50	100.00	100.0
	TOT	23	78.26	25.622	12.5	62.50	87.50	100.00	100.0
CHG FROM BEST*	PLO	11	-19.32	30.292	-87.5	-25.00	-12.50	0.00	12.5
	ADA	12	-9.38	20.032	-37.5	-25.00	0.00	0.00	25.0
	TOT	23	-14.13	25.368	-87.5	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	11	75.00	26.615	25.0	66.67	83.33	100.00	100.0
	ADA	12	76.39	22.426	33.3	62.50	75.00	100.00	100.0
	TOT	23	75.72	23.957	25.0	66.67	75.00	100.00	100.0
FINAL/ET VALUE	PLO	11	64.39	35.373	8.3	25.00	58.33	100.00	100.0
	ADA	12	69.79	27.589	25.0	43.75	75.00	95.83	100.0
	TOT	23	67.21	30.934	8.3	33.33	75.00	100.00	100.0
CHG FROM BEST*	PLO	11	-10.61	16.283	-41.7	-16.67	-8.33	0.00	16.7
	ADA	12	-6.60	20.370	-66.7	-6.25	0.00	0.00	16.7
	TOT	23	-8.51	18.226	-66.7	-16.67	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	11	73.48	25.771	25.0	50.00	83.33	100.00	100.0
	ADA	12	80.56	20.515	50.0	62.50	87.50	100.00	100.0
	TOT	23	77.17	22.921	25.0	50.00	83.33	100.00	100.0
FINAL/ET VALUE	PLO	11	70.08	31.668	16.7	41.67	87.50	100.00	100.0
	ADA	12	70.83	31.079	25.0	33.33	83.33	100.00	100.0
	TOT	23	70.47	30.642	16.7	33.33	87.50	100.00	100.0
CHG FROM BEST*	PLO	11	-3.41	9.650	-25.0	-8.33	0.00	4.17	8.3
	ADA	12	-9.72	20.669	-66.7	-16.67	0.00	0.00	16.7
	TOT	23	-6.70	16.319	-66.7	-16.67	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	11	86.36	20.505	50.0	75.00	100.00	100.00	100.0
	ADA	12	94.79	9.912	75.0	93.75	100.00	100.00	100.0
	TOT	23	90.76	16.086	50.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	11	75.00	30.619	12.5	50.00	87.50	100.00	100.0
	ADA	12	85.42	21.868	37.5	75.00	100.00	100.00	100.0
	TOT	23	80.43	26.335	12.5	62.50	100.00	100.00	100.0
CHG FROM BEST*	PLO	11	-11.36	15.263	-37.5	-25.00	0.00	0.00	0.0
	ADA	12	-9.38	17.778	-50.0	-12.50	0.00	0.00	0.0
	TOT	23	-10.33	16.277	-50.0	-25.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	11	75.57	22.613	37.5	50.00	87.50	93.75	100.0
	ADA	12	69.27	26.038	18.8	50.00	75.00	87.50	100.0
	TOT	23	72.28	24.120	18.8	50.00	87.50	87.50	100.0
FINAL/ET VALUE	PLO	11	69.32	32.650	18.8	31.25	87.50	100.00	100.0
	ADA	12	72.40	28.636	6.3	56.25	78.13	93.75	100.0
	TOT	23	70.92	29.951	6.3	43.75	81.25	93.75	100.0
CHG FROM BEST*	PLO	11	-6.25	14.790	-31.3	-18.75	0.00	6.25	12.5
	ADA	12	3.13	19.125	-43.8	-3.13	6.25	12.50	31.3
	TOT	23	-1.36	17.471	-43.8	-6.25	0.00	6.25	31.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	11	81.82	27.021	25.0	75.00	100.00	100.00	100.0
	ADA	12	81.25	20.296	50.0	62.50	87.50	100.00	100.0
	TOT	23	81.52	23.193	25.0	62.50	87.50	100.00	100.0
FINAL/ET VALUE	PLO	11	71.59	32.157	12.5	50.00	87.50	100.00	100.0
	ADA	12	71.88	31.136	0.0	50.00	75.00	100.00	100.0
	TOT	23	71.74	30.900	0.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	11	-10.23	19.218	-50.0	-25.00	0.00	0.00	12.5
	ADA	12	-9.38	25.071	-62.5	-18.75	0.00	0.00	25.0
	TOT	23	-9.78	21.962	-62.5	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	11	83.33	26.874	33.3	66.67	100.00	100.00	100.0
	ADA	12	88.89	17.885	50.0	83.33	100.00	100.00	100.0
	TOT	23	86.23	22.277	33.3	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	11	76.52	28.824	25.0	50.00	91.67	100.00	100.0
	ADA	12	82.64	25.980	16.7	70.83	100.00	100.00	100.0
	TOT	23	79.71	26.924	16.7	58.33	100.00	100.00	100.0
CHG FROM BEST*	PLO	11	-6.82	16.591	-50.0	-16.67	0.00	0.00	8.3
	ADA	12	-6.25	13.355	-41.7	-12.50	0.00	0.00	8.3
	TOT	23	-6.52	14.641	-50.0	-16.67	0.00	0.00	8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	9	61.11	38.415	0.0	41.67	83.33	83.33	100.0
	ADA	10	80.00	23.636	41.7	58.33	91.67	100.00	100.0
	TOT	19	71.05	32.079	0.0	50.00	83.33	100.00	100.0
FINAL/ET VALUE	PLO	9	61.11	46.585	0.0	0.00	83.33	100.00	100.0
	ADA	10	73.33	37.226	0.0	41.67	100.00	100.00	100.0
	TOT	19	67.54	41.191	0.0	33.33	91.67	100.00	100.0
CHG FROM BEST*	PLO	9	0.00	19.983	-41.7	0.00	0.00	0.00	33.3
	ADA	10	-6.67	22.839	-66.7	-8.33	0.00	0.00	16.7
	TOT	19	-3.51	21.212	-66.7	-8.33	0.00	0.00	33.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	11	93.18	16.167	50.0	100.00	100.00	100.00	100.0
	ADA	12	93.75	11.307	75.0	87.50	100.00	100.00	100.0
	TOT	23	93.48	13.521	50.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	11	85.23	25.506	25.0	75.00	100.00	100.00	100.0
	ADA	12	87.50	19.943	50.0	75.00	100.00	100.00	100.0
	TOT	23	86.41	22.269	25.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	11	-7.95	16.079	-50.0	-12.50	0.00	0.00	0.0
	ADA	12	-6.25	15.540	-50.0	0.00	0.00	0.00	0.0
	TOT	23	-7.07	15.460	-50.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	11	80.68	23.294	50.0	50.00	100.00	100.00	100.0
	ADA	12	87.50	22.613	25.0	75.00	100.00	100.00	100.0
	TOT	23	84.24	22.682	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	11	77.27	26.112	25.0	50.00	75.00	100.00	100.0
	ADA	12	72.92	29.113	25.0	50.00	75.00	100.00	100.0
	TOT	23	75.00	27.178	25.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	11	-3.41	11.307	-25.0	0.00	0.00	0.00	12.5
	ADA	12	-14.58	22.508	-50.0	-37.50	0.00	0.00	0.0
	TOT	23	-9.24	18.547	-50.0	-25.00	0.00	0.00	12.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.17.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=SARCOID)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	11	78.12	20.825	43.6	58.94	83.48	95.23	97.4
	ADA	12	79.97	17.862	49.2	62.27	87.80	94.20	98.2
	TOT	23	79.08	18.909	43.6	61.52	83.86	95.23	98.2
FINAL/ET VALUE	PLO	11	71.50	27.208	27.6	43.71	76.67	95.91	100.0
	ADA	12	75.18	22.763	29.7	54.77	79.75	95.47	99.4
	TOT	23	73.42	24.476	27.6	51.86	76.97	95.91	100.0
CHG FROM BEST*	PLO	11	-6.62	11.458	-32.2	-15.96	-1.52	0.76	4.9
	ADA	12	-4.79	13.292	-38.7	-6.06	-2.37	2.61	13.9
	TOT	23	-5.67	12.202	-38.7	-8.52	-1.52	1.88	13.9

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	4	68.75	23.936	50.0	50.00	62.50	87.50	100.0
	ADA	13	55.77	25.318	25.0	50.00	50.00	75.00	100.0
	TOT	17	58.82	24.908	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	4	43.75	23.936	25.0	25.00	37.50	62.50	75.0
	ADA	13	51.92	18.989	25.0	50.00	50.00	75.00	75.0
	TOT	17	50.00	19.764	25.0	25.00	50.00	75.00	75.0
CHG FROM BEST*	PLO	4	-25.00	20.412	-50.0	-37.50	-25.00	-12.50	0.0
	ADA	13	-3.85	17.218	-25.0	-25.00	0.00	0.00	25.0
	TOT	17	-8.82	19.648	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	4	75.00	10.000	60.0	70.00	80.00	80.00	80.0
	ADA	13	67.69	19.215	40.0	60.00	80.00	80.00	100.0
	TOT	17	69.41	17.489	40.0	60.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	4	65.00	19.149	40.0	50.00	70.00	80.00	80.0
	ADA	13	66.15	22.188	20.0	60.00	80.00	80.00	100.0
	TOT	17	65.88	20.934	20.0	60.00	80.00	80.00	100.0
CHG FROM BEST*	PLO	4	-10.00	20.000	-40.0	-20.00	0.00	0.00	0.0
	ADA	13	-1.54	23.751	-60.0	0.00	0.00	0.00	40.0
	TOT	17	-3.53	22.622	-60.0	0.00	0.00	0.00	40.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	4	87.50	14.434	75.0	75.00	87.50	100.00	100.0
	ADA	13	81.73	23.726	25.0	75.00	87.50	100.00	100.0
	TOT	17	83.09	21.624	25.0	75.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	4	84.38	11.968	75.0	75.00	81.25	93.75	100.0
	ADA	13	77.88	24.555	25.0	62.50	87.50	100.00	100.0
	TOT	17	79.41	22.071	25.0	75.00	87.50	100.00	100.0
CHG FROM BEST*	PLO	4	-3.13	6.250	-12.5	-6.25	0.00	0.00	0.0
	ADA	13	-3.85	24.677	-75.0	0.00	0.00	0.00	37.5
	TOT	17	-3.68	21.544	-75.0	0.00	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	4	91.67	16.667	66.7	83.33	100.00	100.00	100.0
	ADA	13	75.00	29.266	16.7	50.00	91.67	100.00	100.0
	TOT	17	78.92	27.341	16.7	66.67	91.67	100.00	100.0
FINAL/ET VALUE	PLO	4	83.33	33.333	33.3	66.67	100.00	100.00	100.0
	ADA	13	74.36	22.939	33.3	58.33	75.00	91.67	100.0
	TOT	17	76.47	24.867	33.3	58.33	83.33	100.00	100.0
CHG FROM BEST*	PLO	4	-8.33	16.667	-33.3	-16.67	0.00	0.00	0.0
	ADA	13	-0.64	22.685	-50.0	-8.33	0.00	0.00	50.0
	TOT	17	-2.45	21.198	-50.0	-8.33	0.00	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	4	91.67	11.785	75.0	83.33	95.83	100.00	100.0
	ADA	13	77.56	21.078	41.7	58.33	83.33	91.67	100.0
	TOT	17	80.88	19.931	41.7	58.33	91.67	100.00	100.0
FINAL/ET VALUE	PLO	4	83.33	28.054	41.7	66.67	95.83	100.00	100.0
	ADA	13	73.08	27.249	25.0	50.00	83.33	91.67	100.0
	TOT	17	75.49	26.918	25.0	50.00	83.33	100.00	100.0
CHG FROM BEST*	PLO	4	-8.33	16.667	-33.3	-16.67	0.00	0.00	0.0
	ADA	13	-4.49	9.388	-25.0	-8.33	0.00	0.00	8.3
	TOT	17	-5.39	11.001	-33.3	-8.33	0.00	0.00	8.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	13	87.50	17.678	50.0	87.50	100.00	100.00	100.0
	TOT	17	90.44	16.256	50.0	87.50	100.00	100.00	100.0
FINAL/ET VALUE	PLO	4	96.88	6.250	87.5	93.75	100.00	100.00	100.0
	ADA	13	80.77	25.828	25.0	62.50	100.00	100.00	100.0
	TOT	17	84.56	23.605	25.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	-3.13	6.250	-12.5	-6.25	0.00	0.00	0.0
	ADA	13	-6.73	9.703	-25.0	-12.50	0.00	0.00	0.0
	TOT	17	-5.88	8.968	-25.0	-12.50	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	4	78.13	21.949	56.3	59.38	78.13	96.88	100.0
	ADA	13	60.10	24.278	25.0	43.75	62.50	81.25	93.8
	TOT	17	64.34	24.383	25.0	56.25	62.50	81.25	100.0
FINAL/ET VALUE	PLO	4	75.00	23.936	43.8	56.25	81.25	93.75	93.8
	ADA	13	64.42	28.911	18.8	37.50	75.00	87.50	100.0
	TOT	17	66.91	27.490	18.8	43.75	75.00	87.50	100.0
CHG FROM BEST*	PLO	4	-3.13	8.069	-12.5	-9.38	-3.13	3.13	6.3
	ADA	13	4.33	19.329	-25.0	-6.25	0.00	12.50	43.8
	TOT	17	2.57	17.408	-25.0	-6.25	0.00	12.50	43.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	4	84.38	23.662	50.0	68.75	93.75	100.00	100.0
	ADA	13	67.31	32.088	0.0	50.00	75.00	87.50	100.0
	TOT	17	71.32	30.543	0.0	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	4	81.25	37.500	25.0	62.50	100.00	100.00	100.0
	ADA	13	65.38	37.553	0.0	37.50	75.00	100.00	100.0
	TOT	17	69.12	37.007	0.0	37.50	87.50	100.00	100.0
CHG FROM BEST*	PLO	4	-3.13	15.729	-25.0	-12.50	0.00	6.25	12.5
	ADA	13	-1.92	31.394	-87.5	0.00	0.00	12.50	50.0
	TOT	17	-2.21	28.033	-87.5	0.00	0.00	12.50	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	4	91.67	16.667	66.7	83.33	100.00	100.00	100.0
	ADA	13	74.36	33.758	0.0	66.67	91.67	100.00	100.0
	TOT	17	78.43	31.049	0.0	66.67	91.67	100.00	100.0
FINAL/ET VALUE	PLO	4	83.33	33.333	33.3	66.67	100.00	100.00	100.0
	ADA	13	74.36	36.556	0.0	50.00	100.00	100.00	100.0
	TOT	17	76.47	35.014	0.0	50.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	-8.33	16.667	-33.3	-16.67	0.00	0.00	0.0
	ADA	13	0.00	14.829	-33.3	0.00	0.00	8.33	16.7
	TOT	17	-1.96	15.175	-33.3	0.00	0.00	8.33	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	4	85.42	23.936	50.0	70.83	95.83	100.00	100.0
	ADA	12	72.92	31.206	0.0	75.00	83.33	91.67	100.0
	TOT	16	76.04	29.325	0.0	75.00	83.33	91.67	100.0
FINAL/ET VALUE	PLO	4	70.83	47.871	0.0	41.67	91.67	100.00	100.0
	ADA	12	65.28	29.481	0.0	50.00	75.00	83.33	100.0
	TOT	16	66.67	33.194	0.0	50.00	79.17	87.50	100.0
CHG FROM BEST*	PLO	4	-14.58	23.936	-50.0	-29.17	-4.17	0.00	0.0
	ADA	12	-7.64	18.620	-50.0	-16.67	-4.17	0.00	25.0
	TOT	16	-9.38	19.454	-50.0	-16.67	-4.17	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	13	92.31	15.761	50.0	100.00	100.00	100.00	100.0
	TOT	17	94.12	14.057	50.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	13	86.54	16.506	50.0	75.00	100.00	100.00	100.0
	TOT	17	89.71	15.459	50.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	13	-5.77	14.979	-25.0	-25.00	0.00	0.00	25.0
	TOT	17	-4.41	13.215	-25.0	0.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	13	78.85	24.677	25.0	75.00	75.00	100.00	100.0
	TOT	17	83.82	23.287	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	4	100.00	0.000	100.0	100.00	100.00	100.00	100.0
	ADA	13	75.00	25.000	25.0	50.00	75.00	100.00	100.0
	TOT	17	80.88	24.254	25.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	4	0.00	0.000	0.0	0.00	0.00	0.00	0.0
	ADA	13	-3.85	17.218	-25.0	-25.00	0.00	0.00	25.0
	TOT	17	-2.94	15.006	-25.0	0.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.18.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DIAGNOSIS=BEHCET'S)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	4	88.54	11.430	72.2	80.89	91.88	96.19	98.2
	ADA	13	73.42	22.219	31.5	59.81	84.05	90.04	95.9
	TOT	17	76.98	20.940	31.5	70.15	85.04	94.20	98.2
FINAL/ET VALUE	PLO	4	83.94	20.954	52.7	71.97	93.30	95.91	96.5
	ADA	13	72.90	23.927	31.2	48.00	84.55	90.30	97.3
	TOT	17	75.50	23.130	31.2	52.69	87.16	94.39	97.3
CHG FROM BEST*	PLO	4	-4.60	10.073	-19.5	-10.63	-0.28	1.42	1.7
	ADA	13	-0.52	13.791	-39.0	-2.27	-0.68	9.28	16.5
	TOT	17	-1.48	12.840	-39.0	-2.27	-0.68	1.70	16.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	18	72.22	24.085	25.0	50.00	75.00	100.00	100.0			
	ADA	20	65.00	22.064	25.0	50.00	50.00	75.00	100.0			
	TOT	38	68.42	23.019	25.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	52.78	26.965	0.0	25.00	50.00	75.00	100.0			
	ADA	20	51.25	23.613	0.0	37.50	50.00	75.00	100.0			
	TOT	38	51.97	24.920	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	18	-19.44	16.169	-50.0	-25.00	-25.00	0.00	0.0			
	ADA	20	-13.75	24.967	-50.0	-25.00	-12.50	0.00	25.0			
	TOT	38	-16.45	21.178	-50.0	-25.00	-25.00	0.00	25.0			
										5.69	(-8.32, 19.71)	0.415A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	18	76.67	12.367	60.0	60.00	80.00	80.00	100.0			
	ADA	20	68.00	10.052	60.0	60.00	60.00	80.00	80.0			
	TOT	38	72.11	11.891	60.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	18	72.22	18.329	40.0	60.00	80.00	80.00	100.0			
	ADA	20	68.00	13.611	40.0	60.00	60.00	80.00	100.0			
	TOT	38	70.00	15.939	40.0	60.00	80.00	80.00	100.0			
CHG FROM BEST*	PLO	18	-4.44	14.642	-40.0	-20.00	0.00	0.00	20.0			
	ADA	20	0.00	14.510	-40.0	0.00	0.00	0.00	20.0			
	TOT	38	-2.11	14.549	-40.0	0.00	0.00	0.00	20.0			
										4.44	(-5.16, 14.05)	0.354A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	18	85.42	20.224	37.5	75.00	100.00	100.00	100.0			
	ADA	20	80.63	17.432	50.0	62.50	75.00	100.00	100.0			
	TOT	38	82.89	18.704	37.5	62.50	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	18	77.78	22.094	37.5	62.50	81.25	100.00	100.0			
	ADA	20	81.25	19.237	50.0	62.50	87.50	100.00	100.0			
	TOT	38	79.61	20.431	37.5	62.50	87.50	100.00	100.0			
CHG FROM BEST*	PLO	18	-7.64	17.750	-62.5	-12.50	0.00	0.00	12.5			
	ADA	20	0.63	13.126	-25.0	-6.25	0.00	0.00	25.0			
	TOT	38	-3.29	15.834	-62.5	-12.50	0.00	0.00	25.0			
										8.26	(-1.94, 18.47)	0.109A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	18	80.56	19.596	33.3	66.67	83.33	100.00	100.0			
	ADA	20	76.25	20.816	33.3	62.50	75.00	95.83	100.0			
	TOT	38	78.29	20.092	33.3	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	18	72.22	30.250	25.0	33.33	83.33	100.00	100.0			
	ADA	20	65.83	24.912	25.0	50.00	62.50	87.50	100.0			
	TOT	38	68.86	27.378	25.0	50.00	70.83	100.00	100.0			
CHG FROM BEST*	PLO	18	-8.33	19.174	-58.3	-16.67	0.00	0.00	16.7			
	ADA	20	-10.42	17.286	-50.0	-20.83	-8.33	0.00	25.0			
	TOT	38	-9.43	17.985	-58.3	-16.67	-8.33	0.00	25.0			
										-2.08	(-14.08, 9.91)	0.727A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	18	79.17	20.661	33.3	66.67	83.33	100.00	100.0			
	ADA	20	75.00	16.222	41.7	62.50	79.17	83.33	100.0			
	TOT	38	76.97	18.322	33.3	66.67	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	18	77.55	26.704	16.7	75.00	85.42	100.00	100.0			
	ADA	20	67.92	22.340	25.0	50.00	66.67	83.33	100.0			
	TOT	38	72.48	24.651	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	18	-1.62	15.599	-33.3	-8.33	0.00	4.17	41.7			
	ADA	20	-7.08	16.944	-50.0	-12.50	-8.33	0.00	16.7			
	TOT	38	-4.50	16.336	-50.0	-8.33	0.00	0.00	41.7			
										-5.46	(-16.22, 5.29)	0.310A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	18	90.97	15.930	37.5	87.50	100.00	100.00	100.0			
	ADA	20	92.50	12.434	62.5	81.25	100.00	100.00	100.0			
	TOT	38	91.78	14.021	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	87.50	23.483	12.5	75.00	100.00	100.00	100.0			
	ADA	20	84.38	18.968	50.0	75.00	93.75	100.00	100.0			
	TOT	38	85.86	20.991	12.5	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-3.47	15.930	-37.5	-12.50	0.00	0.00	25.0			
	ADA	20	-8.13	11.666	-37.5	-12.50	0.00	0.00	0.0			
	TOT	38	-5.92	13.858	-37.5	-12.50	0.00	0.00	25.0			
										-4.65	(-13.78, 4.47)	0.308A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	18	72.92	24.630	6.3	68.75	81.25	87.50	93.8			
	ADA	20	63.44	25.430	12.5	43.75	68.75	84.38	100.0			
	TOT	38	67.93	25.176	6.3	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	18	64.70	34.363	0.0	31.25	75.00	93.75	100.0			
	ADA	20	63.75	27.099	12.5	43.75	62.50	87.50	100.0			
	TOT	38	64.20	30.329	0.0	43.75	68.75	93.75	100.0			
CHG FROM BEST*	PLO	18	-8.22	26.299	-75.0	-25.00	1.04	12.50	18.8			
	ADA	20	0.31	12.901	-25.0	-6.25	0.00	9.38	25.0			
	TOT	38	-3.73	20.539	-75.0	-12.50	0.00	12.50	25.0			
										8.53	(-4.88, 21.94)	0.205A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	18	78.47	26.708	12.5	75.00	81.25	100.00	100.0			
	ADA	20	68.75	21.651	37.5	50.00	62.50	87.50	100.0			
	TOT	38	73.36	24.345	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	74.31	29.228	0.0	50.00	75.00	100.00	100.0			
	ADA	20	64.38	27.885	0.0	50.00	68.75	87.50	100.0			
	TOT	38	69.08	28.584	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-4.17	18.689	-50.0	0.00	0.00	0.00	25.0			
	ADA	20	-4.38	25.090	-50.0	-18.75	0.00	6.25	37.5			
	TOT	38	-4.28	21.994	-50.0	-12.50	0.00	0.00	37.5			
										-0.21	(-14.90, 14.48)	0.977A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	18	86.11	23.914	16.7	83.33	100.00	100.00	100.0			
	ADA	20	80.00	27.226	16.7	66.67	95.83	100.00	100.0			
	TOT	38	82.89	25.553	16.7	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	74.54	34.945	0.0	50.00	95.83	100.00	100.0			
	ADA	20	79.58	28.928	16.7	62.50	95.83	100.00	100.0			
	TOT	38	77.19	31.580	0.0	58.33	95.83	100.00	100.0			
CHG FROM BEST*	PLO	18	-11.57	20.836	-75.0	-16.67	0.00	0.00	8.3			
	ADA	20	-0.42	20.318	-33.3	-12.50	0.00	0.00	58.3			
	TOT	38	-5.70	21.056	-75.0	-16.67	0.00	0.00	58.3			
										11.16	(-2.39, 24.71)	0.104A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	17	76.23	18.386	41.7	62.50	83.33	83.33	100.0			
	ADA	20	62.50	29.924	0.0	37.50	75.00	83.33	100.0			
	TOT	37	68.81	25.902	0.0	50.00	83.33	83.33	100.0			
FINAL/ET VALUE	PLO	17	74.51	28.637	0.0	58.33	83.33	100.00	100.0			
	ADA	20	58.33	29.863	0.0	37.50	66.67	83.33	100.0			
	TOT	37	65.77	30.032	0.0	41.67	75.00	83.33	100.0			
CHG FROM BEST*	PLO	17	-1.72	23.061	-75.0	-8.33	0.00	0.00	33.3			
	ADA	20	-4.17	18.634	-41.7	-8.33	0.00	0.00	50.0			
	TOT	37	-3.04	20.522	-75.0	-8.33	0.00	0.00	50.0			
										-2.45	(-16.36, 11.46)	0.723A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	18	98.61	5.893	75.0	100.00	100.00	100.00	100.0			
	ADA	20	90.00	12.566	75.0	75.00	100.00	100.00	100.0			
	TOT	38	94.08	10.771	75.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	95.83	12.862	50.0	100.00	100.00	100.00	100.0			
	ADA	20	83.75	21.877	25.0	75.00	100.00	100.00	100.0			
	TOT	38	89.47	18.952	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-2.78	14.575	-50.0	0.00	0.00	0.00	25.0			
	ADA	20	-6.25	22.762	-75.0	-25.00	0.00	0.00	25.0			
	TOT	38	-4.61	19.150	-75.0	0.00	0.00	0.00	25.0			
										-3.47	(-16.21, 9.27)	0.584A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	18	83.33	22.687	25.0	75.00	100.00	100.00	100.0			
	ADA	20	81.25	21.267	50.0	62.50	87.50	100.00	100.0			
	TOT	38	82.24	21.676	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	18	79.17	24.630	25.0	75.00	75.00	100.00	100.0			
	ADA	20	68.75	27.951	25.0	50.00	75.00	100.00	100.0			
	TOT	38	73.68	26.602	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	18	-4.17	17.678	-25.0	-25.00	0.00	0.00	50.0			
	ADA	20	-12.50	20.679	-50.0	-25.00	-12.50	0.00	25.0			
	TOT	38	-8.55	19.518	-50.0	-25.00	0.00	0.00	50.0			
										-8.33	(-21.06, 4.40)	0.193A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.19.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=1)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	18	80.51	17.921	39.2	69.02	86.57	94.58	97.9			
	ADA	20	73.42	15.141	44.7	60.95	72.80	86.80	97.0			
	TOT	38	76.78	16.678	39.2	63.22	82.82	88.98	97.9			
FINAL/ET VALUE	PLO	18	77.42	21.965	30.5	63.60	87.29	94.39	100.0			
	ADA	20	71.45	18.645	39.9	61.14	68.71	84.34	98.5			
	TOT	38	74.28	20.232	30.5	63.22	78.86	93.07	100.0			
CHG FROM BEST*	PLO	18	-3.09	12.266	-34.8	-8.52	-0.42	2.95	19.7			
	ADA	20	-1.97	11.533	-22.9	-10.28	-3.28	5.74	25.8			
	TOT	38	-2.50	11.737	-34.8	-8.52	-1.55	3.79	25.8			
										1.12	(-6.71, 8.95)	0.774A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	49	62.76	19.177	25.0	50.00	75.00	75.00	100.0			
	ADA	54	62.04	19.268	25.0	50.00	50.00	75.00	100.0			
	TOT	103	62.38	19.134	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	49	46.94	24.808	0.0	25.00	50.00	75.00	100.0			
	ADA	54	56.48	25.321	0.0	50.00	50.00	75.00	100.0			
	TOT	103	51.94	25.411	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	49	-15.82	22.064	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	54	-5.56	23.626	-75.0	-25.00	0.00	0.00	50.0			
	TOT	103	-10.44	23.359	-100.0	-25.00	0.00	0.00	50.0			
										10.26	(1.30, 19.22)	0.025A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	49	70.61	14.777	40.0	60.00	80.00	80.00	100.0			
	ADA	53	69.06	16.439	20.0	60.00	80.00	80.00	100.0			
	TOT	102	69.80	15.605	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	49	60.82	18.690	20.0	60.00	60.00	80.00	100.0			
	ADA	53	64.72	21.177	20.0	60.00	60.00	80.00	100.0			
	TOT	102	62.84	20.019	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	49	-9.80	18.313	-60.0	-20.00	0.00	0.00	20.0			
	ADA	53	-4.34	16.351	-40.0	-20.00	0.00	0.00	40.0			
	TOT	102	-6.96	17.451	-60.0	-20.00	0.00	0.00	40.0			
										5.46	(-1.35, 12.27)	0.115A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	49	83.42	16.999	37.5	75.00	87.50	100.00	100.0			
	ADA	54	84.49	18.955	25.0	75.00	87.50	100.00	100.0			
	TOT	103	83.98	17.971	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	49	74.49	23.518	12.5	62.50	75.00	100.00	100.0			
	ADA	54	80.79	19.833	25.0	62.50	81.25	100.00	100.0			
	TOT	103	77.79	21.787	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	49	-8.93	18.400	-87.5	-12.50	0.00	0.00	25.0			
	ADA	54	-3.70	15.854	-37.5	-12.50	0.00	0.00	37.5			
	TOT	103	-6.19	17.228	-87.5	-12.50	0.00	0.00	37.5			
										5.22	(-1.47, 11.92)	0.125A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	49	74.32	19.457	25.0	58.33	75.00	91.67	100.0			
	ADA	54	72.99	24.547	16.7	50.00	75.00	100.00	100.0			
	TOT	103	73.62	22.174	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	49	68.28	23.491	8.3	50.00	66.67	91.67	100.0			
	ADA	54	71.06	24.953	16.7	50.00	75.00	100.00	100.0			
	TOT	103	69.74	24.190	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	49	-6.04	15.428	-50.0	-12.50	-8.33	0.00	33.3			
	ADA	54	-1.93	15.500	-66.7	-8.33	0.00	0.00	50.0			
	TOT	103	-3.88	15.527	-66.7	-8.33	0.00	0.00	50.0			
										4.11	(-1.94, 10.16)	0.181A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	49	75.26	17.849	25.0	66.67	75.00	91.67	100.0			
	ADA	54	76.23	24.599	12.5	58.33	83.33	100.00	100.0			
	TOT	103	75.77	21.554	12.5	58.33	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	49	70.49	24.308	16.7	58.33	75.00	91.67	100.0			
	ADA	54	72.88	26.366	16.7	58.33	83.33	100.00	100.0			
	TOT	103	71.74	25.312	16.7	58.33	75.00	91.67	100.0			
CHG FROM BEST*	PLO	49	-4.76	14.583	-37.5	-16.67	0.00	0.00	25.0			
	ADA	54	-3.36	13.881	-66.7	-8.33	0.00	0.00	25.0			
	TOT	103	-4.03	14.167	-66.7	-8.33	0.00	0.00	25.0			
										1.41	(-4.16, 6.97)	0.617A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	49	88.78	17.163	50.0	75.00	100.00	100.00	100.0			
	ADA	54	86.11	20.982	25.0	75.00	100.00	100.00	100.0			
	TOT	103	87.38	19.214	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	49	83.42	22.591	12.5	75.00	87.50	100.00	100.0			
	ADA	54	81.71	24.369	12.5	75.00	93.75	100.00	100.0			
	TOT	103	82.52	23.440	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	49	-5.36	12.500	-37.5	-12.50	0.00	0.00	25.0			
	ADA	54	-4.40	15.195	-50.0	-12.50	0.00	0.00	37.5			
	TOT	103	-4.85	13.919	-50.0	-12.50	0.00	0.00	37.5			
										0.96	(-4.51, 6.43)	0.729A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	49	68.11	23.219	6.3	50.00	75.00	87.50	100.0			
	ADA	54	68.33	24.840	0.0	56.25	81.25	87.50	100.0			
	TOT	103	68.22	23.965	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	49	64.16	26.875	0.0	50.00	68.75	87.50	100.0			
	ADA	54	67.44	26.748	0.0	43.75	75.00	93.75	100.0			
	TOT	103	65.88	26.728	0.0	43.75	75.00	87.50	100.0			
CHG FROM BEST*	PLO	49	-3.95	14.189	-50.0	-12.50	0.00	6.25	25.0			
	ADA	54	-0.89	16.971	-62.5	-6.25	0.00	6.25	31.3			
	TOT	103	-2.35	15.709	-62.5	-6.25	0.00	6.25	31.3			
										3.07	(-3.08, 9.22)	0.325A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	49	69.39	25.523	25.0	50.00	75.00	100.00	100.0			
	ADA	54	72.22	26.784	0.0	50.00	75.00	100.00	100.0			
	TOT	103	70.87	26.102	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	49	61.99	29.088	0.0	37.50	62.50	87.50	100.0			
	ADA	54	68.06	32.183	0.0	50.00	75.00	100.00	100.0			
	TOT	103	65.17	30.751	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	49	-7.40	19.250	-50.0	-25.00	0.00	0.00	50.0			
	ADA	54	-4.17	24.763	-75.0	-12.50	0.00	0.00	37.5			
	TOT	103	-5.70	22.263	-75.0	-25.00	0.00	0.00	50.0			
										3.23	(-5.50, 11.96)	0.465A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	49	80.95	25.965	0.0	66.67	91.67	100.00	100.0			
	ADA	54	83.64	26.050	0.0	75.00	100.00	100.00	100.0			
	TOT	103	82.36	25.917	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	49	77.81	28.046	0.0	66.67	91.67	100.00	100.0			
	ADA	54	80.86	26.778	0.0	66.67	100.00	100.00	100.0			
	TOT	103	79.41	27.297	0.0	66.67	91.67	100.00	100.0			
CHG FROM BEST*	PLO	49	-3.15	15.649	-50.0	-8.33	0.00	8.33	29.2			
	ADA	54	-2.78	16.025	-66.7	-8.33	0.00	0.00	50.0			
	TOT	103	-2.95	15.771	-66.7	-8.33	0.00	0.00	50.0			
										0.37	(-5.83, 6.57)	0.906A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	46	67.57	28.773	0.0	50.00	75.00	91.67	100.0			
	ADA	46	70.47	31.400	0.0	41.67	83.33	100.00	100.0			
	TOT	92	69.02	29.985	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	46	59.24	30.542	0.0	33.33	70.83	83.33	100.0			
	ADA	46	65.85	34.868	0.0	50.00	75.00	100.00	100.0			
	TOT	92	62.55	32.765	0.0	41.67	75.00	83.33	100.0			
CHG FROM BEST*	PLO	46	-8.33	17.656	-58.3	-16.67	-8.33	0.00	50.0			
	ADA	46	-4.62	15.347	-66.7	-8.33	0.00	0.00	33.3			
	TOT	92	-6.48	16.556	-66.7	-16.67	0.00	0.00	50.0			
										3.71	(-3.14, 10.57)	0.284A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	49	92.86	13.502	50.0	100.00	100.00	100.00	100.0			
	ADA	54	93.98	14.517	25.0	100.00	100.00	100.00	100.0			
	TOT	103	93.45	13.986	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	49	88.52	18.371	25.0	75.00	100.00	100.00	100.0			
	ADA	54	90.74	17.030	50.0	75.00	100.00	100.00	100.0			
	TOT	103	89.68	17.628	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	49	-4.34	9.393	-25.0	0.00	0.00	0.00	0.0			
	ADA	54	-3.24	16.141	-50.0	0.00	0.00	0.00	25.0			
	TOT	103	-3.76	13.311	-50.0	0.00	0.00	0.00	25.0			
										1.10	(-4.14, 6.33)	0.679A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	49	79.34	21.583	25.0	75.00	75.00	100.00	100.0			
	ADA	53	83.02	22.878	25.0	75.00	100.00	100.00	100.0			
	TOT	102	81.25	22.232	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	49	74.49	23.657	0.0	50.00	75.00	100.00	100.0			
	ADA	53	76.89	25.405	25.0	50.00	75.00	100.00	100.0			
	TOT	102	75.74	24.489	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	49	-4.85	13.697	-25.0	-25.00	0.00	0.00	25.0			
	ADA	53	-6.13	18.929	-50.0	0.00	0.00	0.00	25.0			
	TOT	102	-5.51	16.555	-50.0	-25.00	0.00	0.00	25.0			
										-1.29	(-7.82, 5.25)	0.697A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.20.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS=2)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	49	75.24	15.570	39.1	66.06	74.49	89.66	98.3			
	ADA	54	75.94	19.967	14.7	60.79	82.97	92.42	100.0			
	TOT	103	75.61	17.927	14.7	63.71	78.30	91.36	100.0			
FINAL/ET VALUE	PLO	49	71.23	18.503	27.6	60.34	74.39	87.20	100.0			
	ADA	54	74.26	21.288	18.5	60.64	82.88	92.88	99.4			
	TOT	103	72.82	19.973	18.5	60.34	75.53	90.49	100.0			
CHG FROM BEST*	PLO	49	-4.01	9.275	-32.2	-7.69	-1.33	2.46	10.7			
	ADA	54	-1.68	10.793	-38.7	-4.47	-0.07	3.52	17.9			
	TOT	103	-2.79	10.118	-38.7	-6.33	-1.14	2.92	17.9			
										2.33	(-1.62, 6.28)	0.245A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	43	62.79	26.374	0.0	50.00	50.00	75.00	100.0			
	ADA	35	64.29	21.253	25.0	50.00	75.00	75.00	100.0			
	TOT	78	63.46	24.071	0.0	50.00	62.50	75.00	100.0			
FINAL/ET VALUE	PLO	43	50.58	30.123	0.0	25.00	50.00	75.00	100.0			
	ADA	35	52.86	19.900	0.0	50.00	50.00	75.00	75.0			
	TOT	78	51.60	25.906	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	43	-12.21	22.738	-75.0	-25.00	0.00	0.00	25.0			
	ADA	35	-11.43	22.963	-100.0	-25.00	0.00	0.00	25.0			
	TOT	78	-11.86	22.694	-100.0	-25.00	0.00	0.00	25.0			
										0.78	(-9.57, 11.14)	0.881A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	43	70.70	17.099	40.0	60.00	80.00	80.00	100.0			
	ADA	35	70.57	14.337	40.0	60.00	80.00	80.00	100.0			
	TOT	78	70.64	15.819	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	43	58.60	23.256	20.0	40.00	60.00	80.00	100.0			
	ADA	35	63.43	19.088	20.0	60.00	60.00	80.00	100.0			
	TOT	78	60.77	21.488	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	43	-12.09	19.586	-60.0	-20.00	0.00	0.00	20.0			
	ADA	35	-7.14	18.403	-60.0	-20.00	0.00	0.00	20.0			
	TOT	78	-9.87	19.103	-60.0	-20.00	0.00	0.00	20.0			
										4.95	(-3.69, 13.59)	0.258A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	43	86.34	13.588	62.5	75.00	87.50	100.00	100.0			
	ADA	35	85.36	16.462	50.0	75.00	87.50	100.00	100.0			
	TOT	78	85.90	14.853	50.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	43	68.02	25.777	25.0	50.00	75.00	87.50	100.0			
	ADA	35	79.64	21.456	25.0	62.50	87.50	100.00	100.0			
	TOT	78	73.24	24.485	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	43	-18.31	23.520	-75.0	-37.50	-12.50	0.00	12.5			
	ADA	35	-5.71	17.767	-75.0	-12.50	0.00	0.00	25.0			
	TOT	78	-12.66	21.929	-75.0	-25.00	0.00	0.00	25.0			
										12.60	(3.01, 22.19)	0.011A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	43	75.48	22.753	16.7	66.67	83.33	91.67	100.0			
	ADA	35	74.40	23.789	29.2	50.00	75.00	100.00	100.0			
	TOT	78	75.00	23.077	16.7	58.33	79.17	100.00	100.0			
FINAL/ET VALUE	PLO	43	66.28	26.970	8.3	41.67	75.00	91.67	100.0			
	ADA	35	72.38	22.667	25.0	50.00	75.00	91.67	100.0			
	TOT	78	69.02	25.158	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	43	-9.21	19.911	-66.7	-16.67	0.00	0.00	41.7			
	ADA	35	-2.02	16.981	-58.3	-8.33	0.00	8.33	25.0			
	TOT	78	-5.98	18.881	-66.7	-8.33	0.00	0.00	41.7			
										7.18	(-1.28, 15.64)	0.095A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	43	76.55	24.617	16.7	50.00	83.33	100.00	100.0			
	ADA	35	73.33	21.275	33.3	58.33	75.00	91.67	100.0			
	TOT	78	75.11	23.087	16.7	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	43	68.02	28.691	8.3	41.67	75.00	100.00	100.0			
	ADA	35	68.81	26.224	25.0	41.67	75.00	91.67	100.0			
	TOT	78	68.38	27.437	8.3	41.67	75.00	91.67	100.0			
CHG FROM BEST*	PLO	43	-8.53	13.788	-50.0	-16.67	-8.33	0.00	16.7			
	ADA	35	-4.52	12.016	-50.0	-8.33	0.00	0.00	16.7			
	TOT	78	-6.73	13.094	-50.0	-8.33	-4.17	0.00	16.7			
										4.00	(-1.90, 9.91)	0.181A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	43	87.21	19.949	25.0	75.00	100.00	100.00	100.0			
	ADA	35	88.21	18.427	37.5	87.50	100.00	100.00	100.0			
	TOT	78	87.66	19.164	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	43	77.91	25.419	12.5	62.50	87.50	100.00	100.0			
	ADA	35	83.75	20.795	25.0	75.00	100.00	100.00	100.0			
	TOT	78	80.53	23.493	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	43	-9.30	18.519	-62.5	-12.50	0.00	0.00	37.5			
	ADA	35	-4.46	9.536	-25.0	-12.50	0.00	0.00	12.5			
	TOT	78	-7.13	15.267	-62.5	-12.50	0.00	0.00	37.5			
										4.84	(-2.04, 11.72)	0.165A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	43	68.17	25.799	0.0	50.00	75.00	87.50	100.0			
	ADA	35	67.50	20.993	25.0	50.00	62.50	87.50	100.0			
	TOT	78	67.87	23.617	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	43	62.60	29.690	0.0	50.00	62.50	87.50	100.0			
	ADA	35	67.68	25.567	18.8	43.75	75.00	87.50	100.0			
	TOT	78	64.88	27.855	0.0	50.00	68.75	87.50	100.0			
CHG FROM BEST*	PLO	43	-5.57	18.499	-58.3	-12.50	-6.25	6.25	31.3			
	ADA	35	0.18	18.221	-43.8	-6.25	0.00	6.25	43.8			
	TOT	78	-2.99	18.481	-58.3	-12.50	0.00	6.25	43.8			
										5.75	(-2.58, 14.08)	0.173A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	43	73.26	27.083	12.5	50.00	75.00	100.00	100.0			
	ADA	35	69.64	26.824	12.5	50.00	75.00	100.00	100.0			
	TOT	78	71.63	26.853	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	43	62.21	31.984	0.0	37.50	75.00	87.50	100.0			
	ADA	35	68.21	30.968	0.0	37.50	75.00	100.00	100.0			
	TOT	78	64.90	31.472	0.0	37.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	43	-11.05	20.268	-75.0	-25.00	0.00	0.00	25.0			
	ADA	35	-1.43	21.814	-87.5	0.00	0.00	12.50	50.0			
	TOT	78	-6.73	21.386	-87.5	-12.50	0.00	0.00	50.0			
										9.62	(0.11, 19.13)	0.048A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	43	82.17	24.840	0.0	66.67	91.67	100.00	100.0			
	ADA	35	81.43	21.870	25.0	66.67	91.67	100.00	100.0			
	TOT	78	81.84	23.407	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	43	70.54	32.293	0.0	41.67	83.33	100.00	100.0			
	ADA	35	76.43	29.669	0.0	50.00	91.67	100.00	100.0			
	TOT	78	73.18	31.083	0.0	50.00	91.67	100.00	100.0			
CHG FROM BEST*	PLO	43	-11.63	21.527	-75.0	-25.00	0.00	0.00	50.0			
	ADA	35	-5.00	20.232	-75.0	-16.67	0.00	0.00	33.3			
	TOT	78	-8.65	21.084	-75.0	-16.67	0.00	0.00	50.0			
										6.63	(-2.87, 16.13)	0.169A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	36	62.96	37.872	0.0	33.33	75.00	100.00	100.0			
	ADA	33	64.14	27.440	0.0	50.00	66.67	83.33	100.0			
	TOT	69	63.53	33.060	0.0	41.67	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	36	49.19	36.783	0.0	12.50	50.00	83.33	100.0			
	ADA	33	59.09	29.636	0.0	50.00	66.67	83.33	100.0			
	TOT	69	53.93	33.683	0.0	33.33	58.33	83.33	100.0			
CHG FROM BEST*	PLO	36	-13.77	21.863	-58.3	-29.17	0.00	0.00	33.3			
	ADA	33	-5.05	14.869	-50.0	-8.33	0.00	0.00	25.0			
	TOT	69	-9.60	19.218	-58.3	-16.67	0.00	0.00	33.3			
										8.72	(-0.34, 17.79)	0.059A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	43	94.19	13.181	50.0	100.00	100.00	100.00	100.0			
	ADA	35	94.29	10.651	75.0	100.00	100.00	100.00	100.0			
	TOT	78	94.23	12.036	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	43	93.02	14.766	50.0	100.00	100.00	100.00	100.0			
	ADA	35	90.71	14.958	50.0	75.00	100.00	100.00	100.0			
	TOT	78	91.99	14.800	50.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	43	-1.16	13.311	-50.0	0.00	0.00	0.00	25.0			
	ADA	35	-3.57	8.876	-25.0	0.00	0.00	0.00	0.0			
	TOT	78	-2.24	11.528	-50.0	0.00	0.00	0.00	25.0			
										-2.41	(-7.64, 2.82)	0.362A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	43	80.23	24.126	25.0	75.00	100.00	100.00	100.0			
	ADA	35	75.00	25.725	25.0	75.00	75.00	100.00	100.0			
	TOT	78	77.88	24.831	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	43	73.26	26.945	25.0	50.00	75.00	100.00	100.0			
	ADA	35	73.57	25.684	25.0	50.00	75.00	100.00	100.0			
	TOT	78	73.40	26.217	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	43	-6.98	19.153	-75.0	0.00	0.00	0.00	50.0			
	ADA	35	-1.43	13.480	-25.0	0.00	0.00	0.00	25.0			
	TOT	78	-4.49	16.972	-75.0	0.00	0.00	0.00	50.0			
										5.55	(-2.09, 13.19)	0.152A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.21.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: NUMBER OF UVEITIS FLARES IN THE PAST 12 MONTHS>=3)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	43	76.35	19.547	25.7	55.45	82.88	94.20	98.7			
	ADA	35	74.76	17.227	35.6	60.38	74.49	90.04	99.4			
	TOT	78	75.64	18.442	25.7	59.81	81.74	91.93	99.4			
FINAL/ET VALUE	PLO	43	68.54	23.222	21.1	47.08	74.96	88.21	100.0			
	ADA	35	73.26	19.865	31.2	57.16	76.97	91.93	99.4			
	TOT	78	70.66	21.770	21.1	50.61	75.25	90.30	100.0			
CHG FROM BEST*	PLO	43	-7.81	14.063	-48.0	-12.21	-5.11	0.38	20.6			
	ADA	35	-1.51	11.094	-39.0	-3.90	-0.57	2.84	13.9			
	TOT	78	-4.98	13.121	-48.0	-9.02	-1.70	1.82	20.6			
										6.30	(0.49, 12.11)	0.034A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	54	64.81	23.046	0.0	50.00	75.00	75.00	100.0			
	ADA	56	60.71	18.984	25.0	50.00	50.00	75.00	100.0			
	TOT	110	62.73	21.079	0.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	54	50.00	26.600	0.0	25.00	50.00	75.00	100.0			
	ADA	56	56.70	19.360	25.0	50.00	50.00	75.00	100.0			
	TOT	110	53.41	23.334	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	54	-14.81	20.899	-75.0	-25.00	-25.00	0.00	25.0			
	ADA	56	-4.02	21.201	-50.0	-25.00	0.00	0.00	50.0			
	TOT	110	-9.32	21.646	-75.0	-25.00	0.00	0.00	50.0			
										10.80	(2.84, 18.76)	0.008A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	54	68.52	14.846	40.0	60.00	60.00	80.00	100.0			
	ADA	56	71.79	14.156	40.0	60.00	80.00	80.00	100.0			
	TOT	110	70.18	14.525	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	54	55.56	21.161	20.0	40.00	60.00	80.00	100.0			
	ADA	56	65.54	19.439	20.0	60.00	60.00	80.00	100.0			
	TOT	110	60.64	20.822	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	54	-12.96	20.247	-60.0	-20.00	-20.00	0.00	20.0			
	ADA	56	-6.25	18.641	-60.0	-20.00	0.00	0.00	30.0			
	TOT	110	-9.55	19.648	-60.0	-20.00	0.00	0.00	30.0			
										6.71	(-0.64, 14.06)	0.073A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	54	83.33	16.289	37.5	75.00	87.50	100.00	100.0			
	ADA	56	87.95	15.441	50.0	75.00	100.00	100.00	100.0			
	TOT	110	85.68	15.959	37.5	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	54	68.29	24.729	12.5	50.00	75.00	87.50	100.0			
	ADA	56	83.93	18.109	25.0	75.00	87.50	100.00	100.0			
	TOT	110	76.25	22.902	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-15.05	21.221	-75.0	-25.00	-12.50	0.00	25.0			
	ADA	56	-4.02	16.533	-75.0	-12.50	0.00	0.00	25.0			
	TOT	110	-9.43	19.687	-75.0	-12.50	0.00	0.00	25.0			
										11.03	(3.85, 18.20)	0.003A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	54	72.15	21.595	16.7	58.33	75.00	91.67	100.0			
	ADA	56	78.57	21.780	25.0	66.67	83.33	100.00	100.0			
	TOT	110	75.42	21.830	16.7	58.33	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	65.97	26.074	8.3	50.00	70.83	91.67	100.0			
	ADA	56	74.18	23.212	25.0	52.08	75.00	100.00	100.0			
	TOT	110	70.15	24.888	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	54	-6.17	20.663	-66.7	-16.67	0.00	0.00	41.7			
	ADA	56	-4.39	17.470	-66.7	-8.33	0.00	0.00	25.0			
	TOT	110	-5.27	19.037	-66.7	-12.50	0.00	0.00	41.7			
										1.78	(-5.44, 9.01)	0.626A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	54	73.77	21.501	16.7	58.33	75.00	91.67	100.0			
	ADA	56	77.75	21.071	33.3	62.50	83.33	100.00	100.0			
	TOT	110	75.80	21.280	16.7	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	54	68.21	26.018	8.3	50.00	75.00	91.67	100.0			
	ADA	56	71.76	26.865	25.0	46.88	83.33	95.83	100.0			
	TOT	110	70.02	26.392	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	54	-5.56	16.409	-50.0	-16.67	-6.25	0.00	41.7			
	ADA	56	-5.99	15.876	-66.7	-16.67	0.00	0.00	25.0			
	TOT	110	-5.78	16.067	-66.7	-16.67	0.00	0.00	41.7			
										-0.43	(-6.54, 5.67)	0.888A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	54	86.57	19.555	25.0	75.00	100.00	100.00	100.0			
	ADA	56	89.51	16.648	37.5	87.50	100.00	100.00	100.0			
	TOT	110	88.07	18.109	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	79.17	24.524	12.5	75.00	87.50	100.00	100.0			
	ADA	56	84.93	19.935	37.5	75.00	100.00	100.00	100.0			
	TOT	110	82.10	22.391	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	54	-7.41	18.255	-62.5	-12.50	0.00	0.00	37.5			
	ADA	56	-4.58	11.524	-50.0	-12.50	0.00	0.00	37.5			
	TOT	110	-5.97	15.201	-62.5	-12.50	0.00	0.00	37.5			
										2.83	(-2.92, 8.58)	0.331A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	54	64.35	24.871	0.0	50.00	68.75	81.25	100.0			
	ADA	56	69.31	23.027	25.0	50.00	81.25	87.50	100.0			
	TOT	110	66.88	23.969	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	54	60.15	29.554	0.0	37.50	62.50	87.50	100.0			
	ADA	56	68.19	25.625	18.8	43.75	75.00	93.75	100.0			
	TOT	110	64.24	27.792	0.0	43.75	68.75	87.50	100.0			
CHG FROM BEST*	PLO	54	-4.21	18.684	-58.3	-12.50	0.00	6.25	31.3			
	ADA	56	-1.12	17.842	-62.5	-6.25	0.00	6.25	31.3			
	TOT	110	-2.63	18.242	-62.5	-12.50	0.00	6.25	31.3			
										3.09	(-3.81, 9.99)	0.377A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	54	69.44	25.660	12.5	50.00	75.00	100.00	100.0			
	ADA	56	72.77	25.238	12.5	50.00	75.00	100.00	100.0			
	TOT	110	71.14	25.384	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	61.57	30.604	0.0	37.50	75.00	87.50	100.0			
	ADA	56	71.43	28.970	0.0	50.00	75.00	100.00	100.0			
	TOT	110	66.59	30.057	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-7.87	22.028	-75.0	-25.00	0.00	0.00	50.0			
	ADA	56	-1.34	24.504	-87.5	0.00	0.00	12.50	50.0			
	TOT	110	-4.55	23.445	-87.5	-12.50	0.00	0.00	50.0			
										6.53	(-2.29, 15.35)	0.145A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	54	77.62	27.272	0.0	66.67	91.67	100.00	100.0			
	ADA	56	83.33	23.463	25.0	66.67	100.00	100.00	100.0			
	TOT	110	80.53	25.449	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	54	70.22	32.481	0.0	50.00	79.17	100.00	100.0			
	ADA	56	81.85	26.405	0.0	66.67	100.00	100.00	100.0			
	TOT	110	76.14	29.982	0.0	58.33	91.67	100.00	100.0			
CHG FROM BEST*	PLO	54	-7.41	20.710	-75.0	-16.67	0.00	0.00	50.0			
	ADA	56	-1.49	18.265	-75.0	0.00	0.00	0.00	50.0			
	TOT	110	-4.39	19.640	-75.0	-8.33	0.00	0.00	50.0			
										5.92	(-1.45, 13.29)	0.114A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	48	63.89	32.902	0.0	50.00	75.00	87.50	100.0			
	ADA	51	67.73	31.279	0.0	50.00	79.17	91.67	100.0			
	TOT	99	65.87	31.970	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	48	54.43	32.199	0.0	33.33	58.33	83.33	100.0			
	ADA	51	63.97	32.722	0.0	41.67	75.00	83.33	100.0			
	TOT	99	59.34	32.657	0.0	33.33	66.67	83.33	100.0			
CHG FROM BEST*	PLO	48	-9.46	22.622	-58.3	-16.67	-4.17	0.00	50.0			
	ADA	51	-3.76	17.285	-66.7	-8.33	0.00	0.00	50.0			
	TOT	99	-6.52	20.152	-66.7	-16.67	0.00	0.00	50.0			
										5.70	(-2.30, 13.71)	0.160A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	54	94.91	11.264	50.0	100.00	100.00	100.00	100.0			
	ADA	56	94.64	10.351	75.0	100.00	100.00	100.00	100.0			
	TOT	110	94.77	10.760	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	91.67	15.357	50.0	75.00	100.00	100.00	100.0			
	ADA	56	91.07	16.116	50.0	75.00	100.00	100.00	100.0			
	TOT	110	91.36	15.679	50.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-3.24	11.942	-50.0	0.00	0.00	0.00	25.0			
	ADA	56	-3.57	13.840	-50.0	0.00	0.00	0.00	25.0			
	TOT	110	-3.41	12.885	-50.0	0.00	0.00	0.00	25.0			
										-0.33	(-5.22, 4.56)	0.894A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	54	79.17	23.667	25.0	75.00	75.00	100.00	100.0			
	ADA	55	84.09	20.048	25.0	75.00	100.00	100.00	100.0			
	TOT	109	81.65	21.954	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	54	72.22	25.544	0.0	50.00	75.00	100.00	100.0			
	ADA	55	79.55	21.565	25.0	75.00	75.00	100.00	100.0			
	TOT	109	75.92	23.797	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	54	-6.94	17.789	-75.0	-25.00	0.00	0.00	50.0			
	ADA	55	-4.55	17.408	-50.0	-25.00	0.00	0.00	25.0			
	TOT	109	-5.73	17.557	-75.0	-25.00	0.00	0.00	50.0			
										2.40	(-4.28, 9.08)	0.478A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.22.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE < 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	54	73.90	17.543	25.7	62.39	75.91	88.42	98.7			
	ADA	56	77.90	17.459	35.6	62.27	84.70	92.65	99.4			
	TOT	110	75.93	17.535	25.7	62.39	81.74	91.74	99.4			
FINAL/ET VALUE	PLO	54	68.15	21.379	21.1	50.61	74.05	86.89	100.0			
	ADA	56	75.96	19.526	31.2	60.08	84.55	93.07	99.4			
	TOT	110	72.13	20.737	21.1	54.39	75.72	90.30	100.0			
CHG FROM BEST*	PLO	54	-5.75	13.714	-48.0	-9.85	-3.62	2.54	20.6			
	ADA	56	-1.94	12.187	-39.0	-4.94	-0.63	3.18	25.8			
	TOT	110	-3.81	13.040	-48.0	-8.37	-1.23	2.84	25.8			
										3.81	(-1.09, 8.71)	0.126A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	55	63.18	23.001	25.0	50.00	50.00	75.00	100.0			
	ADA	53	66.04	21.424	25.0	50.00	50.00	75.00	100.0			
	TOT	108	64.58	22.184	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	55	48.18	27.994	0.0	25.00	50.00	75.00	100.0			
	ADA	53	51.89	26.787	0.0	50.00	50.00	75.00	100.0			
	TOT	108	50.00	27.343	0.0	25.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	55	-15.00	22.361	-100.0	-25.00	0.00	0.00	25.0			
	ADA	53	-14.15	25.244	-100.0	-25.00	0.00	0.00	25.0			
	TOT	108	-14.58	23.711	-100.0	-25.00	0.00	0.00	25.0			
										0.85	(-8.24, 9.94)	0.853A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	55	74.55	15.613	40.0	60.00	80.00	80.00	100.0			
	ADA	52	66.73	14.914	20.0	60.00	60.00	80.00	100.0			
	TOT	107	70.75	15.704	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	55	67.64	19.048	20.0	60.00	80.00	80.00	100.0			
	ADA	52	64.23	19.133	20.0	60.00	60.00	80.00	100.0			
	TOT	107	65.98	19.076	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	55	-6.91	15.971	-60.0	-20.00	0.00	0.00	20.0			
	ADA	52	-2.50	14.400	-20.0	-20.00	0.00	0.00	40.0			
	TOT	107	-4.77	15.317	-60.0	-20.00	0.00	0.00	40.0			
										4.41	(-1.43, 10.25)	0.137A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	55	86.14	16.258	37.5	75.00	87.50	100.00	100.0			
	ADA	53	79.95	19.356	25.0	62.50	75.00	100.00	100.0			
	TOT	108	83.10	18.031	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	55	76.59	23.577	12.5	62.50	75.00	100.00	100.0			
	ADA	53	76.89	21.567	25.0	62.50	75.00	100.00	100.0			
	TOT	108	76.74	22.508	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	55	-9.55	20.407	-87.5	-12.50	0.00	0.00	12.5			
	ADA	53	-3.07	15.679	-37.5	-12.50	0.00	0.00	37.5			
	TOT	108	-6.37	18.445	-87.5	-12.50	0.00	0.00	37.5			
										6.48	(-0.48, 13.44)	0.068A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	55	79.09	19.568	25.0	66.67	83.33	100.00	100.0			
	ADA	53	69.26	24.463	16.7	50.00	75.00	91.67	100.0			
	TOT	108	74.27	22.549	16.7	58.33	75.00	95.83	100.0			
FINAL/ET VALUE	PLO	55	70.00	25.939	8.3	50.00	75.00	91.67	100.0			
	ADA	53	66.67	24.677	16.7	50.00	66.67	91.67	100.0			
	TOT	108	68.36	25.265	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	55	-9.09	14.722	-58.3	-16.67	-8.33	0.00	16.7			
	ADA	53	-2.59	15.509	-50.0	-8.33	0.00	0.00	50.0			
	TOT	108	-5.90	15.393	-58.3	-8.33	0.00	0.00	50.0			
										6.50	(0.73, 12.26)	0.028A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	55	78.56	20.419	25.0	66.67	83.33	100.00	100.0			
	ADA	53	72.25	22.952	12.5	58.33	75.00	91.67	100.0			
	TOT	108	75.46	21.829	12.5	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	55	72.58	26.856	16.7	50.00	83.33	100.00	100.0			
	ADA	53	69.50	24.182	16.7	50.00	75.00	91.67	100.0			
	TOT	108	71.06	25.507	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	55	-5.98	12.698	-37.5	-16.67	0.00	0.00	25.0			
	ADA	53	-2.75	11.292	-33.3	-8.33	0.00	0.00	16.7			
	TOT	108	-4.40	12.082	-37.5	-8.33	0.00	0.00	25.0			
										3.23	(-1.36, 7.82)	0.165A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	55	90.23	16.438	37.5	87.50	100.00	100.00	100.0			
	ADA	53	86.32	20.983	25.0	75.00	100.00	100.00	100.0			
	TOT	108	88.31	18.820	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	84.32	23.350	12.5	75.00	100.00	100.00	100.0			
	ADA	53	80.66	24.338	12.5	75.00	87.50	100.00	100.0			
	TOT	108	82.52	23.799	12.5	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	55	-5.91	12.922	-37.5	-12.50	0.00	0.00	25.0			
	ADA	53	-5.66	14.413	-50.0	-12.50	0.00	0.00	25.0			
	TOT	108	-5.79	13.610	-50.0	-12.50	0.00	0.00	25.0			
										0.25	(-4.97, 5.47)	0.925A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	55	73.41	23.361	6.3	62.50	75.00	93.75	100.0			
	ADA	53	64.90	24.273	0.0	50.00	68.75	83.33	100.0			
	TOT	108	69.23	24.084	0.0	56.25	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	55	66.63	28.491	0.0	50.00	75.00	93.75	100.0			
	ADA	53	65.41	27.035	0.0	43.75	68.75	87.50	100.0			
	TOT	108	66.03	27.663	0.0	50.00	71.88	93.75	100.0			
CHG FROM BEST*	PLO	55	-6.78	17.624	-75.0	-12.50	0.00	6.25	25.0			
	ADA	53	0.51	15.298	-43.8	-6.25	0.00	6.25	43.8			
	TOT	108	-3.20	16.849	-75.0	-7.29	0.00	6.25	43.8			
										7.29	(0.99, 13.60)	0.024A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	55	75.23	27.056	12.5	62.50	75.00	100.00	100.0			
	ADA	53	68.63	26.360	0.0	50.00	75.00	100.00	100.0			
	TOT	108	71.99	26.797	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	66.36	30.417	0.0	50.00	75.00	100.00	100.0			
	ADA	53	63.21	32.375	0.0	50.00	62.50	100.00	100.0			
	TOT	108	64.81	31.286	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	55	-8.86	17.124	-62.5	-25.00	0.00	0.00	25.0			
	ADA	53	-5.42	22.932	-75.0	-12.50	0.00	0.00	37.5			
	TOT	108	-7.18	20.163	-75.0	-18.75	0.00	0.00	37.5			
										3.44	(-4.26, 11.14)	0.378A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	55	86.52	22.135	16.7	83.33	100.00	100.00	100.0			
	ADA	53	81.13	26.360	0.0	66.67	91.67	100.00	100.0			
	TOT	108	83.87	24.336	0.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	78.11	28.948	0.0	66.67	91.67	100.00	100.0			
	ADA	53	76.42	29.451	0.0	58.33	91.67	100.00	100.0			
	TOT	108	77.28	29.071	0.0	58.33	91.67	100.00	100.0			
CHG FROM BEST*	PLO	55	-8.41	18.118	-75.0	-16.67	0.00	0.00	29.2			
	ADA	53	-4.72	18.089	-66.7	-16.67	0.00	0.00	58.3			
	TOT	108	-6.60	18.114	-75.0	-16.67	0.00	0.00	58.3			
										3.69	(-3.22, 10.60)	0.292A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	50	70.08	29.278	0.0	58.33	83.33	91.67	100.0			
	ADA	48	65.71	28.315	0.0	41.67	70.83	91.67	100.0			
	TOT	98	67.94	28.746	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	50	61.00	34.521	0.0	33.33	75.00	91.67	100.0			
	ADA	48	60.07	31.649	0.0	41.67	66.67	83.33	100.0			
	TOT	98	60.54	32.978	0.0	41.67	66.67	83.33	100.0			
CHG FROM BEST*	PLO	50	-9.08	18.552	-75.0	-8.33	-2.08	0.00	33.3			
	ADA	48	-5.64	14.031	-41.7	-8.33	0.00	0.00	33.3			
	TOT	98	-7.40	16.500	-75.0	-8.33	0.00	0.00	33.3			
										3.44	(-3.17, 10.06)	0.304A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	55	93.64	13.793	50.0	100.00	100.00	100.00	100.0			
	ADA	53	91.98	15.328	25.0	75.00	100.00	100.00	100.0			
	TOT	108	92.82	14.522	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	91.14	17.459	25.0	87.50	100.00	100.00	100.0			
	ADA	53	87.74	18.748	25.0	75.00	100.00	100.00	100.0			
	TOT	108	89.47	18.099	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	55	-2.50	12.124	-50.0	0.00	0.00	0.00	25.0			
	ADA	53	-4.25	17.497	-75.0	0.00	0.00	0.00	25.0			
	TOT	108	-3.36	14.958	-75.0	0.00	0.00	0.00	25.0			
										-1.75	(-7.47, 3.98)	0.547A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	55	81.14	21.767	25.0	75.00	75.00	100.00	100.0			
	ADA	53	75.94	26.386	25.0	50.00	75.00	100.00	100.0			
	TOT	108	78.59	24.171	25.0	56.25	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	55	76.82	24.464	25.0	50.00	75.00	100.00	100.0			
	ADA	53	68.87	28.967	25.0	50.00	75.00	100.00	100.0			
	TOT	108	72.92	26.940	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	55	-4.32	15.444	-50.0	0.00	0.00	0.00	50.0			
	ADA	53	-7.08	18.591	-50.0	-25.00	0.00	0.00	25.0			
	TOT	108	-5.67	17.037	-50.0	-12.50	0.00	0.00	50.0			
										-2.76	(-9.27, 3.75)	0.403A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.23.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: TIME SINCE LAST FLARE >= 6 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	55	78.94	17.430	39.1	70.61	83.48	94.20	98.3			
	ADA	53	72.15	18.611	14.7	60.19	73.56	86.63	100.0			
	TOT	108	75.61	18.256	14.7	62.23	79.39	90.89	100.0			
FINAL/ET VALUE	PLO	55	73.82	20.542	27.6	63.41	77.80	91.55	100.0			
	ADA	53	70.74	20.777	18.5	57.54	70.80	85.38	99.4			
	TOT	108	72.31	20.619	18.5	59.00	74.64	91.21	100.0			
CHG FROM BEST*	PLO	55	-5.12	9.962	-34.8	-8.64	-1.59	1.88	11.7			
	ADA	53	-1.41	9.520	-38.0	-4.28	-0.11	3.79	16.5			
	TOT	108	-3.30	9.880	-38.0	-7.54	-1.19	2.42	16.5			
										3.72	(0.00, 7.44)	0.050A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	82	65.24	23.490	0.0	50.00	75.00	75.00	100.0			
	ADA	78	61.54	19.193	25.0	50.00	50.00	75.00	100.0			
	TOT	160	63.44	21.516	0.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	82	51.52	27.031	0.0	25.00	50.00	75.00	100.0			
	ADA	78	54.49	21.974	0.0	50.00	50.00	75.00	100.0			
	TOT	160	52.97	24.663	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	82	-13.72	20.843	-75.0	-25.00	0.00	0.00	25.0			
	ADA	78	-7.05	23.458	-100.0	-25.00	0.00	0.00	50.0			
	TOT	160	-10.47	22.338	-100.0	-25.00	0.00	0.00	50.0			
										6.67	(-0.25, 13.59)	0.059A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	82	71.71	15.056	40.0	60.00	80.00	80.00	100.0			
	ADA	78	67.31	14.917	20.0	60.00	60.00	80.00	100.0			
	TOT	160	69.56	15.103	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	82	63.90	20.231	20.0	40.00	60.00	80.00	100.0			
	ADA	78	64.74	18.071	20.0	60.00	60.00	80.00	100.0			
	TOT	160	64.31	19.153	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	82	-7.80	16.256	-40.0	-20.00	0.00	0.00	20.0			
	ADA	78	-2.56	13.905	-40.0	-20.00	0.00	0.00	40.0			
	TOT	160	-5.25	15.335	-40.0	-20.00	0.00	0.00	40.0			
										5.24	(0.51, 9.98)	0.030A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	82	84.91	16.636	37.5	75.00	87.50	100.00	100.0			
	ADA	78	82.37	18.838	25.0	62.50	87.50	100.00	100.0			
	TOT	160	83.67	17.733	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	82	74.09	23.797	12.5	62.50	75.00	100.00	100.0			
	ADA	78	79.65	19.954	37.5	62.50	75.00	100.00	100.0			
	TOT	160	76.80	22.115	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-10.82	21.495	-87.5	-12.50	0.00	0.00	25.0			
	ADA	78	-2.72	15.689	-37.5	-12.50	0.00	0.00	37.5			
	TOT	160	-6.88	19.263	-87.5	-12.50	0.00	0.00	37.5			
										8.10	(2.20, 14.00)	0.007A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	82	76.58	19.627	33.3	58.33	75.00	100.00	100.0			
	ADA	78	71.85	23.744	16.7	50.00	75.00	91.67	100.0			
	TOT	160	74.27	21.792	16.7	58.33	75.00	95.83	100.0			
FINAL/ET VALUE	PLO	82	69.82	25.073	8.3	50.00	75.00	91.67	100.0			
	ADA	78	69.28	24.371	25.0	50.00	75.00	91.67	100.0			
	TOT	160	69.56	24.657	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	82	-6.76	16.701	-66.7	-16.67	-4.17	0.00	33.3			
	ADA	78	-2.56	16.314	-66.7	-8.33	0.00	0.00	50.0			
	TOT	160	-4.71	16.595	-66.7	-8.33	0.00	0.00	50.0			
										4.19	(-0.96, 9.35)	0.110A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	82	75.97	21.016	16.7	58.33	83.33	91.67	100.0			
	ADA	78	73.02	23.035	12.5	58.33	75.00	91.67	100.0			
	TOT	160	74.53	22.003	12.5	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	82	73.17	25.325	8.3	58.33	75.00	91.67	100.0			
	ADA	78	69.58	25.518	16.7	50.00	75.00	91.67	100.0			
	TOT	160	71.42	25.403	8.3	54.17	75.00	91.67	100.0			
CHG FROM BEST*	PLO	82	-2.79	13.161	-37.5	-8.33	0.00	4.17	41.7			
	ADA	78	-3.45	13.133	-66.7	-8.33	0.00	0.00	25.0			
	TOT	160	-3.11	13.110	-66.7	-8.33	0.00	0.00	41.7			
										-0.65	(-4.76, 3.46)	0.755A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	82	89.94	16.010	37.5	87.50	100.00	100.00	100.0			
	ADA	78	86.86	19.831	25.0	75.00	100.00	100.00	100.0			
	TOT	160	88.44	17.984	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	85.21	19.157	25.0	75.00	93.75	100.00	100.0			
	ADA	78	81.65	22.977	12.5	75.00	87.50	100.00	100.0			
	TOT	160	83.48	21.115	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	82	-4.73	12.826	-50.0	-12.50	0.00	0.00	25.0			
	ADA	78	-5.21	13.716	-50.0	-12.50	0.00	0.00	37.5			
	TOT	160	-4.96	13.228	-50.0	-12.50	0.00	0.00	37.5			
										-0.48	(-4.63, 3.66)	0.818A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	82	70.50	22.487	12.5	56.25	75.00	87.50	100.0			
	ADA	78	66.19	24.247	0.0	50.00	68.75	87.50	100.0			
	TOT	160	68.40	23.388	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	82	66.41	26.580	0.0	50.00	71.88	93.75	100.0			
	ADA	78	66.80	26.252	0.0	43.75	68.75	87.50	100.0			
	TOT	160	66.60	26.338	0.0	50.00	68.75	90.63	100.0			
CHG FROM BEST*	PLO	82	-4.09	15.881	-75.0	-12.50	0.00	6.25	25.0			
	ADA	78	0.61	16.511	-62.5	-6.25	0.00	12.50	31.3			
	TOT	160	-1.80	16.312	-75.0	-6.25	0.00	6.25	31.3			
										4.70	(-0.35, 9.76)	0.068A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	82	72.87	25.895	12.5	50.00	75.00	100.00	100.0			
	ADA	78	69.39	25.928	0.0	50.00	68.75	100.00	100.0			
	TOT	160	71.17	25.888	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	66.77	27.793	0.0	50.00	75.00	87.50	100.0			
	ADA	78	67.63	29.569	0.0	50.00	68.75	100.00	100.0			
	TOT	160	67.19	28.585	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-6.10	17.485	-50.0	-25.00	0.00	0.00	50.0			
	ADA	78	-1.76	21.765	-62.5	-12.50	0.00	12.50	37.5			
	TOT	160	-3.98	19.745	-62.5	-12.50	0.00	0.00	50.0			
										4.33	(-1.82, 10.48)	0.166A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	82	84.04	21.604	25.0	75.00	91.67	100.00	100.0			
	ADA	78	81.73	24.620	0.0	66.67	91.67	100.00	100.0			
	TOT	160	82.92	23.080	0.0	70.83	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	82	77.90	26.309	8.3	66.67	89.58	100.00	100.0			
	ADA	78	80.02	26.192	0.0	58.33	91.67	100.00	100.0			
	TOT	160	78.93	26.191	0.0	66.67	91.67	100.00	100.0			
CHG FROM BEST*	PLO	82	-6.15	15.648	-50.0	-16.67	0.00	0.00	29.2			
	ADA	78	-1.71	16.686	-41.7	-8.33	0.00	0.00	58.3			
	TOT	160	-3.98	16.264	-50.0	-12.50	0.00	0.00	58.3			
										4.44	(-0.61, 9.49)	0.084A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	73	68.44	28.884	0.0	50.00	75.00	91.67	100.0			
	ADA	71	66.02	28.916	0.0	41.67	75.00	91.67	100.0			
	TOT	144	67.25	28.824	0.0	50.00	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	73	60.50	33.305	0.0	41.67	75.00	83.33	100.0			
	ADA	71	62.62	30.885	0.0	41.67	66.67	83.33	100.0			
	TOT	144	61.55	32.040	0.0	41.67	70.83	83.33	100.0			
CHG FROM BEST*	PLO	73	-7.93	18.349	-75.0	-16.67	0.00	0.00	33.3			
	ADA	71	-3.40	15.738	-66.7	-8.33	0.00	0.00	50.0			
	TOT	144	-5.70	17.203	-75.0	-8.33	0.00	0.00	50.0			
										4.53	(-1.11, 10.17)	0.114A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	82	94.51	12.438	50.0	100.00	100.00	100.00	100.0			
	ADA	78	92.63	14.020	25.0	75.00	100.00	100.00	100.0			
	TOT	160	93.59	13.225	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	93.45	13.498	50.0	100.00	100.00	100.00	100.0			
	ADA	78	88.78	18.308	25.0	75.00	100.00	100.00	100.0			
	TOT	160	91.17	16.143	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-1.07	10.794	-50.0	0.00	0.00	0.00	25.0			
	ADA	78	-3.85	16.155	-75.0	0.00	0.00	0.00	25.0			
	TOT	160	-2.42	13.700	-75.0	0.00	0.00	0.00	25.0			
										-2.78	(-7.05, 1.49)	0.201A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	82	79.42	23.021	25.0	75.00	75.00	100.00	100.0			
	ADA	78	77.24	24.898	25.0	50.00	75.00	100.00	100.0			
	TOT	160	78.36	23.904	25.0	68.75	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	82	77.13	23.636	0.0	75.00	75.00	100.00	100.0			
	ADA	78	71.79	26.223	25.0	50.00	75.00	100.00	100.0			
	TOT	160	74.53	24.996	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	82	-2.29	14.045	-25.0	0.00	0.00	0.00	50.0			
	ADA	78	-5.45	19.174	-50.0	-25.00	0.00	0.00	25.0			
	TOT	160	-3.83	16.764	-50.0	0.00	0.00	0.00	50.0			
										-3.16	(-8.39, 2.07)	0.234A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.24.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE < 15 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	82	76.95	16.887	39.1	66.06	79.94	91.93	98.3			
	ADA	78	73.68	18.390	14.7	60.19	74.03	89.47	100.0			
	TOT	160	75.36	17.656	14.7	61.67	79.00	90.98	100.0			
FINAL/ET VALUE	PLO	82	73.73	18.838	27.0	63.41	75.78	90.23	100.0			
	ADA	78	72.82	19.549	18.5	59.05	72.57	92.12	99.4			
	TOT	160	73.29	19.133	18.5	60.17	75.59	91.14	100.0			
CHG FROM BEST*	PLO	82	-3.22	9.096	-34.8	-8.26	-1.42	2.46	19.7			
	ADA	78	-0.87	9.989	-38.7	-4.47	-0.13	3.79	25.8			
	TOT	160	-2.07	9.584	-38.7	-5.78	-1.10	2.94	25.8			
										2.35	(-0.63, 5.33)	0.121A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	9	52.78	23.199	25.0	50.00	50.00	50.00	100.0
	ADA	15	63.33	22.887	25.0	50.00	75.00	75.00	100.0
	TOT	24	59.38	23.093	25.0	50.00	50.00	75.00	100.0
FINAL/ET VALUE	PLO	9	27.78	26.352	0.0	0.00	25.00	50.00	75.0
	ADA	15	48.33	25.820	0.0	25.00	50.00	75.00	100.0
	TOT	24	40.63	27.399	0.0	25.00	50.00	50.00	100.0
CHG FROM BEST*	PLO	9	-25.00	33.072	-100.0	-25.00	-25.00	0.00	0.0
	ADA	15	-15.00	24.640	-75.0	-25.00	0.00	0.00	25.0
	TOT	24	-18.75	27.829	-100.0	-25.00	-12.50	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	9	71.11	20.276	40.0	60.00	60.00	80.00	100.0
	ADA	15	74.67	11.872	60.0	60.00	80.00	80.00	100.0
	TOT	24	73.33	15.228	40.0	60.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	9	48.89	20.276	20.0	40.00	60.00	60.00	80.0
	ADA	15	66.67	20.931	20.0	60.00	80.00	80.00	100.0
	TOT	24	60.00	22.067	20.0	40.00	60.00	80.00	100.0
CHG FROM BEST*	PLO	9	-22.22	25.386	-60.0	-40.00	-20.00	0.00	0.0
	ADA	15	-8.00	22.424	-60.0	-20.00	0.00	0.00	20.0
	TOT	24	-13.33	24.077	-60.0	-20.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	9	94.44	12.672	62.5	100.00	100.00	100.00	100.0
	ADA	15	89.17	16.275	50.0	75.00	100.00	100.00	100.0
	TOT	24	91.15	14.963	50.0	87.50	100.00	100.00	100.0
FINAL/ET VALUE	PLO	9	79.17	27.243	25.0	62.50	87.50	100.00	100.0
	ADA	15	80.83	22.093	25.0	75.00	87.50	100.00	100.0
	TOT	24	80.21	23.578	25.0	68.75	87.50	100.00	100.0
CHG FROM BEST*	PLO	9	-15.28	21.449	-62.5	-12.50	-12.50	0.00	0.0
	ADA	15	-8.33	12.199	-37.5	-12.50	0.00	0.00	0.0
	TOT	24	-10.94	16.199	-62.5	-12.50	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	9	78.70	24.335	25.0	66.67	83.33	100.00	100.0
	ADA	15	85.00	21.639	33.3	66.67	100.00	100.00	100.0
	TOT	24	82.64	22.376	25.0	66.67	91.67	100.00	100.0
FINAL/ET VALUE	PLO	9	66.67	34.611	8.3	33.33	83.33	100.00	100.0
	ADA	15	77.78	25.132	16.7	58.33	83.33	100.00	100.0
	TOT	24	73.61	28.833	8.3	54.17	83.33	100.00	100.0
CHG FROM BEST*	PLO	9	-12.04	18.686	-50.0	-16.67	-8.33	0.00	8.3
	ADA	15	-7.22	18.330	-58.3	-8.33	0.00	0.00	16.7
	TOT	24	-9.03	18.211	-58.3	-12.50	-4.17	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	9	79.63	27.985	25.0	58.33	91.67	100.00	100.0
	ADA	15	86.67	16.607	50.0	75.00	91.67	100.00	100.0
	TOT	24	84.03	21.270	25.0	70.83	91.67	100.00	100.0
FINAL/ET VALUE	PLO	9	68.52	36.271	16.7	25.00	91.67	100.00	100.0
	ADA	15	78.33	26.315	16.7	66.67	91.67	100.00	100.0
	TOT	24	74.65	30.044	16.7	58.33	91.67	100.00	100.0
CHG FROM BEST*	PLO	9	-11.11	13.176	-33.3	-25.00	-8.33	0.00	0.0
	ADA	15	-8.33	14.434	-50.0	-8.33	0.00	0.00	0.0
	TOT	24	-9.38	13.751	-50.0	-8.33	-4.17	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	9	83.33	25.000	50.0	50.00	100.00	100.00	100.0
	ADA	15	95.83	10.206	62.5	100.00	100.00	100.00	100.0
	TOT	24	91.15	17.861	50.0	93.75	100.00	100.00	100.0
FINAL/ET VALUE	PLO	9	70.83	38.017	12.5	25.00	87.50	100.00	100.0
	ADA	15	90.00	17.803	50.0	87.50	100.00	100.00	100.0
	TOT	24	82.81	28.027	12.5	81.25	100.00	100.00	100.0
CHG FROM BEST*	PLO	9	-12.50	13.975	-37.5	-25.00	-12.50	0.00	0.0
	ADA	15	-5.83	13.251	-50.0	-12.50	0.00	0.00	0.0
	TOT	24	-8.33	13.627	-50.0	-12.50	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	9	70.14	27.203	25.0	50.00	87.50	87.50	100.0
	ADA	15	75.83	19.026	25.0	62.50	87.50	87.50	93.8
	TOT	24	73.70	22.038	25.0	59.38	87.50	87.50	100.0
FINAL/ET VALUE	PLO	9	61.81	35.964	0.0	31.25	75.00	87.50	100.0
	ADA	15	69.58	26.078	18.8	56.25	81.25	87.50	100.0
	TOT	24	66.67	29.642	0.0	43.75	78.13	87.50	100.0
CHG FROM BEST*	PLO	9	-8.33	16.829	-50.0	-6.25	-6.25	0.00	6.3
	ADA	15	-6.25	20.863	-43.8	-18.75	0.00	0.00	43.8
	TOT	24	-7.03	19.092	-50.0	-12.50	-3.13	0.00	43.8

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	9	72.22	30.477	25.0	37.50	87.50	100.00	100.0
	ADA	15	78.33	25.207	12.5	62.50	87.50	100.00	100.0
	TOT	24	76.04	26.814	12.5	62.50	87.50	100.00	100.0
FINAL/ET VALUE	PLO	9	65.28	42.746	12.5	12.50	100.00	100.00	100.0
	ADA	15	73.33	31.646	12.5	37.50	87.50	100.00	100.0
	TOT	24	70.31	35.511	12.5	31.25	87.50	100.00	100.0
CHG FROM BEST*	PLO	9	-6.94	15.450	-25.0	-25.00	0.00	0.00	12.5
	ADA	15	-5.00	21.023	-50.0	-12.50	0.00	0.00	37.5
	TOT	24	-5.73	18.788	-50.0	-18.75	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	9	80.56	27.951	33.3	58.33	100.00	100.00	100.0
	ADA	15	92.78	19.124	25.0	91.67	100.00	100.00	100.0
	TOT	24	88.19	23.041	25.0	91.67	100.00	100.00	100.0
FINAL/ET VALUE	PLO	9	74.07	38.963	16.7	25.00	100.00	100.00	100.0
	ADA	15	81.67	30.732	16.7	41.67	100.00	100.00	100.0
	TOT	24	78.82	33.422	16.7	41.67	100.00	100.00	100.0
CHG FROM BEST*	PLO	9	-6.48	13.679	-33.3	-8.33	0.00	0.00	8.3
	ADA	15	-11.11	28.113	-75.0	0.00	0.00	0.00	16.7
	TOT	24	-9.38	23.482	-75.0	-4.17	0.00	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	8	64.58	36.934	0.0	41.67	70.83	95.83	100.0
	ADA	14	76.19	24.429	16.7	66.67	83.33	91.67	100.0
	TOT	22	71.97	29.271	0.0	50.00	83.33	91.67	100.0
FINAL/ET VALUE	PLO	8	48.96	36.033	0.0	20.83	45.83	79.17	100.0
	ADA	14	69.64	25.235	0.0	58.33	83.33	83.33	91.7
	TOT	22	62.12	30.508	0.0	41.67	75.00	83.33	100.0
CHG FROM BEST*	PLO	8	-15.63	13.684	-41.7	-20.83	-16.67	-4.17	0.0
	ADA	14	-6.55	16.072	-41.7	-16.67	-8.33	0.00	25.0
	TOT	22	-9.85	15.566	-41.7	-16.67	-8.33	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	9	91.67	17.678	50.0	100.00	100.00	100.00	100.0
	ADA	15	98.33	6.455	75.0	100.00	100.00	100.00	100.0
	TOT	24	95.83	12.039	50.0	100.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	9	83.33	25.000	25.0	75.00	100.00	100.00	100.0
	ADA	15	95.00	10.351	75.0	100.00	100.00	100.00	100.0
	TOT	24	90.63	17.773	25.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	9	-8.33	12.500	-25.0	-25.00	0.00	0.00	0.0
	ADA	15	-3.33	8.797	-25.0	0.00	0.00	0.00	0.0
	TOT	24	-5.21	10.371	-25.0	0.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	9	80.56	24.296	50.0	50.00	100.00	100.00	100.0
	ADA	15	90.00	20.702	25.0	75.00	100.00	100.00	100.0
	TOT	24	86.46	22.091	25.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	9	72.22	34.106	25.0	50.00	100.00	100.00	100.0
	ADA	15	80.00	28.661	25.0	50.00	100.00	100.00	100.0
	TOT	24	77.08	30.321	25.0	50.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	9	-8.33	12.500	-25.0	-25.00	0.00	0.00	0.0
	ADA	15	-10.00	15.811	-50.0	-25.00	0.00	0.00	0.0
	TOT	24	-9.38	14.394	-50.0	-25.00	0.00	0.00	0.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.25.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 15 to < 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	9	77.86	20.124	43.6	62.39	88.33	95.23	98.7
	ADA	15	84.05	15.953	35.6	78.30	90.04	94.20	95.5
	TOT	24	81.73	17.468	35.6	72.03	89.36	94.68	98.7
FINAL/ET VALUE	PLO	9	67.03	29.633	27.6	32.12	86.89	90.42	94.7
	ADA	15	78.58	21.798	29.6	67.31	90.04	92.88	97.3
	TOT	24	74.25	25.045	27.6	54.68	89.32	91.75	97.3
CHG FROM BEST*	PLO	9	-10.83	11.807	-30.3	-15.96	-8.71	-0.57	2.1
	ADA	15	-5.47	14.127	-38.3	-5.42	-1.33	0.19	10.7
	TOT	24	-7.48	13.304	-38.3	-10.25	-3.28	0.09	10.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL HEALTH									
BEST VALUE*	PLO	18	63.89	19.596	25.0	50.00	75.00	75.00	100.0
	ADA	16	71.88	22.127	25.0	50.00	75.00	87.50	100.0
	TOT	34	67.65	20.898	25.0	50.00	75.00	75.00	100.0
FINAL/ET VALUE	PLO	18	48.61	24.959	0.0	25.00	50.00	75.00	100.0
	ADA	16	59.38	27.195	25.0	37.50	50.00	75.00	100.0
	TOT	34	53.68	26.207	0.0	25.00	50.00	75.00	100.0
CHG FROM BEST*	PLO	18	-15.28	17.445	-50.0	-25.00	-25.00	0.00	25.0
	ADA	16	-12.50	24.152	-75.0	-25.00	0.00	0.00	25.0
	TOT	34	-13.97	20.589	-75.0	-25.00	-12.50	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
GENERAL VISION									
BEST VALUE*	PLO	18	71.11	15.676	40.0	60.00	80.00	80.00	100.0
	ADA	15	74.67	14.075	40.0	60.00	80.00	80.00	100.0
	TOT	33	72.73	14.848	40.0	60.00	80.00	80.00	100.0
FINAL/ET VALUE	PLO	18	57.78	22.637	20.0	40.00	60.00	80.00	100.0
	ADA	15	64.00	24.142	20.0	40.00	60.00	80.00	100.0
	TOT	33	60.61	23.176	20.0	40.00	60.00	80.00	100.0
CHG FROM BEST*	PLO	18	-13.33	21.693	-60.0	-20.00	-10.00	0.00	20.0
	ADA	15	-10.67	22.509	-60.0	-20.00	0.00	0.00	20.0
	TOT	33	-12.12	21.760	-60.0	-20.00	0.00	0.00	20.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
OCULAR PAIN									
BEST VALUE*	PLO	18	79.17	14.220	62.5	62.50	75.00	87.50	100.0
	ADA	16	87.50	12.910	62.5	75.00	87.50	100.00	100.0
	TOT	34	83.09	14.062	62.5	75.00	81.25	100.00	100.0
FINAL/ET VALUE	PLO	18	61.81	24.053	12.5	50.00	62.50	75.00	100.0
	ADA	16	84.38	19.632	25.0	75.00	87.50	100.00	100.0
	TOT	34	72.43	24.576	12.5	62.50	75.00	87.50	100.0
CHG FROM BEST*	PLO	18	-17.36	17.750	-50.0	-25.00	-12.50	0.00	0.0
	ADA	16	-3.13	20.666	-75.0	0.00	0.00	0.00	25.0
	TOT	34	-10.66	20.210	-75.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
NEAR VISION									
BEST VALUE*	PLO	18	69.91	24.277	16.7	58.33	75.00	83.33	100.0
	ADA	16	74.48	22.250	25.0	58.33	79.17	91.67	100.0
	TOT	34	72.06	23.109	16.7	58.33	75.00	91.67	100.0
FINAL/ET VALUE	PLO	18	60.42	25.415	25.0	33.33	54.17	87.50	100.0
	ADA	16	69.79	22.127	25.0	50.00	75.00	83.33	100.0
	TOT	34	64.83	24.039	25.0	50.00	66.67	83.33	100.0
CHG FROM BEST*	PLO	18	-9.49	22.858	-50.0	-33.33	-8.33	0.00	41.7
	ADA	16	-4.69	16.093	-50.0	-12.50	0.00	4.17	16.7
	TOT	34	-7.23	19.819	-50.0	-16.67	0.00	0.00	41.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DISTANCE VISION									
BEST VALUE*	PLO	18	75.46	17.958	33.3	75.00	79.17	83.33	100.0
	ADA	16	74.22	19.258	33.3	64.58	75.00	91.67	100.0
	TOT	34	74.88	18.306	33.3	66.67	75.00	83.33	100.0
FINAL/ET VALUE	PLO	18	58.80	23.995	25.0	41.67	54.17	83.33	100.0
	ADA	16	68.75	25.000	25.0	50.00	70.83	91.67	100.0
	TOT	34	63.48	24.620	25.0	41.67	62.50	83.33	100.0
CHG FROM BEST*	PLO	18	-16.67	16.169	-50.0	-25.00	-12.50	0.00	0.0
	ADA	16	-5.47	16.854	-50.0	-12.50	0.00	4.17	16.7
	TOT	34	-11.40	17.204	-50.0	-25.00	-8.33	0.00	16.7

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
SOCIAL FUNCTIONING									
BEST VALUE*	PLO	18	84.03	22.608	25.0	75.00	93.75	100.00	100.0
	ADA	16	85.94	19.298	37.5	75.00	93.75	100.00	100.0
	TOT	34	84.93	20.821	25.0	75.00	93.75	100.00	100.0
FINAL/ET VALUE	PLO	18	71.53	31.450	12.5	37.50	87.50	100.00	100.0
	ADA	16	82.03	21.875	37.5	68.75	93.75	100.00	100.0
	TOT	34	76.47	27.484	12.5	50.00	87.50	100.00	100.0
CHG FROM BEST*	PLO	18	-12.50	25.000	-62.5	-25.00	-12.50	0.00	37.5
	ADA	16	-3.91	8.802	-25.0	0.00	0.00	0.00	0.0
	TOT	34	-8.46	19.394	-62.5	-12.50	0.00	0.00	37.5

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
MENTAL HEALTH									
BEST VALUE*	PLO	18	61.11	30.959	0.0	43.75	75.00	81.25	93.8
	ADA	16	63.80	23.958	25.0	43.75	65.63	87.50	93.8
	TOT	34	62.38	27.505	0.0	43.75	71.88	87.50	93.8
FINAL/ET VALUE	PLO	18	50.58	34.276	0.0	18.75	53.13	87.50	100.0
	ADA	16	64.45	27.737	18.8	37.50	68.75	93.75	100.0
	TOT	34	57.11	31.691	0.0	31.25	56.25	87.50	100.0
CHG FROM BEST*	PLO	18	-10.53	26.646	-58.3	-37.50	-3.13	6.25	31.3
	ADA	16	0.65	11.704	-18.8	-6.25	0.00	6.25	31.3
	TOT	34	-5.27	21.451	-58.3	-12.50	0.00	6.25	31.3

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
ROLE DIFFICULTIES									
BEST VALUE*	PLO	18	70.14	28.160	12.5	50.00	75.00	100.00	100.0
	ADA	16	70.31	25.769	25.0	50.00	75.00	100.00	100.0
	TOT	34	70.22	26.653	12.5	50.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	18	50.69	33.616	0.0	25.00	50.00	75.00	100.0
	ADA	16	60.94	36.479	0.0	31.25	68.75	100.00	100.0
	TOT	34	55.51	34.842	0.0	25.00	62.50	75.00	100.0
CHG FROM BEST*	PLO	18	-19.44	26.851	-75.0	-37.50	-18.75	0.00	25.0
	ADA	16	-9.38	34.004	-87.5	-18.75	0.00	0.00	50.0
	TOT	34	-14.71	30.381	-87.5	-25.00	-6.25	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DEPENDENCY									
BEST VALUE*	PLO	18	74.07	36.368	0.0	50.00	95.83	100.00	100.0
	ADA	16	75.00	28.545	25.0	54.17	83.33	100.00	100.0
	TOT	34	74.51	32.434	0.0	50.00	87.50	100.00	100.0
FINAL/ET VALUE	PLO	18	57.41	40.914	0.0	8.33	66.67	100.00	100.0
	ADA	16	72.92	34.089	0.0	45.83	91.67	100.00	100.0
	TOT	34	64.71	38.109	0.0	33.33	75.00	100.00	100.0
CHG FROM BEST*	PLO	18	-16.67	32.084	-75.0	-33.33	0.00	0.00	50.0
	ADA	16	-2.08	11.587	-33.3	0.00	0.00	0.00	16.7
	TOT	34	-9.80	25.415	-75.0	-25.00	0.00	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
DRIVING									
BEST VALUE*	PLO	17	62.25	38.428	0.0	50.00	83.33	91.67	100.0
	ADA	14	61.01	37.893	0.0	25.00	79.17	91.67	100.0
	TOT	31	61.69	37.553	0.0	25.00	83.33	91.67	100.0
FINAL/ET VALUE	PLO	17	50.25	32.691	0.0	33.33	50.00	83.33	100.0
	ADA	14	51.79	42.640	0.0	0.00	75.00	83.33	100.0
	TOT	31	50.94	36.857	0.0	8.33	50.00	83.33	100.0
CHG FROM BEST*	PLO	17	-12.01	30.401	-58.3	-37.50	-8.33	0.00	50.0
	ADA	14	-9.23	15.520	-50.0	-12.50	-4.17	0.00	8.3
	TOT	31	-10.75	24.480	-58.3	-25.00	-8.33	0.00	50.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
COLOR VISION									
BEST VALUE*	PLO	18	94.44	10.695	75.0	100.00	100.00	100.00	100.0
	ADA	16	92.19	11.968	75.0	75.00	100.00	100.00	100.0
	TOT	34	93.38	11.195	75.0	75.00	100.00	100.00	100.0
FINAL/ET VALUE	PLO	18	86.11	21.390	50.0	75.00	100.00	100.00	100.0
	ADA	16	87.50	18.257	50.0	75.00	100.00	100.00	100.0
	TOT	34	86.76	19.690	50.0	75.00	100.00	100.00	100.0
CHG FROM BEST*	PLO	18	-8.33	14.852	-50.0	-25.00	0.00	0.00	0.0
	ADA	16	-4.69	18.750	-50.0	-12.50	0.00	0.00	25.0
	TOT	34	-6.62	16.639	-50.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
PERIPHERAL VISION									
BEST VALUE*	PLO	18	83.33	21.004	25.0	75.00	87.50	100.00	100.0
	ADA	15	85.00	15.811	50.0	75.00	75.00	100.00	100.0
	TOT	33	84.09	18.560	25.0	75.00	75.00	100.00	100.0
FINAL/ET VALUE	PLO	18	63.89	24.588	25.0	50.00	75.00	75.00	100.0
	ADA	15	81.67	19.970	50.0	75.00	75.00	100.00	100.0
	TOT	33	71.97	24.010	25.0	50.00	75.00	100.00	100.0
CHG FROM BEST*	PLO	18	-19.44	21.955	-75.0	-25.00	-25.00	0.00	0.0
	ADA	15	-3.33	12.910	-25.0	0.00	0.00	0.00	25.0
	TOT	33	-12.12	19.884	-75.0	-25.00	0.00	0.00	25.0

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.26.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: PREDNISONE DOSE AT LAST FLARE >= 30 MG/DAY)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX
TOTAL SCORE									
BEST VALUE*	PLO	18	73.41	20.097	25.7	58.48	78.52	89.66	96.2
	ADA	16	73.62	17.660	40.1	57.20	74.02	91.08	97.0
	TOT	34	73.51	18.704	25.7	57.50	76.07	89.85	97.0
FINAL/ET VALUE	PLO	18	60.59	23.531	21.1	42.01	59.64	76.59	100.0
	ADA	16	71.54	22.504	31.2	50.28	78.15	89.85	99.4
	TOT	34	65.74	23.372	21.1	47.08	70.30	87.16	100.0
CHG FROM BEST*	PLO	18	-12.82	18.588	-48.0	-23.71	-8.83	1.14	20.6
	ADA	16	-2.07	11.951	-39.0	-5.04	-0.13	3.17	13.4
	TOT	34	-7.76	16.510	-48.0	-13.30	-3.72	2.39	20.6

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL

TESTSTATISTICAL ANALYSIS IS OMITTED DUE TO SMALL N.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	64	67.58	23.855	0.0	50.00	75.00	75.00	100.0			
	ADA	70	63.21	20.730	25.0	50.00	75.00	75.00	100.0			
	TOT	134	65.30	22.300	0.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	64	53.13	27.639	0.0	25.00	50.00	75.00	100.0			
	ADA	70	57.50	21.003	0.0	50.00	50.00	75.00	100.0			
	TOT	134	55.41	24.403	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	64	-14.45	20.800	-75.0	-25.00	-12.50	0.00	25.0			
	ADA	70	-5.71	22.591	-75.0	-25.00	0.00	0.00	50.0			
	TOT	134	-9.89	22.111	-75.0	-25.00	0.00	0.00	50.0			
										8.74	(1.30, 16.18)	0.022A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	64	71.88	16.220	40.0	60.00	80.00	80.00	100.0			
	ADA	69	71.01	14.767	20.0	60.00	80.00	80.00	100.0			
	TOT	133	71.43	15.430	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	64	61.56	22.902	20.0	40.00	60.00	80.00	100.0			
	ADA	69	66.52	19.084	20.0	60.00	80.00	80.00	100.0			
	TOT	133	64.14	21.074	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	64	-10.31	19.838	-60.0	-20.00	0.00	0.00	20.0			
	ADA	69	-4.49	18.112	-60.0	-20.00	0.00	0.00	40.0			
	TOT	133	-7.29	19.114	-60.0	-20.00	0.00	0.00	40.0			
										5.82	(-0.69, 12.33)	0.079A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	64	84.18	15.787	37.5	75.00	87.50	100.00	100.0			
	ADA	70	85.18	18.219	25.0	75.00	87.50	100.00	100.0			
	TOT	134	84.70	17.044	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	64	70.90	22.278	25.0	56.25	75.00	87.50	100.0			
	ADA	70	83.04	19.740	25.0	75.00	87.50	100.00	100.0			
	TOT	134	77.24	21.778	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-13.28	19.143	-75.0	-25.00	-12.50	0.00	25.0			
	ADA	70	-2.14	16.481	-75.0	-12.50	0.00	0.00	37.5			
	TOT	134	-7.46	18.592	-75.0	-12.50	0.00	0.00	37.5			
										11.14	(5.05, 17.23)	<0.001A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	64	75.85	21.786	16.7	66.67	75.00	100.00	100.0			
	ADA	70	76.90	23.705	16.7	58.33	83.33	100.00	100.0			
	TOT	134	76.40	22.730	16.7	66.67	79.17	100.00	100.0			
FINAL/ET VALUE	PLO	64	70.90	24.617	8.3	50.00	75.00	91.67	100.0			
	ADA	70	72.32	24.960	16.7	50.00	75.00	100.00	100.0			
	TOT	134	71.64	24.714	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	64	-4.95	17.969	-66.7	-10.42	0.00	0.00	41.7			
	ADA	70	-4.58	18.851	-66.7	-8.33	0.00	0.00	50.0			
	TOT	134	-4.76	18.367	-66.7	-8.33	0.00	0.00	50.0			
										0.36	(-5.94, 6.67)	0.909A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	64	76.69	20.902	16.7	66.67	83.33	91.67	100.0			
	ADA	70	76.55	23.141	16.7	58.33	83.33	100.00	100.0			
	TOT	134	76.62	22.018	16.7	58.33	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	64	72.40	24.583	8.3	58.33	75.00	91.67	100.0			
	ADA	70	71.70	27.676	16.7	50.00	83.33	100.00	100.0			
	TOT	134	72.03	26.149	8.3	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-4.30	13.908	-50.0	-8.33	0.00	0.00	41.7			
	ADA	70	-4.85	15.658	-66.7	-8.33	0.00	0.00	25.0			
	TOT	134	-4.59	14.795	-66.7	-8.33	0.00	0.00	41.7			
										-0.55	(-5.63, 4.53)	0.829A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	64	88.28	18.750	25.0	75.00	100.00	100.00	100.0			
	ADA	70	88.21	19.021	25.0	75.00	100.00	100.00	100.0			
	TOT	134	88.25	18.821	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	64	82.42	23.958	12.5	75.00	87.50	100.00	100.0			
	ADA	70	82.59	23.672	12.5	75.00	100.00	100.00	100.0			
	TOT	134	82.51	23.719	12.5	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-5.86	16.512	-62.5	-12.50	0.00	0.00	37.5			
	ADA	70	-5.63	13.382	-50.0	-12.50	0.00	0.00	37.5			
	TOT	134	-5.74	14.902	-62.5	-12.50	0.00	0.00	37.5			
										0.23	(-4.88, 5.35)	0.928A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	64	68.16	25.362	0.0	50.00	75.00	87.50	100.0			
	ADA	70	68.39	24.701	0.0	50.00	78.13	87.50	100.0			
	TOT	134	68.28	24.925	0.0	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	64	64.45	29.857	0.0	50.00	75.00	87.50	100.0			
	ADA	70	67.50	27.432	0.0	43.75	75.00	93.75	100.0			
	TOT	134	66.04	28.548	0.0	43.75	75.00	87.50	100.0			
CHG FROM BEST*	PLO	64	-3.71	16.915	-56.3	-12.50	0.00	6.25	31.3			
	ADA	70	-0.89	18.592	-62.5	-6.25	0.00	6.25	43.8			
	TOT	134	-2.24	17.800	-62.5	-12.50	0.00	6.25	43.8			
										2.82	(-3.28, 8.91)	0.362A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	64	72.46	25.313	12.5	50.00	75.00	100.00	100.0			
	ADA	70	72.86	26.493	0.0	50.00	75.00	100.00	100.0			
	TOT	134	72.67	25.840	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	64	65.23	29.502	0.0	50.00	75.00	87.50	100.0			
	ADA	70	70.18	29.816	0.0	50.00	75.00	100.00	100.0			
	TOT	134	67.82	29.659	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-7.23	18.474	-50.0	-25.00	0.00	0.00	50.0			
	ADA	70	-2.68	24.067	-87.5	-12.50	0.00	12.50	50.0			
	TOT	134	-4.85	21.619	-87.5	-12.50	0.00	0.00	50.0			
										4.55	(-2.83, 11.93)	0.225A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	64	81.90	26.292	0.0	75.00	91.67	100.00	100.0			
	ADA	70	82.26	26.691	0.0	75.00	100.00	100.00	100.0			
	TOT	134	82.09	26.402	0.0	75.00	95.83	100.00	100.0			
FINAL/ET VALUE	PLO	64	74.93	32.602	0.0	66.67	91.67	100.00	100.0			
	ADA	70	79.76	29.440	0.0	58.33	100.00	100.00	100.0			
	TOT	134	77.46	30.967	0.0	66.67	91.67	100.00	100.0			
CHG FROM BEST*	PLO	64	-6.97	18.441	-75.0	-12.50	0.00	0.00	29.2			
	ADA	70	-2.50	18.841	-75.0	0.00	0.00	0.00	50.0			
	TOT	134	-4.63	18.715	-75.0	-8.33	0.00	0.00	50.0			
										4.47	(-1.91, 10.85)	0.169A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	57	68.27	31.866	0.0	50.00	83.33	91.67	100.0			
	ADA	64	69.47	30.411	0.0	50.00	83.33	91.67	100.0			
	TOT	121	68.90	30.981	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	57	60.82	31.887	0.0	33.33	66.67	83.33	100.0			
	ADA	64	63.48	32.982	0.0	41.67	75.00	87.50	100.0			
	TOT	121	62.22	32.363	0.0	41.67	75.00	83.33	100.0			
CHG FROM BEST*	PLO	57	-7.46	21.460	-58.3	-16.67	0.00	0.00	50.0			
	ADA	64	-5.99	16.780	-66.7	-10.42	0.00	0.00	50.0			
	TOT	121	-6.68	19.060	-66.7	-16.67	0.00	0.00	50.0			
										1.47	(-5.43, 8.36)	0.674A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	64	95.70	10.498	50.0	100.00	100.00	100.00	100.0			
	ADA	70	93.21	14.066	25.0	100.00	100.00	100.00	100.0			
	TOT	134	94.40	12.506	25.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	64	93.75	13.363	50.0	100.00	100.00	100.00	100.0			
	ADA	70	87.50	19.388	25.0	75.00	100.00	100.00	100.0			
	TOT	134	90.49	17.012	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-1.95	10.259	-50.0	0.00	0.00	0.00	25.0			
	ADA	70	-5.71	17.116	-75.0	-25.00	0.00	0.00	25.0			
	TOT	134	-3.92	14.332	-75.0	0.00	0.00	0.00	25.0			
										-3.76	(-8.64, 1.12)	0.130A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	64	81.64	21.475	25.0	75.00	75.00	100.00	100.0			
	ADA	69	81.52	24.121	25.0	75.00	100.00	100.00	100.0			
	TOT	133	81.58	22.800	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	64	77.34	23.452	25.0	75.00	75.00	100.00	100.0			
	ADA	69	77.17	26.339	25.0	50.00	75.00	100.00	100.0			
	TOT	133	77.26	24.897	25.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	64	-4.30	17.568	-75.0	0.00	0.00	0.00	50.0			
	ADA	69	-4.35	18.168	-50.0	0.00	0.00	0.00	25.0			
	TOT	133	-4.32	17.814	-75.0	0.00	0.00	0.00	50.0			
										-0.05	(-6.19, 6.09)	0.987A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.27.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	64	76.92	17.613	25.7	65.34	80.38	92.97	98.7			
	ADA	70	76.87	19.033	14.7	61.52	84.30	92.50	100.0			
	TOT	134	76.90	18.300	14.7	63.22	82.95	92.88	100.0			
FINAL/ET VALUE	PLO	64	72.34	20.739	21.1	61.63	76.06	89.38	100.0			
	ADA	70	74.62	21.419	18.5	57.54	84.45	93.07	99.4			
	TOT	134	73.53	21.049	18.5	60.34	77.90	92.12	100.0			
CHG FROM BEST*	PLO	64	-4.59	11.475	-44.4	-9.02	-2.08	2.59	20.6			
	ADA	70	-2.25	12.316	-39.0	-4.85	-0.42	3.52	25.8			
	TOT	134	-3.37	11.935	-44.4	-8.52	-1.14	2.92	25.8			
										2.34	(-1.74, 6.41)	0.259A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	46	59.78	21.395	25.0	50.00	50.00	75.00	100.0			
	ADA	39	63.46	19.740	25.0	50.00	50.00	75.00	100.0			
	TOT	85	61.47	20.613	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	46	44.02	25.919	0.0	25.00	50.00	50.00	100.0			
	ADA	39	48.72	26.251	0.0	25.00	50.00	50.00	100.0			
	TOT	85	46.18	26.023	0.0	25.00	50.00	50.00	100.0			
CHG FROM BEST*	PLO	46	-15.76	22.582	-100.0	-25.00	-25.00	0.00	25.0			
	ADA	39	-14.74	24.814	-100.0	-25.00	0.00	0.00	25.0			
	TOT	85	-15.29	23.495	-100.0	-25.00	-25.00	0.00	25.0			
										1.02	(-9.21, 11.25)	0.844A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	46	71.30	14.393	40.0	60.00	80.00	80.00	100.0			
	ADA	39	66.41	14.233	40.0	60.00	60.00	80.00	100.0			
	TOT	85	69.06	14.444	40.0	60.00	60.00	80.00	100.0			
FINAL/ET VALUE	PLO	46	62.17	18.002	20.0	40.00	60.00	80.00	100.0			
	ADA	39	62.05	19.355	20.0	60.00	60.00	80.00	100.0			
	TOT	85	62.12	18.522	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	46	-9.13	16.169	-60.0	-20.00	0.00	0.00	20.0			
	ADA	39	-4.36	14.289	-40.0	-20.00	0.00	0.00	20.0			
	TOT	85	-6.94	15.432	-60.0	-20.00	0.00	0.00	20.0			
										4.77	(-1.87, 11.41)	0.157A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	46	85.87	16.999	37.5	75.00	87.50	100.00	100.0			
	ADA	39	82.05	17.157	50.0	62.50	87.50	100.00	100.0			
	TOT	85	84.12	17.077	37.5	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	46	74.73	26.937	12.5	62.50	81.25	100.00	100.0			
	ADA	39	75.96	20.153	50.0	50.00	75.00	100.00	100.0			
	TOT	85	75.29	23.934	12.5	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	46	-11.14	23.158	-87.5	-12.50	0.00	0.00	12.5			
	ADA	39	-6.09	15.140	-37.5	-12.50	0.00	0.00	25.0			
	TOT	85	-8.82	19.935	-87.5	-12.50	0.00	0.00	25.0			
										5.05	(-3.56, 13.66)	0.247A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	46	75.72	19.470	25.0	58.33	75.00	91.67	100.0			
	ADA	39	68.91	22.476	29.2	50.00	66.67	91.67	100.0			
	TOT	85	72.60	21.054	25.0	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	46	64.31	27.367	8.3	41.67	66.67	91.67	100.0			
	ADA	39	67.31	22.490	25.0	50.00	75.00	83.33	100.0			
	TOT	85	65.69	25.145	8.3	50.00	66.67	83.33	100.0			
CHG FROM BEST*	PLO	46	-11.41	17.065	-58.3	-25.00	-8.33	0.00	25.0			
	ADA	39	-1.60	11.049	-25.0	-8.33	0.00	0.00	25.0			
	TOT	85	-6.91	15.344	-58.3	-16.67	0.00	0.00	25.0			
										9.81	(3.48, 16.14)	0.003A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	46	76.00	21.430	25.0	58.33	83.33	91.67	100.0			
	ADA	39	72.44	20.042	12.5	58.33	75.00	83.33	100.0			
	TOT	85	74.36	20.759	12.5	58.33	75.00	91.67	100.0			
FINAL/ET VALUE	PLO	46	68.30	28.941	16.7	41.67	75.00	91.67	100.0			
	ADA	39	68.80	21.265	25.0	58.33	75.00	83.33	100.0			
	TOT	85	68.53	25.560	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	46	-7.70	15.290	-50.0	-16.67	-8.33	0.00	25.0			
	ADA	39	-3.63	10.034	-25.0	-8.33	0.00	0.00	16.7			
	TOT	85	-5.83	13.226	-50.0	-16.67	0.00	0.00	25.0			
										4.07	(-1.62, 9.76)	0.159A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	46	88.86	17.125	37.5	87.50	100.00	100.00	100.0			
	ADA	39	87.50	18.805	37.5	75.00	100.00	100.00	100.0			
	TOT	85	88.24	17.819	37.5	87.50	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	46	81.25	24.116	12.5	75.00	87.50	100.00	100.0			
	ADA	39	83.33	19.520	25.0	75.00	87.50	100.00	100.0			
	TOT	85	82.21	22.023	12.5	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	46	-7.61	14.548	-50.0	-12.50	0.00	0.00	25.0			
	ADA	39	-4.17	12.279	-37.5	-12.50	0.00	0.00	25.0			
	TOT	85	-6.03	13.586	-50.0	-12.50	0.00	0.00	25.0			
										3.44	(-2.43, 9.31)	0.247A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	46	69.97	23.035	18.8	50.00	75.00	87.50	100.0			
	ADA	39	64.96	21.724	12.5	50.00	68.75	81.25	100.0			
	TOT	85	67.67	22.451	12.5	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	46	62.50	28.119	6.3	37.50	62.50	87.50	100.0			
	ADA	39	65.65	24.239	6.3	56.25	68.75	81.25	100.0			
	TOT	85	63.95	26.303	6.3	50.00	68.75	83.33	100.0			
CHG FROM BEST*	PLO	46	-7.47	19.796	-75.0	-18.75	-3.13	6.25	25.0			
	ADA	39	0.69	12.393	-18.8	-6.25	0.00	6.25	31.3			
	TOT	85	-3.73	17.210	-75.0	-6.25	0.00	6.25	31.3			
										8.17	(0.89, 15.45)	0.028A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	46	72.28	27.878	12.5	50.00	75.00	100.00	100.0			
	ADA	39	66.99	24.246	12.5	50.00	62.50	87.50	100.0			
	TOT	85	69.85	26.255	12.5	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	46	62.50	31.732	0.0	25.00	75.00	100.00	100.0			
	ADA	39	62.50	32.317	0.0	50.00	62.50	100.00	100.0			
	TOT	85	62.50	31.810	0.0	37.50	62.50	100.00	100.0			
CHG FROM BEST*	PLO	46	-9.78	21.068	-75.0	-25.00	0.00	0.00	25.0			
	ADA	39	-4.49	23.383	-75.0	-12.50	0.00	0.00	37.5			
	TOT	85	-7.35	22.185	-75.0	-12.50	0.00	0.00	37.5			
										5.30	(-4.30, 14.89)	0.275A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	46	82.79	23.465	25.0	66.67	91.67	100.00	100.0			
	ADA	39	82.26	21.390	25.0	66.67	91.67	100.00	100.0			
	TOT	85	82.55	22.406	25.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	46	73.73	28.489	8.3	50.00	83.33	100.00	100.0			
	ADA	39	78.21	25.335	16.7	58.33	91.67	100.00	100.0			
	TOT	85	75.78	27.022	8.3	58.33	83.33	100.00	100.0			
CHG FROM BEST*	PLO	46	-9.06	20.550	-75.0	-16.67	0.00	0.00	50.0			
	ADA	39	-4.06	17.086	-41.7	-16.67	0.00	0.00	58.3			
	TOT	85	-6.76	19.094	-75.0	-16.67	0.00	0.00	58.3			
										5.00	(-3.25, 13.24)	0.231A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	42	66.17	30.413	0.0	50.00	75.00	91.67	100.0			
	ADA	35	61.79	28.232	0.0	41.67	66.67	83.33	100.0			
	TOT	77	64.18	29.333	0.0	41.67	75.00	83.33	100.0			
FINAL/ET VALUE	PLO	42	54.66	35.644	0.0	33.33	58.33	83.33	100.0			
	ADA	35	59.52	30.728	0.0	41.67	66.67	83.33	100.0			
	TOT	77	56.87	33.373	0.0	33.33	66.67	83.33	100.0			
CHG FROM BEST*	PLO	42	-11.51	19.012	-75.0	-25.00	-8.33	0.00	33.3			
	ADA	35	-2.26	13.533	-41.7	-8.33	0.00	4.17	33.3			
	TOT	77	-7.31	17.274	-75.0	-16.67	0.00	0.00	33.3			
										9.25	(1.61, 16.88)	0.018A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	46	92.39	14.785	50.0	100.00	100.00	100.00	100.0			
	ADA	39	93.59	11.059	75.0	75.00	100.00	100.00	100.0			
	TOT	85	92.94	13.145	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	46	88.32	19.437	25.0	75.00	100.00	100.00	100.0			
	ADA	39	92.95	12.759	50.0	75.00	100.00	100.00	100.0			
	TOT	85	90.44	16.776	25.0	75.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	46	-4.08	13.958	-50.0	0.00	0.00	0.00	25.0			
	ADA	39	-0.64	12.149	-50.0	0.00	0.00	0.00	25.0			
	TOT	85	-2.50	13.195	-50.0	0.00	0.00	0.00	25.0			
										3.44	(-2.26, 9.13)	0.234A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	46	78.53	24.247	25.0	50.00	75.00	100.00	100.0			
	ADA	39	77.56	22.794	25.0	75.00	75.00	100.00	100.0			
	TOT	85	78.09	23.457	25.0	75.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	46	71.20	26.857	0.0	50.00	75.00	100.00	100.0			
	ADA	39	69.23	24.643	25.0	50.00	75.00	100.00	100.0			
	TOT	85	70.29	25.732	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	46	-7.34	15.041	-50.0	-25.00	0.00	0.00	25.0			
	ADA	39	-8.33	17.522	-50.0	-25.00	0.00	0.00	25.0			
	TOT	85	-7.79	16.135	-50.0	-25.00	0.00	0.00	25.0			
										-1.00	(-8.02, 6.03)	0.779A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.28.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >= 60 DAYS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	46	76.00	17.604	39.1	61.63	79.94	90.11	98.3			
	ADA	39	71.92	16.273	40.1	57.80	72.31	86.14	97.0			
	TOT	85	74.13	17.030	39.1	60.19	77.42	89.55	98.3			
FINAL/ET VALUE	PLO	46	69.60	21.596	27.6	50.61	73.54	90.23	100.0			
	ADA	39	71.26	17.933	29.7	59.05	72.46	83.98	99.4			
	TOT	85	70.36	19.900	27.6	51.86	72.50	85.19	100.0			
CHG FROM BEST*	PLO	46	-6.40	12.515	-48.0	-12.01	-1.80	2.08	11.7			
	ADA	39	-0.65	7.877	-22.9	-4.47	-0.95	3.79	13.9			
	TOT	85	-3.76	10.967	-48.0	-7.42	-1.33	2.46	13.9			
										5.75	(1.14, 10.35)	0.015A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	33	69.70	24.010	0.0	50.00	75.00	75.00	100.0			
	ADA	32	65.63	19.828	25.0	50.00	75.00	75.00	100.0			
	TOT	65	67.69	21.974	0.0	50.00	75.00	75.00	100.0			
FINAL/ET VALUE	PLO	33	54.55	26.112	0.0	25.00	50.00	75.00	100.0			
	ADA	32	59.38	18.784	25.0	50.00	50.00	75.00	100.0			
	TOT	65	56.92	22.754	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	33	-15.15	22.482	-75.0	-25.00	-25.00	0.00	25.0			
	ADA	32	-6.25	21.997	-50.0	-25.00	0.00	0.00	50.0			
	TOT	65	-10.77	22.521	-75.0	-25.00	0.00	0.00	50.0			
										8.90	(-2.13, 19.93)	0.112A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	33	69.70	16.674	40.0	60.00	80.00	80.00	100.0			
	ADA	32	73.13	13.060	40.0	60.00	80.00	80.00	100.0			
	TOT	65	71.38	14.987	40.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	33	60.61	23.709	20.0	40.00	60.00	80.00	100.0			
	ADA	32	66.88	17.309	20.0	60.00	80.00	80.00	80.0			
	TOT	65	63.69	20.884	20.0	60.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	33	-9.09	21.847	-60.0	-20.00	0.00	0.00	20.0			
	ADA	32	-6.25	18.622	-60.0	-20.00	0.00	0.00	40.0			
	TOT	65	-7.69	20.215	-60.0	-20.00	0.00	0.00	40.0			
										2.84	(-7.24, 12.92)	0.575A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	33	84.09	17.194	37.5	75.00	87.50	100.00	100.0			
	ADA	32	85.55	19.079	25.0	75.00	100.00	100.00	100.0			
	TOT	65	84.81	18.019	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	33	70.08	22.522	25.0	62.50	75.00	87.50	100.0			
	ADA	32	85.55	16.223	50.0	75.00	87.50	100.00	100.0			
	TOT	65	77.69	21.020	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-14.02	21.369	-75.0	-25.00	-12.50	0.00	25.0			
	ADA	32	0.00	10.999	-25.0	0.00	0.00	0.00	37.5			
	TOT	65	-7.12	18.351	-75.0	-12.50	0.00	0.00	37.5			
										14.02	(5.55, 22.48)	0.002A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	33	73.74	21.461	25.0	58.33	75.00	100.00	100.0			
	ADA	32	78.65	25.306	16.7	66.67	91.67	100.00	100.0			
	TOT	65	76.15	23.380	16.7	58.33	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	69.57	25.483	8.3	50.00	75.00	91.67	100.0			
	ADA	32	74.35	23.856	25.0	56.25	75.00	95.83	100.0			
	TOT	65	71.92	24.620	8.3	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	33	-4.17	20.145	-66.7	-8.33	0.00	0.00	41.7			
	ADA	32	-4.30	20.940	-66.7	-8.33	0.00	0.00	50.0			
	TOT	65	-4.23	20.379	-66.7	-8.33	0.00	0.00	50.0			
										-0.13	(-10.31, 10.05)	0.980A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DISTANCE VISION												
BEST VALUE*	PLO	33	75.76	19.473	25.0	66.67	75.00	91.67	100.0			
	ADA	32	77.86	20.885	33.3	58.33	83.33	95.83	100.0			
	TOT	65	76.79	20.050	25.0	58.33	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	33	73.86	23.275	16.7	66.67	75.00	91.67	100.0			
	ADA	32	71.68	26.095	25.0	46.88	83.33	91.67	100.0			
	TOT	65	72.79	24.534	16.7	50.00	83.33	91.67	100.0			
CHG FROM BEST*	PLO	33	-1.89	14.400	-33.3	-8.33	0.00	0.00	41.7			
	ADA	32	-6.18	19.207	-66.7	-8.33	0.00	4.17	25.0			
	TOT	65	-4.01	16.942	-66.7	-8.33	0.00	0.00	41.7			
										-4.29	(-12.69, 4.11)	0.311A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
SOCIAL FUNCTIONING												
BEST VALUE*	PLO	33	89.02	15.549	50.0	75.00	100.00	100.00	100.0			
	ADA	32	88.28	18.767	37.5	81.25	100.00	100.00	100.0			
	TOT	65	88.65	17.077	37.5	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	85.23	18.075	37.5	75.00	87.50	100.00	100.0			
	ADA	32	81.25	25.000	25.0	62.50	100.00	100.00	100.0			
	TOT	65	83.27	21.682	25.0	75.00	87.50	100.00	100.0			
CHG FROM BEST*	PLO	33	-3.79	17.811	-37.5	-12.50	0.00	0.00	37.5			
	ADA	32	-7.03	15.534	-50.0	-12.50	0.00	0.00	37.5			
	TOT	65	-5.38	16.678	-50.0	-12.50	0.00	0.00	37.5			
										-3.24	(-11.54, 5.05)	0.437A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
MENTAL HEALTH												
BEST VALUE*	PLO	33	64.96	24.752	6.3	50.00	68.75	81.25	100.0			
	ADA	32	70.12	25.781	18.8	43.75	81.25	87.50	100.0			
	TOT	65	67.50	25.199	6.3	50.00	75.00	87.50	100.0			
FINAL/ET VALUE	PLO	33	62.12	28.596	0.0	43.75	68.75	87.50	100.0			
	ADA	32	68.36	27.903	12.5	43.75	81.25	93.75	100.0			
	TOT	65	65.19	28.211	0.0	43.75	75.00	87.50	100.0			
CHG FROM BEST*	PLO	33	-2.84	17.890	-43.8	-12.50	0.00	12.50	31.3			
	ADA	32	-1.76	16.743	-43.8	-6.25	0.00	6.25	31.3			
	TOT	65	-2.31	17.208	-43.8	-12.50	0.00	6.25	31.3			
										1.08	(-7.51, 9.68)	0.802A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
ROLE DIFFICULTIES												
BEST VALUE*	PLO	33	72.73	23.892	25.0	50.00	75.00	100.00	100.0			
	ADA	32	75.39	26.656	0.0	50.00	75.00	100.00	100.0			
	TOT	65	74.04	25.127	0.0	50.00	75.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	64.77	26.416	12.5	50.00	75.00	75.00	100.0			
	ADA	32	73.83	28.105	0.0	56.25	75.00	100.00	100.0			
	TOT	65	69.23	27.429	0.0	50.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-7.95	21.153	-50.0	-25.00	0.00	0.00	37.5			
	ADA	32	-1.56	18.716	-50.0	-6.25	0.00	0.00	37.5			
	TOT	65	-4.81	20.094	-50.0	-12.50	0.00	0.00	37.5			
										6.39	(-3.52, 16.30)	0.202A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DEPENDENCY												
BEST VALUE*	PLO	33	79.80	25.433	0.0	66.67	83.33	100.00	100.0			
	ADA	32	80.47	28.681	0.0	70.83	95.83	100.00	100.0			
	TOT	65	80.13	26.870	0.0	66.67	91.67	100.00	100.0			
FINAL/ET VALUE	PLO	33	71.46	33.530	0.0	58.33	83.33	100.00	100.0			
	ADA	32	79.95	29.242	16.7	62.50	100.00	100.00	100.0			
	TOT	65	75.64	31.537	0.0	58.33	91.67	100.00	100.0			
CHG FROM BEST*	PLO	33	-8.33	21.041	-75.0	-16.67	0.00	0.00	16.7			
	ADA	32	-0.52	19.736	-75.0	0.00	0.00	0.00	50.0			
	TOT	65	-4.49	20.628	-75.0	0.00	0.00	0.00	50.0			
										7.81	(-2.31, 17.93)	0.128A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
DRIVING												
BEST VALUE*	PLO	31	66.67	31.402	0.0	50.00	75.00	91.67	100.0			
	ADA	27	74.69	26.603	0.0	50.00	83.33	91.67	100.0			
	TOT	58	70.40	29.294	0.0	50.00	83.33	91.67	100.0			
FINAL/ET VALUE	PLO	31	61.29	30.998	0.0	41.67	75.00	83.33	100.0			
	ADA	27	67.13	29.786	0.0	50.00	75.00	83.33	100.0			
	TOT	58	64.01	30.316	0.0	50.00	75.00	83.33	100.0			
CHG FROM BEST*	PLO	31	-5.38	24.678	-58.3	-16.67	0.00	0.00	50.0			
	ADA	27	-7.56	14.980	-66.7	-16.67	0.00	0.00	12.5			
	TOT	58	-6.39	20.594	-66.7	-16.67	0.00	0.00	50.0			
										-2.19	(-13.13, 8.76)	0.691A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
COLOR VISION												
BEST VALUE*	PLO	33	95.45	9.792	75.0	100.00	100.00	100.00	100.0			
	ADA	32	95.31	11.773	50.0	100.00	100.00	100.00	100.0			
	TOT	65	95.38	10.728	50.0	100.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	93.18	14.352	50.0	100.00	100.00	100.00	100.0			
	ADA	32	89.84	17.802	50.0	75.00	100.00	100.00	100.0			
	TOT	65	91.54	16.103	50.0	100.00	100.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-2.27	11.463	-50.0	0.00	0.00	0.00	25.0			
	ADA	32	-5.47	15.206	-50.0	-12.50	0.00	0.00	25.0			
	TOT	65	-3.85	13.427	-50.0	0.00	0.00	0.00	25.0			
										-3.20	(-9.86, 3.47)	0.341A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
PERIPHERAL VISION												
BEST VALUE*	PLO	33	83.33	19.432	25.0	75.00	75.00	100.00	100.0			
	ADA	31	86.29	20.247	25.0	75.00	100.00	100.00	100.0			
	TOT	64	84.77	19.729	25.0	75.00	100.00	100.00	100.0			
FINAL/ET VALUE	PLO	33	80.30	18.496	25.0	75.00	75.00	100.00	100.0			
	ADA	31	79.84	22.748	25.0	50.00	75.00	100.00	100.0			
	TOT	64	80.08	20.500	25.0	75.00	75.00	100.00	100.0			
CHG FROM BEST*	PLO	33	-3.03	16.247	-25.0	0.00	0.00	0.00	50.0			
	ADA	31	-6.45	21.377	-50.0	-25.00	0.00	0.00	25.0			
	TOT	64	-4.69	18.832	-50.0	-25.00	0.00	0.00	50.0			
										-3.42	(-12.87, 6.03)	0.472A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.29.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE < 1 MONTH AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
TOTAL SCORE												
BEST VALUE*	PLO	33	75.75	16.156	40.9	63.98	77.23	90.38	98.2			
	ADA	32	78.91	18.127	31.5	61.15	87.01	92.97	100.0			
	TOT	65	77.31	17.094	31.5	63.22	82.88	92.88	100.0			
FINAL/ET VALUE	PLO	33	72.16	18.733	36.5	59.70	75.53	87.65	100.0			
	ADA	32	75.92	19.949	40.6	57.01	84.77	92.82	98.2			
	TOT	65	74.01	19.282	36.5	57.54	78.08	91.17	100.0			
CHG FROM BEST*	PLO	33	-3.59	12.285	-37.7	-9.02	-1.52	3.22	20.6			
	ADA	32	-3.00	11.789	-38.7	-4.60	-1.23	0.60	17.9			
	TOT	65	-3.30	11.953	-38.7	-8.26	-1.33	2.54	20.6			
										0.59	(-5.38, 6.56)	0.844A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.30.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >=1 to < 2 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL HEALTH												
BEST VALUE*	PLO	32	64.84	23.640	25.0	50.00	50.00	75.00	100.0			
	ADA	38	61.18	21.512	25.0	50.00	50.00	75.00	100.0			
	TOT	70	62.86	22.418	25.0	50.00	50.00	75.00	100.0			
FINAL/ET VALUE	PLO	32	50.78	29.433	0.0	25.00	50.00	75.00	100.0			
	ADA	38	55.92	22.835	0.0	50.00	50.00	75.00	100.0			
	TOT	70	53.57	25.990	0.0	50.00	50.00	75.00	100.0			
CHG FROM BEST*	PLO	32	-14.06	18.984	-50.0	-25.00	0.00	0.00	25.0			
	ADA	38	-5.26	23.364	-75.0	-25.00	0.00	0.00	50.0			
	TOT	70	-9.29	21.774	-75.0	-25.00	0.00	0.00	50.0			
										8.80	(-1.48, 19.08)	0.092A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.30.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >=1 to < 2 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
GENERAL VISION												
BEST VALUE*	PLO	32	73.75	15.606	40.0	60.00	80.00	80.00	100.0			
	ADA	37	69.19	16.052	20.0	60.00	80.00	80.00	100.0			
	TOT	69	71.30	15.896	20.0	60.00	80.00	80.00	100.0			
FINAL/ET VALUE	PLO	32	62.50	21.997	20.0	40.00	60.00	80.00	100.0			
	ADA	37	66.22	20.730	20.0	60.00	60.00	80.00	100.0			
	TOT	69	64.49	21.250	20.0	40.00	60.00	80.00	100.0			
CHG FROM BEST*	PLO	32	-11.25	17.552	-60.0	-20.00	0.00	0.00	20.0			
	ADA	37	-2.97	17.774	-60.0	-20.00	0.00	0.00	30.0			
	TOT	69	-6.81	18.027	-60.0	-20.00	0.00	0.00	30.0			
										8.28	(-0.24, 16.79)	0.057A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.30.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >=1 to < 2 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
OCULAR PAIN												
BEST VALUE*	PLO	32	83.20	15.427	50.0	75.00	87.50	100.00	100.0			
	ADA	38	84.87	17.715	25.0	75.00	87.50	100.00	100.0			
	TOT	70	84.11	16.611	25.0	75.00	87.50	100.00	100.0			
FINAL/ET VALUE	PLO	32	70.70	22.809	25.0	50.00	75.00	87.50	100.0			
	ADA	38	80.92	22.273	25.0	62.50	87.50	100.00	100.0			
	TOT	70	76.25	22.936	25.0	62.50	75.00	100.00	100.0			
CHG FROM BEST*	PLO	32	-12.50	16.498	-50.0	-25.00	-12.50	0.00	12.5			
	ADA	38	-3.95	19.946	-75.0	-12.50	0.00	0.00	25.0			
	TOT	70	-7.86	18.816	-75.0	-12.50	0.00	0.00	25.0			
										8.55	(-0.28, 17.39)	0.058A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]

TABLE 14.2__1000.4.1.1.30.I

CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/EARLY TERMINATION VISIT
IN VISUAL FUNCTIONING QUESTIONNAIRE (VFQ-25)
LOCF
ALL SUBJECTS INCLUDING JAPAN (STUDY M10-877)
(INTENT-TO-TREAT ANALYSIS SET, SUBGROUP: DURATION OF CURRENT FLARE >=1 to < 2 MONTHS AT BASELINE)

VISIT	TREATMENT	N	MEAN	SD	MIN	Q1	MEDIAN	Q3	MAX	DIFF.$	95% CI#	P-VALUE@
NEAR VISION												
BEST VALUE*	PLO	32	77.99	21.901	16.7	66.67	83.33	95.83	100.0			
	ADA	38	75.44	22.507	16.7	50.00	79.17	100.00	100.0			
	TOT	70	76.61	22.108	16.7	66.67	83.33	100.00	100.0			
FINAL/ET VALUE	PLO	32	72.66	23.687	25.0	58.33	75.00	91.67	100.0			
	ADA	38	70.61	26.047	16.7	50.00	75.00	100.00	100.0			
	TOT	70	71.55	24.838	16.7	50.00	75.00	91.67	100.0			
CHG FROM BEST*	PLO	32	-5.34	15.563	-50.0	-12.50	-4.17	0.00	25.0			
	ADA	38	-4.82	17.180	-50.0	-8.33	0.00	0.00	25.0			
	TOT	70	-5.06	16.345	-50.0	-8.33	0.00	0.00	25.0			
										0.51	(-7.37, 8.40)	0.897A

* BEST MEANS BEST STATE ACHIEVED PRIOR TO WEEK 6.
NOTE: ONLY SUBJECTS WITH BOTH BEST STATE ACHIEVED AND FINAL/ET VISIT VALUES ARE SHOWN.
SUBJECTS WHO DO NOT HAVE VALUES AT/AFTER WEEK 6 (E.G. DUE TO PREMATURE DISCONTINUATION
PRIOR TO WEEK 6) WERE EXCLUDED.
TOTAL SCORE AND SUBSCORES WERE CALCULATED BASED ON ALL NON-MISSING SUBSCORES OR ITEMS.
PLO=PLACEBO, ADA=ADALIMUMAB, TOT=TOTAL
$ MEAN DIFFERENCE IN CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT OF ADALIMUMAB MINUS PLACEBO.
# 95% CONFIDENCE INTERVAL FOR DIFFERENCE OF ADALIMUMAB MINUS PLACEBO.
@ P-VALUE FOR DIFFERENCES BETWEEN TREATMENT GROUPS.
A: FROM ANOVA OF CHANGE FROM BEST STATE ACHIEVED PRIOR TO WEEK 6 TO FINAL/ET VISIT WITH TREATMENT AS FACTOR.

Program Source Code: [redacted]